

CITATION REPORT

List of articles citing

Molecular characterization of a peripheral receptor for cannab

DOI: 10.1038/365061a0
Nature, 1993, 365, 61-5.

Source: <https://exaly.com/paper-pdf/23868804/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2252	.		
2251	Wissenschaft aktuell. 1993 , 27, 240-242		
2250	Pharmacology. Medical uses of marijuana?. <i>Nature</i> , 1993 , 365, 12-3	50.4	21
2249	Adenosine Receptor Classification: Quo Vadimus?. 1994 , 13, 1953-1976		9
2248	Delta-9-tetrahydrocannabinol treatment results in a suppression of interleukin-2-induced cellular activities in human and murine lymphocytes. 1994 , 16, 593-603		7
2247	Suppression of experimental autoimmune encephalomyelitis by cannabinoids. 1994 , 28, 209-14		113
2246	Orphan seven transmembrane domain receptors: reversing pharmacology. 1994 , 12, 47-9		18
2245	Pharmacology. Endogenous cannabinoids. <i>Nature</i> , 1994 , 372, 619	50.4	13
2244	Science signals a new understanding of marihuana. 1994 , 13, 307-17		2
2243	(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. 1994 , 37, 1889-93		296
2242	Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis. 1994 , 55, 107-15		157
2241	New dawn of cannabinoid pharmacology. 1994 , 15, 40-1		43
2240	Binding and functional studies with the peripheral and neuronal cannabinoid receptors. 1994 , 54, 313-314		4
2239	Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. 1994 , 63, 637-52		225
2238	Phospholipase participation in cannabinoid-induced release of free arachidonic acid. 1994 , 48, 1253-64		49
2237	Search for endogenous ligands of the cannabinoid receptor. 1994 , 48, 1537-44		123
2236	Suppression of the humoral immune response by cannabinoids is partially mediated through inhibition of adenylate cyclase by a pertussis toxin-sensitive G-protein coupled mechanism. 1994 , 48, 1899-908		112

2235	SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. 1994 , 350, 240-4	1363
2234	Molecular cloning of a novel candidate G protein-coupled receptor from rat brain. 1994 , 351, 375-9	17
2233	Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions. 1994 , 15, 298-306	343
2232	Inhibition of macrophage inducible protein expression by delta-9-tetrahydrocannabinol. 1994 , 54, 1831-44	22
2231	Opioid and cannabinoid receptors. 1994 , 4, 406-12	22
2230	CNS Cannabinoid Receptors. 1994 , 2, 255-260	7
2229	(-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. 1994 , 37, 3867-70	35
2228	Conformational analysis of the prototype nonclassical cannabinoid CP-47,497, using 2D NMR and computer molecular modeling. 1994 , 37, 1418-26	31
2227	Anandamide (arachidonylethanolamide), a brain cannabinoid receptor agonist, reduces sperm fertilizing capacity in sea urchins by inhibiting the acrosome reaction. 1994 , 91, 7678-82	143
2226	The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. 1995 , 92, 9460-4	160
2225	Molecular cloning of an orphan G-protein-coupled receptor that constitutively activates adenylate cyclase. 1995 , 309 (Pt 3), 837-43	105
2224	An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. 1995 , 270, 3726-31	244
2223	Cannabinoid ligand-receptor signaling in the mouse uterus. 1995 , 92, 4332-6	149
2222	Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. 1995 , 232, 54-61	1169
2221	Changes in rat brain cannabinoid binding sites after acute or chronic exposure to their endogenous agonist, anandamide, or to delta 9-tetrahydrocannabinol. 1995 , 51, 731-7	91
2220	Perinatal exposure to delta 9-tetrahydrocannabinol (delta 9-THC) leads to changes in opioid-related behavioral patterns in rats. 1995 , 680, 142-7	63
2219	Anandamides: tolerance and cross-tolerance to delta 9-tetrahydrocannabinol. 1995 , 697, 83-90	57
2218	Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. 1995 , 92, 3376-80	537

2217	Cannabis as a medicine?. 1995 , 74, 359-61	12
2216	Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits. 1995 , 14, 791-7	64
2215	Chapter 2. Centrally Acting Analgesics. 1995 , 30, 11-20	8
2214	Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells. 1995 , 270, 13973-80	140
2213	Anandamide, an endogenous cannabinomimetic eicosanoid: 'killing two birds with one stone'. 1995 , 53, 1-11	123
2212	Neurobehavioral effects of delta 9-THC and cannabinoid (CB1) receptor gene expression in mice. 1995 , 72, 115-25	64
2211	Lipoxygenase-catalyzed oxygenation of arachidonylethanolamide, a cannabinoid receptor agonist. 1995 , 1254, 127-34	138
2210	Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. 1995 , 50, 83-90	2266
2209	Microsomal cytochrome P450-mediated liver and brain anandamide metabolism. 1995 , 50, 677-86	58
2208	Relationships between eicosanoids and cannabinoids. Are eicosanoids cannabimimetic agents?. 1995 , 50, 1735-42	16
2207	Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. 1995 , 278, 279-83	160
2206	Cannabinomimetic behavioral effects of and adenylate cyclase inhibition by two new endogenous anandamides. 1995 , 287, 145-52	50
2205	The MAP kinase signal transduction pathway is activated by the endogenous cannabinoid anandamide. 1995 , 359, 133-6	128
2204	Cannabinoids enhance human B-cell growth at low nanomolar concentrations. 1995 , 369, 177-82	121
2203	The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling. 1995 , 375, 143-7	148
2202	Pharmacology of cannabinoid receptors. 1995 , 35, 607-34	419
2201	Activation of inwardly rectifying potassium channels (GIRK1) by co-expressed rat brain cannabinoid receptors in <i>Xenopus</i> oocytes. 1995 , 186, 91-4	135
2200	A review of recent advances in cannabinoid research and the 1994 International Symposium on Cannabis and the Cannabinoids. 1995 , 56, 1933-40	28

2199	Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. 1995 , 56, 1941-7	238
2198	Construction of a 3D model of the cannabinoid CB1 receptor: determination of helix ends and helix orientation. 1995 , 56, 1971-82	85
2197	Cannabinoid photolabelling of a G-protein gamma-subunit in mouse peritoneal cells. 1995 , 56, 1991-8	
2196	Pharmacological and behavioral evaluation of alkylated anandamide analogs. 1995 , 56, 2041-8	60
2195	Anandamide inhibits macrophage-mediated killing of tumor necrosis factor-sensitive cells. 1995 , 56, 2065-72	53
2194	Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. 1996 , 39, 4515-9	155
2193	Unsaturated side chain beta-11-hydroxyhexahydrocannabinol analogs. 1996 , 39, 3790-6	63
2192	Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. 1996 , 118, 2023-8	269
2191	The conformational properties of the highly selective cannabinoid receptor ligand CP-55,940. 1996 , 271, 10640-7	48
2190	Determination of the cannabinoid receptors in mouse x rat hybridoma NG108-15 cells and rat GH4C1 cells. 1996 , 212, 123-6	18
2189	Membrane localization of N-acylphosphatidylethanolamine in central neurons: studies with exogenous phospholipases. 1996 , 14, 63-70	35
2188	Endogenous cannabinoid ligands--chemical and biological studies. 1996 , 14, 45-9	35
2187	Cannabinoids, immunity and resistance to infections. 1996 , 69, 15-23	13
2186	Cannabinoid receptor genes. 1996 , 48, 275-305	57
2185	Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. 1996 , 58, PL103-10	120
2184	Characterization and distribution of binding sites for [3H]-SR 141716A, a selective brain (CB1) cannabinoid receptor antagonist, in rodent brain. 1996 , 58, 1239-47	99
2183	Effects of topical anandamides on intraocular pressure in normotensive rabbits. 1996 , 58, 1849-60	45
2182	A role for central cannabinoid and opioid systems in peripheral delta 9-tetrahydrocannabinol-induced analgesia in mice. 1996 , 301, 75-81	48

2181	123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. 1996 , 307, 331-8	205
2180	Delta-9-tetrahydrocannabinol: an inhibitor of STAT1 alpha protein tyrosine phosphorylation. 1996 , 51, 967-73	2
2179	Tetrahydrocannabinol inhibition of macrophage nitric oxide production. 1996 , 52, 743-51	64
2178	Role of cyclic AMP in the actions of cannabinoid receptors. 1996 , 52, 819-27	126
2177	Immune regulation by cannabinoid compounds through the inhibition of the cyclic AMP signaling cascade and altered gene expression. 1996 , 52, 1133-40	37
2176	Cloning and characterisation of the human adenosine A3 receptor gene. 1996 , 384, 243-6	26
2175	Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. 1996 , 393, 231-5	258
2174	Potential biosynthetic connections between the two cannabimimetic eicosanoids, anandamide and 2-arachidonoyl-glycerol, in mouse neuroblastoma cells. 1996 , 227, 281-8	83
2173	Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. 1996 , 220, 101-4	22
2172	What is the role of the gamma-hydroxybutyrate receptor?. 1996 , 47, 455-9	4
2171	Anandamide--a new look on fatty acid ethanolamides. 1996 , 15, 49-67	13
2170	(Aminoalkyl)indole isothiocyanates as potential electrophilic affinity ligands for the brain cannabinoid receptor. 1996 , 39, 1967-74	18
2169	The ALIAMide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. 1996 , 93, 3984-9	308
2168	Molecular neurobiology of the cannabinoid receptor. 1996 , 39, 197-221	52
2167	The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. 1996 , 45, 183-92	117
2166	Pharmacophoric requirements for cannabinoid side chains. Naphthoyl and naphthylmethyl substituted β -tetrahydrocannabinol analogs. 1996 , 33, 559-562	6
2165	Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. 1996 , 1307, 132-6	139
2164	Heterologous expression of G-protein-coupled receptors. 1996 , 14, 426-30	123

2163	Developmental aspects of anandamide: ontogeny of response and prenatal exposure. 1996 , 21, 157-72	45
2162	Aversive effects of the synthetic cannabinoid CP 55,940 in rats. 1996 , 53, 657-64	147
2161	Cannabinoid receptor down-regulation without alteration of the inhibitory effect of CP 55,940 on adenylyl cyclase in the cerebellum of CP 55,940-tolerant mice. 1996 , 706, 13-20	82
2160	C-Attached aminoalkylindoles: potent cannabinoid mimetics. 1996 , 6, 17-22	27
2159	Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. 1996 , 6, 189-194	83
2158	New class of potent ligands for the human peripheral cannabinoid receptor. 1996 , 6, 2263-2268	82
2157	Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. 1996 , 126, 165-72	250
2156	Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. 1996 , 237, 704-11	194
2155	Cannabinoid enantiomer action on the cytoarchitecture. 1996 , 20, 147-57	19
2154	Neuroprotective (+) 3S, 4S cannabinoids with modified 5?-side chain. 1996 , 6, 1553-1558	6
2153	Inhibition of macrophage nitric oxide production by tetrahydrocannabinol in vivo and in vitro. 1996 , 18, 749-52	25
2152	Cannabis: pharmacology and toxicology in animals and humans. 1996 , 91, 1585-1614	31
2151	Cannabinoid receptor-mediated inhibition of dopamine release in the retina. 1996 , 354, 791-5	70
2150	Endogenous and Synthetic Cannabinoids: Recent Advances. 1996 , 2, 429-451	8
2149	Fine mapping of the autosomal dominant juvenile open angle glaucoma (GLC1A) region and evaluation of candidate genes. 1996 , 6, 862-9	35
2148	Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development. 1996 , 55, 756-61	86
2147	(-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase. 1996 , 271, 9902-5	104
2146	Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. 1996 , 271, 19238-42	134

2145	HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. 1996 , 13, 49-57	57
2144	Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. 1996 , 271, 13175-83	97
2143	Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. 1996 , 271, 6941-6	74
2142	Stereospecific cannabinoid synthesis: The application of new techniques to a classical problem. 1996 , 19, 185-244	1
2141	Adenosine receptors. 1996 , 321-347	
2140	Cannabis. 1997 , 77, 164-6	7
2139	A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. 1997 , 272, 22330-9	367
2138	Biosynthesis, uptake, and degradation of anandamide and palmitoylethanolamide in leukocytes. 1997 , 272, 3315-23	296
2137	Evidence against cannabinoid receptor involvement in intraocular pressure effects of cannabinoids in rabbits. 1997 , 29, 1-5	15
2136	Biosynthesis, release and degradation of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells. 1997 , 322 (Pt 2), 671-7	232
2135	Differential effects of CB1 and CB2 agonists on cAMP levels and MAP kinase activation in human peripheral blood mononuclear cells. 1997 , 25, 2175	2
2134	Induction of interleukin-2 receptor alpha gene by delta9-tetrahydrocannabinol is mediated by nuclear factor kappaB and CB1 cannabinoid receptor. 1997 , 16, 301-9	29
2133	New approaches to antiglaucoma therapy. 1997 , 40, 2793-809	77
2132	Importance of the C-1 substituent in classical cannabinoids to CB2 receptor selectivity: synthesis and characterization of a series of O,2-propano-delta 8-tetrahydrocannabinol analogs. 1997 , 40, 3312-8	15
2131	Inhibition of protein kinase A and cyclic AMP response element (CRE)-specific transcription factor binding by delta9-tetrahydrocannabinol (delta9-THC): a putative mechanism of cannabinoid-induced immune modulation. 1997 , 53, 1477-84	16
2130	Examination of the effect of the cannabinoid receptor agonist, CP 55,940, on electrically evoked transmitter release from rat brain slices. 1997 , 324, 187-92	61
2129	Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. 1997 , 330, 231-40	126
2128	Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. 1997 , 339, 53-61	128

2127	Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone. 1997 , 327, 227-32	38
2126	Identification of a gene that causes primary open angle glaucoma. 1997 , 275, 668-70	1124
2125	SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. 1997 , 319, R3-4	108
2124	Occurrence and metabolism of anandamide and related acyl-ethanolamides in ovaries of the sea urchin <i>Paracentrotus lividus</i> . 1997 , 1345, 338-48	67
2123	Metabolic stimulation of mouse spleen lymphocytes by low doses of delta9-tetrahydrocannabinol. 1997 , 60, 1709-17	10
2122	Receptor mediation in cannabinoid stimulated arachidonic acid mobilization and anandamide synthesis. 1997 , 60, 1563-73	57
2121	Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylyl cyclase. 1997 , 40, 3228-33	139
2120	Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. 1997 , 40, 3626-34	57
2119	Regulation of immune functions in rat splenocytes after acute and chronic in vivo treatment with CP-55,940, a synthetic cannabinoid compound. 1997 , 80, 143-8	26
2118	Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. 1997 , 46, 100-8	115
2117	Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. 1998 , 82, 1131-49	181
2116	College on problems of drug dependence meeting, Puerto Rico (June 1996) marijuana use and dependence. 1997 , 45, 1-11	16
2115	Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. 1997 , 17, 5327-33	501
2114	Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. 1997 , 78, 43-50	439
2113	Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. 1997 , 94, 4188-92	218
2112	Anandamide, a Natural Ligand for the Peripheral Cannabinoid Receptor Is a Novel Synergistic Growth Factor for Hematopoietic Cells. 1997 , 90, 1448-1457	91
2111	Neuroendocrine peptide receptors on cells of the immune system. 1997 , 69, 132-54	3
2110	Modulation of neurotransmission by cannabinoids in the basal ganglia. 1997 , 9, 199-203	57

2109	Ocular activity of topically administered anandamide in the rabbit. 1997 , 41, 217-20	22
2108	Delta9-tetrahydrocannabinol stimulates glucose utilization in C6 glioma cells. 1997 , 767, 64-71	30
2107	Pharmacology of cannabinoid CB1 and CB2 receptors. 1997 , 74, 129-80	1074
2106	The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats. 1997 , 57, 7-12	84
2105	Changes in rat spleen cannabinoid receptors after chronic CP-55,940: an autoradiographic study. 1997 , 58, 73-8	17
2104	Expression in <i>Escherichia coli</i> and characterisation of the human central CB1 and peripheral CB2 cannabinoid receptors. 1997 , 19, 425-428	25
2103	Cannabinoid CB1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. 1997 , 356, 197-202	55
2102	Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in the human and guinea-pig hippocampus. 1997 , 356, 583-9	111
2101	The cannabinoid receptor: computer-aided molecular modeling and docking of ligand. 1997 , 15, 149-53, 179	27
2100	Synthesis, pharmacology, and molecular modeling of novel 4-alkyloxy indole derivatives related to cannabimimetic aminoalkyl indoles (AAIs). 1997 , 5, 1591-600	15
2099	Liquid chromatographic-atmospheric pressure chemical ionization mass spectrometric determination of anandamide and its analogs in rat brain and peripheral tissues. 1997 , 690, 7-13	75
2098	<i>Cannabis sativa</i> L. Nutzpflanze mit Vergangenheit und Zukunft. 1997 , 27, 123-129	1
2097	Binding of [¹²⁵ I] AB-MECA to the human cloned adenosine A3 receptor using the semliki forest virus expression system. 1997 , 40, 35-40	9
2096	Identification and characterization of a novel synthetic cannabinoid CP 55,940 binder in rat brain cytosol. 1998 , 181, 21-7	3
2095	Cannabinoid receptors and their endogenous agonist, anandamide. 1998 , 23, 575-81	50
2094	Watching the pot boil. 1998 , 4, 1008-9	9
2093	An analgesia circuit activated by cannabinoids. <i>Nature</i> , 1998 , 395, 381-3	50.4 350
2092	Control of pain initiation by endogenous cannabinoids. <i>Nature</i> , 1998 , 394, 277-81	50.4 887

2091	Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. 1998 , 124, 1363-8	84
2090	The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. 1998 , 125, 533-41	66
2089	Behavioural and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. 1998 , 125, 1567-77	137
2088	Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabitol, a minimally CNS-active cannabinoid. 1998 , 55, 1013-23	56
2087	The cannabinoid agonist Win55,212-2 inhibits calcium channels by receptor-mediated and direct pathways in cultured rat hippocampal neurons. 1998 , 783, 77-84	124
2086	An invertebrate G-protein coupled receptor is a chimeric cannabinoid/melanocortin receptor. 1998 , 780, 170-173	30
2085	Morphine and anandamide coupling to nitric oxide stimulates GnRH and CRF release from rat median eminence: neurovascular regulation. 1998 , 790, 236-44	72
2084	Anandamide modulates sleep and memory in rats. 1998 , 812, 270-4	100
2083	Local effects of cannabinoids on spontaneous activity and evoked inhibition in the globus pallidus. 1998 , 352, 199-205	20
2082	An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. 1998 , 353, 23-31	410
2081	Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. 1998 , 359, 49-54	29
2080	Endocannabinoids. 1998 , 359, 1-18	384
2079	Biphasic effects of anandamide. 1998 , 59, 347-52	213
2078	Antisense oligodeoxynucleotides to the kappa1 receptor enhance delta9-THC-induced antinociceptive tolerance. 1998 , 59, 399-404	27
2077	Characterization of delta9-tetrahydrocannabinol and anandamide antinociception in nonarthritic and arthritic rats. 1998 , 60, 183-91	133
2076	The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. 1998 , 60, 559-66	120
2075	Immunohistochemical localization of the neural cannabinoid receptor in rat brain. 1998 , 51, 391-402	190
2074	PrGen: Pseudoreceptor Modeling Using Receptor-mediated Ligand Alignment and Pharmacophore Equilibration. 1998 , 17, 122-130	16

2073	Cardiovascular actions of cannabinoids and their generation during shock. 1998 , 76, 824-36	88
2072	The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by delta9-tetrahydrocannabinol or anandamide. 1998 , 140, 11-9	146
2071	Cannabinoid receptors and immunity. 1998 , 19, 373-81	202
2070	Cannabis and endogenous cannabinoid systems. 1998 , 51, 173-87	119
2069	Expression of the CB1 cannabinoid receptor in macrophage-like cells from brain tissue: immunochemical characterization by fusion protein antibodies. 1998 , 82, 13-21	53
2068	Autoimmunovascular regulation: morphine and anandamide and ancondamide stimulated nitric oxide release. 1998 , 83, 70-6	76
2067	Marijuana, immunity and infection. 1998 , 83, 102-15	158
2066	Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. 1998 , 83, 116-23	127
2065	Regulation of the cAMP cascade, gene expression and immune function by cannabinoid receptors. 1998 , 83, 124-32	57
2064	Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. 1998 , 21, 521-8	555
2063	Cannabinoid receptor CB1 mRNA is highly expressed in the rat ciliary body: implications for the antiglaucoma properties of marihuana. 1998 , 58, 240-5	78
2062	Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. 1998 , 75, 111-119	386
2061	The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. 1998 , 76, 189-99	266
2060	Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. 1998 , 83, 393-411	1279
2059	Inhibition of GABAergic inhibitory postsynaptic currents by cannabinoids in rat corpus striatum. 1998 , 85, 395-403	193
2058	Self-administration of the cannabinoid receptor agonist WIN 55,212-2 in drug-naive mice. 1998 , 85, 327-30	167
2057	Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice. 1998 , 45, 67-74	36
2056	Pharmacophoric requirements for cannabinoid side chains: multiple bond and C1'-substituted delta 8-tetrahydrocannabinols. 1998 , 41, 1195-200	62

2055	Recent developments in the pathophysiology of acute pain. 1998 , 1, 27-36	2
2054	Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors. 1998 , 63, PL1-6	132
2053	Regulation of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells. 1998 , 63, PL197-204	7
2052	Inhibition of opioid-degrading enzymes potentiates delta9-tetrahydrocannabinol-induced antinociception in mice. 1998 , 37, 215-22	21
2051	Correlation between cannabinoid mediated effects on paired pulse depression and induction of long term potentiation in the rat hippocampal slice. 1998 , 37, 1123-30	51
2050	'Endocannabinoids' and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. 1998 , 1392, 153-75	240
2049	Isotope dilution GC/MS determination of anandamide and other fatty acylethanolamides in rat blood plasma. 1998 , 422, 373-6	82
2048	The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines. 1998 , 425, 419-25	61
2047	The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. 1998 , 433, 139-42	89
2046	Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells. 1998 , 436, 6-10	216
2045	Cannabinoid receptors and their endogenous agonists. 1998 , 38, 179-200	301
2044	High-level expression of the human CB2 cannabinoid receptor using a baculovirus system. 1998 , 55, 1893-905	20
2043	Potent cyano and carboxamido side-chain analogues of 1', 1'-dimethyl-delta8-tetrahydrocannabinol. 1998 , 41, 4400-7	30
2042	Pharmacology and potential therapeutic uses of cannabis. 1998 , 81, 77-84	49
2041	Classical/nonclassical hybrid cannabinoids: southern aliphatic chain-functionalized C-6beta methyl, ethyl, and propyl analogues. 1998 , 41, 3596-608	49
2040	Cannabinoid receptor agonists and antagonists. 1998 , 8, 301-313	36
2039	Complete cDNA sequence, genomic structure, and chromosomal localization of the LPA receptor gene, lpA1/vzg-1/Gpcr26. 1998 , 51, 364-78	47
2038	Biochemistry of the endogenous ligands of cannabinoid receptors. 1998 , 5, 386-404	98

2037	The neurobiology of cannabinoid transmission: from anandamide signaling to higher cerebral functions and disease. 1998 , 5, 379-85	5
2036	Cannabinoid transmission and reward-related events. 1998 , 5, 502-33	209
2035	Brain cannabinoid systems as targets for the therapy of neurological disorders. 1998 , 5, 534-51	114
2034	Endogenous cannabinoid signaling. 1998 , 5, 462-73	131
2033	The functional neuroanatomy of brain cannabinoid receptors. 1998 , 5, 417-31	163
2032	A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. 1998 , 265, 2081-5	241
2031	Towards cannabinoid drugs--revisited. 1998 , 35, 199-243	44
2030	Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. 1998 , 341, 39-44	297
2029	Inhibition of the cAMP signaling cascade via cannabinoid receptors: a putative mechanism of immune modulation by cannabinoid compounds. 1998 , 102-103, 59-63	16
2028	Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. 1998 , 41, 5353-61	122
2027	Effects of cannabinoids on preimplantation mouse embryo development and implantation are mediated by brain-type cannabinoid receptors. 1998 , 58, 1490-5	92
2026	Evidence that cannabinoid-induced inhibition of electrically evoked contractions of the myenteric plexus - longitudinal muscle preparation of guinea-pig small intestine can be modulated by Ca ²⁺ and camp. 1998 , 76, 340-346	27
2025	Cannabinoid receptor agonist efficacy for stimulating [35S]GTPgammaS binding to rat cerebellar membranes correlates with agonist-induced decreases in GDP affinity. 1998 , 273, 16865-73	152
2024	Marijuana smoking vs cannabinoids for glaucoma therapy. 1998 , 116, 1433-7	56
2023	Analysis of the medical use of marijuana and its societal implications. 1998 , 38, 220-7	10
2022	The therapeutic applications of cannabinoid agonists and antagonists. 1998 , 3, 39-54	3
2021	The peripheral cannabinoid receptor, Cb2, in retrovirally-induced leukemic transformation and normal hematopoiesis. 1998 , 32, 29-43	23
2020	Hippocampal neurotoxicity of Delta9-tetrahydrocannabinol. 1998 , 18, 5322-32	229

2019	Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. 1998 , 12, 1035-44	846
2018	Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. 1998 , 54, 180-8	108
2017	Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation. 1998 , 92, 3605-3615	141
2016	Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. 1998 , 54, 834-43	171
2015	Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. 1998 , 53, 676-83	95
2014	Physiological regulation of G protein-linked signaling. 1999 , 79, 1373-430	372
2013	Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. 1999 , 19, 6795-805	233
2012	Cannabinoid suppression of noxious heat-evoked activity in wide dynamic range neurons in the lumbar dorsal horn of the rat. 1999 , 81, 575-83	113
2011	Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca ²⁺ channel current. 1999 , 276, H2085-93	136
2010	Methods for the synthesis of tritium-labelled fatty acids and their derivatives, oxylipins and steroids. 1999 , 68, 859-879	14
2009	Stage-specific excitation of cannabinoid receptor exhibits differential effects on mouse embryonic development. 1999 , 60, 839-44	73
2008	Amphibian Melanophore Technology as a Functional Screen for Antagonists of G-Protein Coupled 7-Transmembrane Receptors. 1999 , 4, 269-278	8
2007	Mesenteric vasodilation mediated by endothelial anandamide receptors. 1999 , 33, 429-34	230
2006	Novel conformationally restricted tetracyclic analogs of delta8-tetrahydrocannabinol. 1999 , 9, 2119-24	35
2005	Structure elucidation and conformational properties of synthetic cannabinoids (-)-2-(6a,7,10,10a-tetrahydro-6,6,9-trimethyl-1-hydroxy-6H-dibenzopyran-2-yl)-2-hexyl-1,3-dithiolane and its methylated analog. 1999 , 18, 947-56	8
2004	Anandamide and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors distinct from CB1 cannabinoid receptors in cultured astrocytes. 1999 , 11, 691-9	72
2003	Development of agonists, partial agonists and antagonists in the 8-Tetrahydrocannabinol series. 1999 , 55, 13907-13926	18
2002	Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. 1999 , 126, 457-66	94

2001	Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. 1999 , 126, 665-72	314
2000	Inhibition of the production of endothelium-derived hyperpolarizing factor by cannabinoid receptor agonists. 1999 , 126, 949-60	51
1999	Cannabinoid agonists and antagonists discriminated by receptor binding in rat cerebellum. 1999 , 128, 684-8	12
1998	Biomedical benefits of cannabinoids?. 1999 , 4, 111-26	14
1997	Mutagenicity, developmental toxicity and carcinogenicity of cannabis. 1999 , 4, 5-12	18
1996	Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. 1999 , 359, 65-70	62
1995	CB1 receptor density and CB1 receptor-mediated functional effects in rat hippocampus are decreased by an intracerebroventricularly administered antisense oligodeoxynucleotide. 1999 , 360, 421-7	9
1994	Inhibitory effect of the cannabinoid receptor agonist WIN 55,212-2 on pentagastrin-induced gastric acid secretion in the anaesthetized rat. 1999 , 360, 715-8	38
1993	Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. 1999 , 144, 144-50	59
1992	Cannabinoid receptors and their role in the regulation of the serotonin transporter in human placenta. 1999 , 181, 491-7	57
1991	Synergistic interactions of endogenous opioids and cannabinoid systems. 1999 , 848, 183-90	131
1990	Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. 1999 , 371, 187-96	68
1989	Cannabinoid penetration into mouse brain as determined by ex vivo binding. 1999 , 374, 417-21	25
1988	Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. 1999 , 374, 445-55	77
1987	Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. 1999 , 377, 117-25	106
1986	Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. 1999 , 378, 237-48	66
1985	The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. 1999 , 384, 37-42	90
1984	Opiate, cannabinoid, and eicosanoid signaling converges on common intracellular pathways nitric oxide coupling. 1999 , 57, 23-34	37

1983	Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. 1999 , 11, 189-93	95
1982	Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina. 1999 , 415, 80-90	94
1981	Human neuroimaging of acute and chronic marijuana use: implications for frontocerebellar dysfunction. 1999 , 14, 291-304	40
1980	Chapter 20. Pharmacology of Cannabinoid Receptor Agonists and Antagonists. 1999 , 34, 199-208	7
1979	Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. 1999 , 42, 2295-314	177
1978	Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. 1999 , 96, 14136-41	539
1977	Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. 1999 , 42, 769-76	402
1976	Adverse effects of cannabis and cannabinoids. 1999 , 83, 637-49	130
1975	Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. 1999 , 283, 401-4	1186
1974	Effects of cannabinoids on the immune system and central nervous system: therapeutic implications. 1999 , 12, 317-26	17
1973	Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors. 1999 , 1440, 266-74	83
1972	Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. 1999 , 276, 71-4	66
1971	Spinal cannabinoids are anti-allodynic in rats with persistent inflammation. 1999 , 82, 199-205	127
1970	Blockade of cannabinoid receptors by SR141716 selectively increases Fos expression in rat mesocorticolimbic areas via reduced dopamine D2 function. 1999 , 91, 607-20	78
1969	Finding of the endocannabinoid signalling system in Hydra, a very primitive organism: possible role in the feeding response. 1999 , 92, 377-87	135
1968	Cannabinoid CB1 receptors are localized primarily on cholecystokinin-containing GABAergic interneurons in the rat hippocampal formation. 1999 , 93, 969-75	277
1967	Cannabinoid receptors undergo axonal flow in sensory nerves. 1999 , 92, 1171-5	165
1966	Expression of cannabinoid receptors and their gene transcripts in human blood cells. 1999 , 23, 1063-77	34

1965	The effects of cannabinoids on the brain. 1999 , 58, 315-48	648
1964	Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opioid and CB1-cannabinoid receptors in the caudate-putamen. 1999 , 67, 148-57	54
1963	Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. 1999 , 353, 560	53
1962	Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments. 1999 , 40, 415-21	12
1961	Inhibition of luteinizing hormone secretion by delta9-tetrahydrocannabinol in the ovariectomized rat: effect of pretreatment with neurotransmitter or neuropeptide receptor antagonists. 1999 , 64, 664-71	9
1960	Extrapyramidal and neuroendocrine effects of AM404, an inhibitor of the carrier-mediated transport of anandamide. 1999 , 65, 327-36	46
1959	Discovery and characterization of endogenous cannabinoids. 1999 , 65, 573-95	146
1958	Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. 1999 , 65, 627-35	78
1957	Presence and functional regulation of cannabinoid receptors in immune cells. 1999 , 65, 637-44	60
1956	Cannabinoids as potential new analgesics. 1999 , 65, 675-85	55
1955	Anandamide stimulates phospholipase D activity in PC12 cells but not in NIH 3T3 fibroblasts. 1999 , 447, 209-12	12
1954	Stimulation of peripheral cannabinoid receptor CB2 induces MCP-1 and IL-8 gene expression in human promyelocytic cell line HL60. 1999 , 448, 273-7	43
1953	Structure-activity relationships of anandamide, an endogenous cannabinoid ligand. 1999 , 65, 607-16	45
1952	Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. 1999 , 96, 5780-5	862
1951	HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. 1999 , 96, 14228-33	476
1950	Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. 1999 , 1, E4	59
1949	Biosynthesis and inactivation of N-arachidonylethanolamine (anandamide) and N-docosahexaenylethanolamine in bovine retina. 1999 , 370, 300-7	109
1948	Non-methylene-interrupted polyunsaturated fatty acids: effective substitute for arachidonate of phosphatidylinositol. 1999 , 264, 683-8	31

1947	Recent advantages in cannabinoid research. 1999 , 6 Suppl 3, 16-20	14
1946	Role of cannabinoid receptor in the brain as it relates to drug reward. 2000 , 84, 229-36	28
1945	A role for the endogenous cannabinoid system in the peripheral control of pain initiation. 2000 , 129, 471-82	23
1944	Functional CB1 cannabinoid receptors in human vascular endothelial cells. 2000 , 346, 835	103
1943	The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. 2000 , 347, 369-73	130
1942	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. 2000 , 351, 817	108
1941	The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt. 2000 , 347, 369-373	197
1940	N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. 2000 , 351, 817-824	275
1939	A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen <i>Brucella suis</i> . 2000 , 67, 335-44	15
1938	Functional CB1 cannabinoid receptors in human vascular endothelial cells. 2000 , 346, 835-840	242
1937	Cannabinoid receptors on goldfish retinal bipolar cells: electron-microscope immunocytochemistry and whole-cell recordings. 2000 , 17, 391-401	64
1936	Expression of CB2 cannabinoid receptor mRNA in adult rat retina. 2000 , 17, 91-5	102
1935	Localisation of cannabinoid receptors in the rat brain using antibodies to the intracellular C-terminal tail of CB. 2000 , 422, 159-71	281
1934	Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. 2000 , 29, 58-69	201
1933	Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. 2000 , 38, 477-82	52
1932	Psychoactive cannabinoids and membrane signaling. 2000 , 15, 535-549	3
1931	Naturally occurring antinociceptive substances from plants. 2000 , 14, 401-18	244
1930	A historical overview of chemical research on cannabinoids. 2000 , 108, 1-13	167

1929	2-Arachidonoylglycerol and the cannabinoid receptors. 2000 , 108, 89-106	177
1928	The endocannabinoid system: a physiological perspective on its role in psychomotor control. 2000 , 108, 151-8	45
1927	Endocannabinoids as cardiovascular modulators. 2000 , 108, 159-68	124
1926	Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. 2000 , 108, 211-20	114
1925	Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors. 2000 , 12, 533-9	89
1924	Comparative biology of the endocannabinoid system possible role in the immune response. 2000 , 267, 4917-27	92
1923	Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. 2000 , 6, 313-9	534
1922	The serotonin transporter and clozapine response. 2000 , 5, 124-5	38
1921	No association between (AAT) _n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population. 2000 , 5, 128-30	57
1920	O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. 2000 , 129, 1577-84	43
1919	Central and peripheral cannabinoid modulation of gastrointestinal transit in physiological states or during the diarrhoea induced by croton oil. 2000 , 129, 1627-32	68
1918	Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. 2000 , 130, 1720-6	18
1917	Molecular probes for the cannabinoid receptors. 2000 , 108, 37-52	63
1916	Cannabinoid receptors and the regulation of immune response. 2000 , 108, 169-90	228
1915	The Synthesis of N-Vanillyl-arachidonoyl-amide (Arvanil) and its Analogs: An Improved Procedure for the Synthesis of the Key Synthone Methyl 14-Hydroxy-(all-cis)-5,8,11-tetradecatrienoate. 2000 , 56, 9195-9202	27
1914	Cannabis and cannabinoid receptors. 2000 , 71 Suppl 1, S6-12	28
1913	Receptors for abused drugs: development and plasticity. 2000 , 22, 773-84	2
1912	Cardiovascular effects of endocannabinoids--the plot thickens. 2000 , 61, 71-84	37

1911	The pharmacological basis of contemporary pain management. 2000 , 88, 163-85	65
1910	Anti-CD40, anti-CD3, and IL-2 stimulation induce contrasting changes in CB1 mRNA expression in mouse splenocytes. 2000 , 110, 161-7	31
1909	Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)-tetrahydrocannabinol-induced inhibition of natural killer activity. 2000 , 387, 343-7	52
1908	Dynorphin B and spinal analgesia: induction of antinociception by the cannabinoids CP55,940, Delta(9)-THC and anandamide. 2000 , 857, 337-42	60
1907	Role of the superior colliculus in the motor effects of cannabinoids and dopamine. 2000 , 853, 207-14	13
1906	Activational role of cannabinoids on movement. 2000 , 391, 269-74	154
1905	Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse. 2000 , 391, 151-61	25
1904	Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinol. 2000 , 395, 1-7	28
1903	Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. 2000 , 396, 141-9	418
1902	Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. 2000 , 396, 85-92	76
1901	Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. 2000 , 401, 17-25	49
1900	Inhibition of small intestinal secretion by cannabinoids is CB1 receptor-mediated in rats. 2000 , 409, 207-11	39
1899	Cannabinoid receptors and reward in the rat: a conditioned place preference study. 2000 , 151, 25-30	126
1898	A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. 2000 , 238, 334-8	30
1897	2-arachidonoylglycerol: an endogenous cannabinoid receptor agonist. 2001 , 88, 200-6	1
1896	Large-scale analysis of gene expression changes during acute and chronic exposure to [Delta]9-THC in rats. 2000 , 3, 175-85	51
1895	The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. 2000 , 58, 814-20	172
1894	Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. 2000 , 83, 1167-80	148

1893	Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. 2000 , 83, 3287-93	238
1892	When and where are N-acylethanolamine phospholipids and anandamide formed?. 2001 , 88, 223-7	3
1891	The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. 2000 , 97, 9561-6	456
1890	Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. 2000 , 275, 605-12	297
1889	Recent advances in cannabinoid receptor agonists and antagonists. 2000 , 10, 1529-1538	21
1888	Immunoactive cannabinoids: therapeutic prospects for marijuana constituents. 2000 , 97, 9363-4	21
1887	Cannabinoid CB1 receptor-mediated inhibition of prolactin release and signaling mechanisms in GH4C1 cells. 2000 , 141, 1675-85	20
1886	Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. 2000 , 141, 118-26	228
1885	[The importance of the endogenous cannabinoid system in various neuropsychiatric disorders]. 2000 , 68, 433-8	6
1884	Cellular and molecular mechanisms underlying learning and memory impairments produced by cannabinoids. 2000 , 7, 132-9	137
1883	Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. 2000 , 165, 373-80	187
1882	Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. 2000 , 275, 15621-8	84
1881	Naltrexone does not block the subjective effects of oral Delta(9)-tetrahydrocannabinol in humans. 2000 , 59, 251-60	52
1880	Time course for the induction and maintenance of tolerance to Delta(9)-tetrahydrocannabinol in mice. 2000 , 60, 113-9	80
1879	Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. 2000 , 60, 133-40	206
1878	The endocannabinoid system as a target for therapeutic drugs. 2000 , 21, 218-24	352
1877	Endocannabinoids and multiple sclerosis: a blessing from the 'inner bliss'?. 2000 , 21, 195-7	11
1876	New perspectives on enigmatic vanilloid receptors. 2000 , 23, 491-7	181

1875	Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. 2000 , 27, 757-62	36
1874	Role of the highly conserved Asp-Arg-Tyr motif in signal transduction of the CB2 cannabinoid receptor. 2000 , 466, 300-4	36
1873	Activation of rabbit blood platelets by anandamide through its cleavage into arachidonic acid. 2000 , 471, 12-6	29
1872	QSAR analysis of Delta(8)-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency. 2000 , 43, 59-70	26
1871	Natural and synthetic endocannabinoids and their structure-activity relationships. 2000 , 6, 1381-97	44
1870	A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors. 2000 , 43, 2300-9	33
1869	Cannabinoids modulate pain by multiple mechanisms of action. 2000 , 1, 2-14	68
1868	Cannabinoids: worthwhile analgesics?. 2000 , 1, 18-19	1
1867	Cannabinoids in clinical practice. 2000 , 60, 1303-14	181
1866	Novel cannabimol probes for CB1 and CB2 cannabinoid receptors. 2000 , 43, 3778-85	51
1865	Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. 2001 , 20, 7033-40	205
1864	Endogenous cannabinoids mediate hypotension after experimental myocardial infarction. 2001 , 38, 2048-54	128
1863	R(+)-methanandamide induces cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid receptor-mediated mechanism. 2001 , 286, 1144-52	37
1862	Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. 2001 , 44, 4505-8	62
1861	CB2 cannabinoid receptor-mediated peripheral antinociception. 2001 , 93, 239-245	305
1860	Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. 2001 , 93, 303-315	70
1859	Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. 2001 , 106, 1-4	369
1858	The proximal and distal C-terminal tail domains of the CB1 cannabinoid receptor mediate G protein coupling. 2001 , 107, 161-7	41

1857	The pharmacological activity of inhalation exposure to marijuana smoke in mice. 2001 , 63, 107-16	39
1856	The role of cannabinoids in neurodegenerative diseases. 2001 , 25, 743-65	57
1855	Cannabinoid receptors and pain. 2001 , 63, 569-611	581
1854	Ceramide: a new second messenger of cannabinoid action. 2001 , 22, 19-22	92
1853	Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. 2001 , 118, 61-5	230
1852	Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. 2001 , 1538, 252-9	30
1851	Endogenous cannabinoid as a retrograde messenger from depolarized postsynaptic neurons to presynaptic terminals. 2001 , 40, 205-10	109
1850	Evidence for an endocannabinoid system in the central nervous system of the leech <i>Hirudo medicinalis</i> . 2001 , 87, 145-59	54
1849	Recepteurs cannabinoïdes. 2001 , 14, 207-211	2
1848	Pharmacology and effects of cannabis: a brief review. 2001 , 178, 101-6	560
1847	Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. 2001 , 29, 729-38	672
1846	Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. 2001 , 31, 463-75	458
1845	Functional roles of the tyrosine within the NP(X)(n)Y motif and the cysteines in the C-terminal juxtamembrane region of the CB2 cannabinoid receptor. 2001 , 501, 166-70	19
1844	Differential membrane fluidization by active and inactive cannabinoid analogues. 2001 , 1512, 183-90	22
1843	CP55,940 increases intracellular Ca ²⁺ levels in Madin-Darby canine kidney cells. 2001 , 69, 1541-8	10
1842	The neurobiology and evolution of cannabinoid signalling. 2001 , 356, 381-408	288
1841	Biological activity of plant extracts: novel analgesic drugs. 2001 , 6, 261-79	33
1840	Endocannabinoids Part I: molecular basis of endocannabinoid formation, action and inactivation and development of selective inhibitors. 2001 , 5, 241-65	20

1839	Understanding the Pharmacology and Physiology of Cannabis Dependence. 2001 , 37-57	1
1838	Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. 2001 , 59, 1369-75	124
1837	Lipids in neural function: modulation of behavior by oral administration of endocannabinoids found in foods. 2001 , 5, 169-84; discussion 185-7	8
1836	Cannabinoids and pain. 2001 , 6, 74-9	32
1835	Cannabinoids and the immune system. 2001 , 6, 95-101	50
1834	The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. 2001 , 6, 67-73	43
1833	Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. 2001 , 86, 40-8	132
1832	The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. 2001 , 59, 955-9	88
1831	Airway effects of marijuana, cocaine, and other inhaled illicit agents. 2001 , 7, 43-61	88
1830	Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. 2001 , 360, 67-75	72
1829	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. 2001 , 358, 249-55	104
1828	Cannabinoid-receptor-independent cell signalling by N-acylethanolamines. 2001 , 360, 67-75	53
1827	Cannabinoids for pain and nausea. 2001 , 323, 2-3	15
1826	Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. 2001 , 358, 249-255	151
1825	Cannabinoid CB1-mediated inhibition of stress-induced gastric ulcers in rats. 2001 , 363, 241-4	38
1824	Synergistic effects of opioid and cannabinoid antagonists on food intake. 2001 , 153, 267-70	128
1823	Control of the cell survival/death decision by cannabinoids. 2001 , 78, 613-25	179
1822	[Tetrahydrocannabinol for treatment of chronic pain]. 2001 , 15, 200-4	6

1821	Cannabinoid receptor CB1-like and glutamic acid decarboxylase-like immunoreactivities in the brain of <i>Xenopus laevis</i> . 2001 , 306, 391-8	30
1820	Vanilloïdes, cannabinoïdes et nociception: aspects anatomiques. 2001 , 14, 181-192	
1819	Les r�cepteurs CB1 et leurs ligands. 2001 , 14, 233-242	
1818	Behavioral, pharmacological, and molecular characterization of an amphibian cannabinoid receptor. 2000 , 75, 413-23	72
1817	Selective cannabinoid CB1 receptor-mediated inhibition of inducible nitric oxide synthase protein expression in C6 rat glioma cells. 2001 , 78, 835-41	33
1816	delta(9)-Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3 cells. Involvement of CB1 cannabinoid receptor and Raf-1. 2001 , 268, 531-5	18
1815	Metabolic characterization of sciadonic acid (5c,11c,14c-eicosatrienoic acid) as an effective substitute for arachidonate of phosphatidylinositol. 2001 , 268, 4928-39	29
1814	CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells. 2001 , 65, 346-53	35
1813	Conformational analysis of N-arachidonylethanolamide (anandamide) using nuclear magnetic resonance and theoretical calculations. 2001 , 39, 432-437	16
1812	An ab initio theoretical study of the stereoisomers of tetrahydrocannabinols. 2001 , 15, 323-33	3
1811	Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. 2001 , 26, 1015-21	23
1810	Cannabinoids and neuroprotection. 2001 , 24, 29-51	73
1809	Portal hypertension and the hyperdynamic circulation: nitric oxide in a haze of cannabinoid smoke. 2001 , 34, 1060-1	4
1808	Separation of cannabinoid receptor affinity and efficacy in delta-8-tetrahydrocannabinol side-chain analogues. 2001 , 132, 525-35	8
1807	Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. 2001 , 132, 1281-91	33
1806	Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. 2001 , 132, 1743-54	38
1805	The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. 2001 , 133, 586-94	174
1804	Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. 2001 , 134, 563-70	188

1803	Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. 2001 , 134, 655-63	51
1802	Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranes. 2001 , 134, 664-72	122
1801	Derivatives of monoglycerides as apoptotic agents in T-cells. 2001 , 8, 1103-12	8
1800	The endocannabinoid nervous system: unique opportunities for therapeutic intervention. 2001 , 90, 45-60	194
1799	Behavioral suppression induced by cannabinoids is due to activation of the arachidonic acid cascade in rats. 2001 , 889, 149-54	22
1798	Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: interaction with the opioid system. 2001 , 413, 227-34	87
1797	Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. 2001 , 419, 191-8	188
1796	Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB(1) receptors. 2001 , 423, 203-10	126
1795	Differential expression of cannabinoid CB(2) receptor mRNA in mouse immune cell subpopulations and following B cell stimulation. 2001 , 423, 235-41	66
1794	Modulation of cytokine responses in <i>Corynebacterium parvum</i> -primed endotoxemic mice by centrally administered cannabinoid ligands. 2001 , 425, 73-83	29
1793	Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects. 2001 , 428, 51-7	171
1792	Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. 2001 , 429, 93-100	67
1791	The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. 2001 , 430, 49-58	66
1790	Rapid tolerance to Delta(9)-tetrahydrocannabinol and cross-tolerance between ethanol and Delta(9)-tetrahydrocannabinol in mice. 2001 , 431, 201-7	20
1789	Simultaneous determination of delta9-tetrahydrocannabinol and 11-nor-9-carboxy-delta9-tetrahydrocannabinol in human plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry. 2001 , 25, 531-7	48
1788	Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. 2001 , 276, 20523-8	141
1787	Progesterone receptor and dopamine receptors are required in Delta 9-tetrahydrocannabinol modulation of sexual receptivity in female rats. 2001 , 98, 1249-54	44
1786	Dual role of Fyn in the regulation of FAK+6,7 by cannabinoids in hippocampus. 2001 , 276, 38289-96	46

1785	Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. 2001 , 58, 322-8	371
1784	Endocannabinoids Part II: pathological CNS conditions involving the endocannabinoid system and their possible treatment with endocannabinoid-based drugs. 2001 , 5, 349-362	4
1783	Progesterone receptor and dopamine receptors are required in δ -tetrahydrocannabinol modulation of sexual receptivity in female rats. 2001 , 98, 1249-1254	73
1782	How might cannabinoids influence sexual behavior?. 2001 , 98, 793-5	10
1781	Neuroimmune Circuits, Drugs of Abuse, and Infectious Diseases. 2001 ,	2
1780	Evidence for a New G Protein-Coupled Cannabinoid Receptor in Mouse Brain. 2001 , 60, 155-163	493
1779	Attempts of ranking in a series of synthetic nonpsychotropic cannabinoids. 2001 , 12, 113-27	2
1778	Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. 2002 , 100, 627-34	217
1777	The endocannabinoid system protects rat glioma cells against HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. 2002 , 277, 50348-54	45
1776	Identification of the endogenous cannabinoid system through integrative pharmacological approaches. 2002 , 301, 790-6	24
1775	Recent advances in the cannabinoids. 2002 , 12, 1475-1489	22
1774	DNA microarray analysis of cannabinoid signaling in mouse brain in vivo. 2002 , 62, 828-35	24
1773	The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rap1/B-Raf/ERK pathway. 2002 , 277, 46645-50	183
1772	CB1 and CB2 receptor mRNA expression in human peripheral blood mononuclear cells (PBMC) from various donor types. 2001 , 493, 229-33	22
1771	The palmitoylethanolamide family: a new class of anti-inflammatory agents?. 2002 , 9, 663-74	249
1770	Pain and cannabinoids: science and evidence. 2002 , 9, 41-67	15
1769	Comparison of effects of anandamide at recombinant and endogenous rat vanilloid receptors. 2002 , 89, 882-7	32
1768	Downregulation of cannabinoid receptor 2 (CB2) messenger RNA expression during in vitro stimulation of murine splenocytes with lipopolysaccharide. 2001 , 493, 223-8	13

1767	Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. 2002 , 302, 451-65	119
1766	Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid. 2002 , 147, 255-61	39
1765	Cannabinoid-mediated inhibition of inducible nitric oxide production by rat microglial cells: evidence for CB1 receptor participation. 2001 , 493, 207-14	46
1764	Mechanism of extracellular signal-regulated kinase activation by the CB(1) cannabinoid receptor. 2002 , 62, 1385-92	156
1763	Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties. 2002 , 302, 359-68	86
1762	Decrease in efficacy and potency of nonsteroidal anti-inflammatory drugs by chronic delta(9)-tetrahydrocannabinol administration. 2002 , 303, 340-6	26
1761	Short-term effects of cannabinoids on immune phenotype and function in HIV-1-infected patients. 2002 , 42, 82S-89S	43
1760	Differing effects of the cannabinoid agonist, CP 55,940, in an alcohol or Tween 80 solvent, on prepulse inhibition of the acoustic startle reflex in the rat. 2002 , 13, 15-28	32
1759	Anandamide-induced neuroblastoma cell rounding via the CB1 cannabinoid receptors. 2002 , 13, 593-6	28
1758	Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. 2002 , 99, 2786-93	140
1757	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. 2002 , 363, 183-8	120
1756	De novo-synthesized ceramide is involved in cannabinoid-induced apoptosis. 2002 , 363, 183-188	125
1755	Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. 2002 , 50, 1109-13	53
1754	Cannabinoid receptor genetics and behavior. 2002 ,	
1753	Embryonic cannabinoid receptors are targets for natural and endocannabinoids during early pregnancy. 2002 ,	
1752	Cannabinoid receptors. 2002 ,	
1751	Cannabinoids and endocannabinoids. 2002 ,	1
1750	Marijuana and movement disorders. 2002 ,	

1749	Marijuana and cannabinoid effects on immunity and AIDS. 2002,	2
1748	Paradoxical pharmacological effects of deoxy-tetrahydrocannabinol analogs lacking high CB1 receptor affinity. 2002, 66, 89-99	14
1747	Cannabinoid receptors and their endogenous ligands. 2002, 132, 7-12	66
1746	Evolution of cannabinoid receptors in vertebrates: identification of a CB(2) gene in the puffer fish <i>Fugu rubripes</i> . 2002, 202, 104-7	25
1745	Respiratory and immunologic consequences of marijuana smoking. 2002, 42, 71S-81S	121
1744	Molecules in blastocyst implantation: uterine and embryonic perspectives. 2002, 64, 43-76	79
1743	N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. 2002, 62, 1274-87	162
1742	Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. 2002, 301, 679-89	51
1741	Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling. 2002, 45, 1748-56	44
1740	Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta. 2002, 290, 91-6	46
1739	The therapeutic potential of the cannabinoids in neuroprotection. 2002, 11, 1365-74	56
1738	Endocannabinoids as physiological regulators of colonic propulsion in mice. 2002, 123, 227-34	157
1737	Neuromodulatory role of the endocannabinoid signaling system in alcoholism: an overview. 2002, 66, 287-99	72
1736	Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716). 2002, 45, 2703-13	88
1735	Structure of the third intracellular loop of the human cannabinoid 1 receptor. 2002, 41, 11344-50	34
1734	Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway. 2002, 277, 36527-33	124
1733	Endocannabinoids and their actions. 2002, 65, 225-55	51
1732	CB1 cannabinoid receptor-mediated tyrosine phosphorylation of focal adhesion kinase-related non-kinase. 2002, 525, 164-8	14

1731	Absence of a conserved proline and presence of a conserved tyrosine in the CB2 cannabinoid receptor are crucial for its function. 2002 , 531, 290-4	13
1730	Endogenous cannabinoids: metabolism and their role in reproduction. 2002 , 70, 1963-77	47
1729	Functions of cannabinoid receptors in the hippocampus. 2002 , 42, 993-1007	144
1728	Observational analysis of feeding induced by Delta9-THC and anandamide. 2002 , 76, 241-50	159
1727	Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors. 2002 , 97, 11-21	104
1726	Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. 2002 , 66, 93-9	60
1725	Cannabinoid receptors and their ligands. 2002 , 66, 101-21	384
1724	Molecular biology of cannabinoid receptors. 2002 , 66, 123-42	81
1723	Endocannabinoid structure-activity relationships for interaction at the cannabinoid receptors. 2002 , 66, 143-60	29
1722	CB(1) and CB(2) receptor-mediated signalling: a focus on endocannabinoids. 2002 , 66, 161-71	103
1721	Endocannabinoids and the gut. 2002 , 66, 333-41	46
1720	The endocannabinoid system in invertebrates. 2002 , 66, 353-61	46
1719	The role of endocannabinoids in the hypothalamic regulation of visceral function. 2002 , 66, 301-7	41
1718	Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. 2002 , 66, 173-92	261
1717	Endocannabinoids in pain modulation. 2002 , 66, 235-42	55
1716	Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. 2002 , 66, 243-56	148
1715	Expression of CB2 cannabinoid receptor in <i>Pichia pastoris</i> . 2002 , 26, 496-505	33
1714	[The pharmacology of cannabinoid derivatives: are there applications to treatment of pain?]. 2002 , 21, 493-508	11

1713	Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation. 2002 , 2, 69-82	255
1712	Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. 2002 , 29, 671-7	26
1711	Pre- and postsynaptic localizations of the CB1 cannabinoid receptor in the dorsal horn of the rat spinal cord. 2002 , 110, 755-64	97
1710	Enantiomeric resolution of a novel chiral cannabinoid receptor ligand. 2002 , 54, 415-22	15
1709	A molecular basis of the therapeutic and psychoactive properties of cannabis (delta9-tetrahydrocannabinol). 2002 , 26, 721-30	10
1708	Endocannabinoids and cannabinoid receptor genetics. 2002 , 66, 307-44	91
1707	Endocannabinoid signaling in the brain. 2002 , 296, 678-82	993
1706	The cannabinoid CB1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar Purkinje cells. 2002 , 22, 1690-7	144
1705	Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/Akt signaling. 2002 , 22, 9742-53	336
1704	Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. 2002 , 22, 3864-72	251
1703	Cannabinoids depress inhibitory synaptic inputs received by layer 2/3 pyramidal neurons of the neocortex. 2002 , 88, 534-9	66
1702	Medical Efficacy of Cannabinoids and Marijuana: A Comprehensive Review of the Literature. 2002 , 18, 111-122	26
1701	Characterization of cannabinoid receptors. 2002 , Chapter 1, Unit 1.26	
1700	Cannabis for chronic pain: case series and implications for clinicians. 2002 , 7, 95-9	18
1699	Chronic treatment with the endocannabinoid anandamide increases cytochrome P450 metabolizing system in the rat. 2002 , 449, 61-9	4
1698	Effects of pharmacological manipulations of cannabinoid receptors on severity of dystonia in a genetic model of paroxysmal dyskinesia. 2002 , 454, 145-51	18
1697	Reversal of delta 9-THC hyperphagia by SR141716 and naloxone but not dexfenfluramine. 2002 , 71, 333-40	146
1696	Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. 2002 , 73, 911-9	87

1695	Acute or chronic effects of cannabinoids on spontaneous or pharmacologically induced yawning in rats. 2002 , 74, 205-12	7
1694	From cannabis to cannabinergics: new therapeutic opportunities. 2002 , 95, 103-17	77
1693	Putative neuroprotective actions of N-acyl-ethanolamines. 2002 , 95, 119-26	59
1692	Cannabinoid analgesia. 2002 , 95, 127-35	147
1691	Study of cannabinoid dependence in animals. 2002 , 95, 153-64	117
1690	Cannabinoids and multiple sclerosis. 2002 , 95, 165-74	140
1689	Cannabinoids and cell fate. 2002 , 95, 175-84	125
1688	Tetrahydrocannabinol and endocannabinoids in feeding and appetite. 2002 , 95, 185-90	141
1687	Cannabinoids in the treatment of glaucoma. 2002 , 95, 203-20	111
1686	Altered cannabinoid receptor mRNA expression in peripheral blood mononuclear cells from marijuana smokers. 2002 , 127, 169-76	48
1685	Delta 9-Tetrahydrocannabinol regulates Th1/Th2 cytokine balance in activated human T cells. 2002 , 133, 124-31	179
1684	Cloning and molecular characterization of the rat CB2 cannabinoid receptor. 2002 , 1576, 255-64	124
1683	A critical role for a tyrosine residue in the cannabinoid receptors for ligand recognition. 2002 , 63, 2121-36	58
1682	Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors. 2002 , 14, 941-53	165
1681	Retrograde signaling by endocannabinoids. 2002 , 12, 324-30	170
1680	Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. 2002 , 17, 1180-7	140
1679	Metabolic mapping of the time-dependent effects of delta 9-tetrahydrocannabinol administration in the rat. 2002 , 161, 129-36	40
1678	The cytoplasmic helix of cannabinoid receptor CB2, a conformational study by circular dichroism and (1)H NMR spectroscopy in aqueous and membrane-like environments. 2002 , 60, 169-77	20

1677	Activation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch. 2002 , 60, 357-70	73
1676	C-3 Amido-indole cannabinoid receptor modulators. 2002 , 12, 2399-402	33
1675	Novel 1',1'-chain substituted Delta(8)-tetrahydrocannabinols. 2002 , 12, 3583-6	43
1674	1-Methoxy-, 1-deoxy-11-hydroxy- and 11-hydroxy-1-methoxy-Delta(8)-tetrahydrocannabinols: new selective ligands for the CB2 receptor. 2002 , 10, 4119-29	37
1673	Effect on cancer cell proliferation of palmitoylethanolamide, a fatty acid amide interacting with both the cannabinoid and vanilloid signalling systems. 2002 , 16, 297-302	79
1672	Characterization of ligand binding to the cannabinoid receptor of rat brain membranes using a novel method: application to anandamide. 1995 , 64, 677-83	63
1671	Characterization of CB1 receptors on rat neuronal cell cultures: binding and functional studies using the selective receptor antagonist SR 141716A. 1997 , 68, 402-9	27
1670	Influence of cannabinoids on electrically evoked dopamine release and cyclic AMP generation in the rat striatum. 1997 , 69, 1131-7	89
1669	Ligand binding and modulation of cyclic AMP levels depend on the chemical nature of residue 192 of the human cannabinoid receptor 1. 1998 , 70, 366-73	56
1668	Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. 1998 , 70, 417-23	93
1667	Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. 1998 , 71, 1525-34	100
1666	Relationships between ligand affinities for the cerebellar cannabinoid receptor CB1 and the induction of GDP/GTP exchange. 1999 , 72, 2379-87	87
1665	Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. 1999 , 73, 2447-59	202
1664	Presence and regulation of the endocannabinoid system in human dendritic cells. 2002 , 269, 3771-8	133
1663	Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a helix 6 active conformation. 2002 , 88, 76-86	42
1662	Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilator responses in rat isolated hearts. 2002 , 135, 1191-8	85
1661	Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. 2002 , 135, 1598-606	57
1660	Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. 2002 , 136, 550-7	579

1659	Direct inhibition by cannabinoids of human 5-HT _{3A} receptors: probable involvement of an allosteric modulatory site. 2002 , 137, 589-96	165
1658	Cannabinergic ligands. 2002 , 121, 3-19	119
1657	Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes. 2002 , 121, 57-63	88
1656	Inhibition of pain responses by activation of CB ₂ cannabinoid receptors. 2002 , 121, 191-200	85
1655	Effects of delta-9-tetrahydrocannabinol on human immune function and host defense. 2002 , 121, 229-39	71
1654	The quest for a vascular endothelial cannabinoid receptor. 2002 , 121, 45-56	39
1653	Endocannabinoids and related fatty acid derivatives in pain modulation. 2002 , 121, 159-72	92
1652	Spinal and peripheral mechanisms of cannabinoid antinociception: behavioral, neurophysiological and neuroanatomical perspectives. 2002 , 121, 173-90	128
1651	Endocannabinoid signaling in synchronizing embryo development and uterine receptivity for implantation. 2002 , 121, 201-10	38
1650	N-Acylethanolamines in human reproductive fluids. 2002 , 121, 211-27	184
1649	Evidence that anandamide-signaling regulates human sperm functions required for fertilization. 2002 , 63, 376-87	113
1648	Cannabis and the brain. 2003 , 126, 1252-70	557
1647	Nitric oxide modulates the inhibitory effect of cannabinoids on the immunological activation of guinea pig mast cells. 2003 , 52 Suppl 1, S07-8	10
1646	Effect of maternal under-nutrition on pup body weight and hypothalamic endocannabinoid levels. 2003 , 60, 382-9	31
1645	Agonist-specific coupling of a cloned human alpha _{1A} -adrenoceptor to different second messenger pathways. 2003 , 367, 333-41	6
1644	Alcoholism-related phenotypes and genetic variants of the CB ₁ receptor. 2003 , 253, 275-80	34
1643	Expression of cannabinoid CB ₁ receptor mRNA in basal ganglia of normal and parkinsonian human brain. 2003 , 110, 1279-88	88
1642	[Therapeutic use of cannabinoids in neurology]. 2003 , 17, 367-73	8

1641	The therapeutic potential of cannabis. 2003 , 2, 291-8	253
1640	Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. 2003 , 24, 473-8	27
1639	The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. 2003 , 480, 133-50	205
1638	Effects of D3.49A, R3.50A, and A6.34E mutations on ligand binding and activation of the cannabinoid-2 (CB2) receptor. 2003 , 65, 1077-85	34
1637	Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. 2003 , 65, 1623-31	47
1636	Expression of the murine CB2 cannabinoid receptor using a recombinant Semliki Forest virus. 2003 , 65, 1931-42	10
1635	Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats. 2003 , 967, 290-2	52
1634	Neuroprotective and brain edema-reducing efficacy of the novel cannabinoid receptor agonist BAY 38-7271. 2003 , 989, 99-111	48
1633	Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. 2003 , 458, 207-15	53
1632	Differential distribution of functional cannabinoid CB1 receptors in the mouse gastrointestinal tract. 2003 , 459, 97-105	58
1631	R+-methanandamide inhibits tracheal response to endogenously released acetylcholine via capsaizepine-sensitive receptors. 2003 , 459, 75-81	7
1630	The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. 2003 , 459, 139-50	40
1629	Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. 2003 , 461, 27-34	100
1628	Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. 2003 , 464, 207-15	19
1627	Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. 2003 , 472, 1-21	44
1626	Antitussive effect of WIN 55212-2, a cannabinoid receptor agonist. 2003 , 474, 269-72	12
1625	Identification of the CB1 cannabinoid receptor and fatty acid amide hydrolase (FAAH) in the human placenta. 2003 , 24, 990-5	84
1624	No evidence for direct modulatory effects of delta 9-tetrahydrocannabinol on human polymorphonuclear leukocytes. 2003 , 141, 99-103	21

1623	Attenuation of the ovalbumin-induced allergic airway response by cannabinoid treatment in A/J mice. 2003 , 188, 24-35	47
1622	Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lipopolysaccharide. 2003 , 41, 161-8	240
1621	Endothelin-1 increases 2-arachidonoyl glycerol (2-AG) production in astrocytes. 2003 , 44, 85-90	69
1620	Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. 2003 , 104, 12-8	34
1619	Inhibitoren des Endocannabinoid-Abbaus: potenzielle Therapeutika neurologischer Störungen. 2003 , 115, 3044-3047	1
1618	Inhibitors of endocannabinoid degradation: potential therapeutics for neurological disorders. 2003 , 42, 2938-41	4
1617	Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction. 2003 , 71, 169-89	63
1616	Synthesis and testing of novel phenyl substituted side-chain analogues of classical cannabinoids. 2003 , 13, 3487-90	30
1615	Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. 2003 , 7, 469-75	266
1614	Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. 2003 , 17, 155-9	54
1613	'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. 2003 , 17, 1279-86	72
1612	Ontogenetic development of cannabinoid receptor expression and signal transduction functionality in the human brain. 2003 , 17, 1747-54	143
1611	Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. 2003 , 17, 2750-4	318
1610	3D structural model of the G-protein-coupled cannabinoid CB2 receptor. 2003 , 53, 307-19	99
1609	The molecular logic of endocannabinoid signalling. 2003 , 4, 873-84	1545
1608	Vasodilator actions of abnormal-cannabidiol in rat isolated small mesenteric artery. 2003 , 138, 1320-32	67
1607	Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. 2003 , 139, 775-86	178
1606	Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. 2003 , 140, 115-22	67

1605	Cannabinoid receptor activation in the rostral ventrolateral medulla oblongata evokes cardiorespiratory effects in anaesthetised rats. 2003 , 140, 384-94	52
1604	Inhibition of guinea-pig and human sensory nerve activity and the cough reflex in guinea-pigs by cannabinoid (CB2) receptor activation. 2003 , 140, 261-8	74
1603	Tetrahydrocannabinol-induced neurotoxicity depends on CB1 receptor-mediated c-Jun N-terminal kinase activation in cultured cortical neurons. 2003 , 140, 547-57	58
1602	Neurons on cannabinoids: dead or alive?. 2003 , 140, 439-40	21
1601	Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. 2003 , 140, 1351-62	90
1600	Endogenous cannabinoid system as a modulator of food intake. 2003 , 27, 289-301	233
1599	Cannabinoids: potential anticancer agents. 2003 , 3, 745-55	513
1598	Identification, characterization, and function of a novel oncogene: the peripheral cannabinoid receptor Cb2. 2003 , 996, 10-6	23
1597	Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. 2003 , 38, 403-12	39
1596	Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1 and CB2 cannabinoid receptors. 2003 , 11, 251-63	63
1595	Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors. 2003 , 11, 3121-32	27
1594	Synthesis and structure-activity relationships of a series of pyrrole cannabinoid receptor agonists. 2003 , 11, 3965-73	25
1593	The cannabinoid system and immune modulation. 2003 , 74, 486-96	378
1592	An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. 2003 , 125, 765-74	112
1591	Conformational study of lipophilic ligands in phospholipid model membrane systems by solution NMR. 2003 , 46, 4838-46	21
1590	Rational design and synthesis of an orally active indolopyridone as a novel conformationally constrained cannabinoid ligand possessing antiinflammatory properties. 2003 , 46, 2110-6	55
1589	Participation of the opioid system in cannabinoid-induced antinociception and emotional-like responses. 2003 , 13, 401-10	44
1588	Pharmacophoric requirements for the cannabinoid side chain. Probing the cannabinoid receptor subsite at C1'. 2003 , 46, 3221-9	46

1587	CB1- and CB2-cannabinoid receptor-independent lipolysis induced by WIN 55,212-2 in male rat adipocytes. 2003 , 368, 352-9	16
1586	Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. 2003 , 52, 238-45	107
1585	Topically administered CB(2)-receptor agonist, JWH-133, does not decrease intraocular pressure (IOP) in normotensive rabbits. 2003 , 72, 837-42	11
1584	Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. 2003 , 362, 1517-26	583
1583	The invertebrate ancestry of endocannabinoid signalling: an orthologue of vertebrate cannabinoid receptors in the urochordate <i>Ciona intestinalis</i> . 2003 , 302, 95-101	58
1582	Functional mapping of cannabinoid receptor homologs in mammals, other vertebrates, and invertebrates. 2003 , 312, 297-303	45
1581	Cannabinoid agonists attenuate capsaicin-induced responses in human skin. 2003 , 102, 283-288	82
1580	A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. 2003 , 103, 175-86	85
1579	Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. 2003 , 105, 275-83	139
1578	A peripheral cannabinoid mechanism suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. 2003 , 117, 659-70	91
1577	Preferential limbic expression of the cannabinoid receptor mRNA in the human fetal brain. 2003 , 118, 681-94	101
1576	Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. 2003 , 119, 747-57	143
1575	Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. 2003 , 119, 803-12	140
1574	Modulation of electrically evoked acetylcholine release through cannabinoid CB1 receptors: evidence for an endocannabinoid tone in the human neocortex. 2003 , 120, 455-65	37
1573	The neuronal distribution of cannabinoid receptor type 1 in the trigeminal ganglion of the rat. 2003 , 120, 155-62	112
1572	WIN 55,212-2 decreases the reinforcing actions of cocaine through CB1 cannabinoid receptor stimulation. 2003 , 141, 215-22	61
1571	n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. 2003 , 69, 51-9	116
1570	Treatment of marijuana dependence: a review of the literature. 2003 , 24, 369-76	101

1569	Anandamide and memory in CD1 mice: effects of immobilization stress and of prior experience. 2003 , 79, 204-11	12
1568	CB2 cannabinoid receptor agonists: pain relief without psychoactive effects?. 2003 , 3, 62-7	170
1567	Functional interactions between cannabinoid and metabotropic glutamate receptors in the central nervous system. 2003 , 3, 46-53	47
1566	Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. 2003 , 46, 1512-22	78
1565	Cannabinoids for the treatment of multiple sclerosis: no smoke without fire?. 2003 , 3, 327-34	3
1564	Cannabinoids for gastrointestinal diseases: potential therapeutic applications. 2003 , 12, 39-49	64
1563	Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. 2003 , 112, 415-422	221
1562	Therapeutic potential of cannabinoids in CNS disease. 2003 , 17, 179-202	170
1561	The role of several kinases in mice tolerant to delta 9-tetrahydrocannabinol. 2003 , 305, 593-9	27
1560	Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. 2003 , 111, 43-50	270
1559	Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. 2003 , 9, 679-89	308
1558	N-acylethanolamine signaling in tobacco is mediated by a membrane-associated, high-affinity binding protein. 2003 , 131, 1781-91	29
1557	Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor. 2003 , 306, 363-70	79
1556	The effect of anandamide on prolactin secretion is modulated by estrogen. 2003 , 100, 2134-9	31
1555	Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. 2003 , 100, 14914-9	133
1554	2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. 2003 , 278, 24469-75	99
1553	Microbial infections, immunomodulation, and drugs of abuse. 2003 , 16, 209-19	230
1552	Hypersensitization of the Orexin 1 receptor by the CB1 receptor: evidence for cross-talk blocked by the specific CB1 antagonist, SR141716. 2003 , 278, 23731-7	148

1551	Biphasic modulation of voltage-dependent currents of retinal cones by cannabinoid CB1 receptor agonist WIN 55212-2. 2003 , 20, 177-88	66
1550	G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca ²⁺ -dependent K ⁺ current. 2003 , 278, 46188-94	79
1549	Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. 2003 , 306, 1077-85	65
1548	Inhibition of tumor angiogenesis by cannabinoids. 2003 , 17, 529-31	198
1547	Cannabinoid receptor systems: therapeutic targets for tumour intervention. 2003 , 7, 749-58	10
1546	Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. 2003 , 170, 4953-62	115
1545	Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. 2003 , 9, 1607-33	74
1544	Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. 2003 , 100, 1393-8	281
1543	A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. 2003 , 278, 48973-80	75
1542	Role of endogenous cannabinoids in synaptic signaling. 2003 , 83, 1017-66	1254
1541	Cannabinoids and neuropathic pain. 2003 , 3, 765-72	23
1540	Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle. 2003 , 41, 657-64	170
1539	Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. 2003 , 99, 955-60	204
1538	The peripheral cannabinoid receptor Cb2, a novel oncoprotein, induces a reversible block in neutrophilic differentiation. 2003 , 101, 1336-43	33
1537	Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. 2003 , 15, 91-119	203
1536	Nonpsychotropic cannabinoid receptors regulate microglial cell migration. 2003 , 23, 1398-405	540
1535	Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. 2003 , 69, 158-63	7
1534	Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. 2003 , 23, 7767-75	210

1533	Therapeutic action of cannabinoids in a murine model of multiple sclerosis. 2003 , 23, 2511-6	257
1532	Cannabinoid Function in Spatial Learning: An Update. 2004 , 2, 125-143	11
1531	Cannabinoids as neuroprotective agents in traumatic brain injury. 2004 , 10, 2177-83	38
1530	Cannabinoids as Analgesic Agents: Evidence from In Vivo Studies. 2004 , 2, 75-89	18
1529	The cannabinoid system: from the point of view of a chemist. 2004 , 1-18	1
1528	Cannabinoid receptor expression in peripheral arterial chemoreceptors during postnatal development. 2004 , 97, 1486-95	12
1527	Possible hepatotoxicity of chronic marijuana usage. 2004 , 122, 110-6	29
1526	Search and Rescue: Identification of Cannabinoid Actions Relevant for Neuronal Survival and Protection. 2004 , 2, 103-114	3
1525	How cannabis works in the brain. 2004 , 19-40	2
1524	[Endocannabinoids in the central nervous system]. 2004 , 20, 45-53	4
1523	Cannabinoide - symptomatische Therapie der Multiplen Sklerose?. 2004 , 30, 389-392	
1522	Cannabinoid receptor agonists inhibit sensory nerve activation in guinea pig airways. 2004 , 170, 941-6	20
1521	Oxidative metabolism of endocannabinoids by COX-2. 2004 , 10, 659-67	117
1520	Endocannabinoids and their involvement in the neurovascular system. 2004 , 1, 129-40	14
1519	Functional Organization of Dorsal Horn Interneurons. 2004 , 271-560	3
1518	Single nucleotide polymorphism (SNP) analysis of mouse quantitative trait loci for identification of candidate genes. 2004 , 41, e111	6
1517	Cannabinoids induce cancer cell proliferation via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated transactivation of the epidermal growth factor receptor. 2004 , 64, 1943-50	223
1516	A cyclooxygenase metabolite of anandamide causes inhibition of interleukin-2 secretion in murine splenocytes. 2004 , 311, 683-90	74

1515	Molecular cues to implantation. 2004 , 25, 341-73	826
1514	Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. 2004 , 75, 884-92	29
1513	Augmentation of the development of behavioral tolerance to cannabinoid administration through pavlovian conditioning. 2004 , 49, 94-100	2
1512	Prescribing cannabis: freedom, autonomy, and values. 2004 , 30, 333-6	12
1511	2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. 2004 , 135, 517-24	70
1510	A role for caveolae/lipid rafts in the uptake and recycling of the endogenous cannabinoid anandamide. 2004 , 279, 41991-7	104
1509	Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system. 2004 , 101, 3264-8	30
1508	Recent advances in the cannabinoids. 2004 , 14, 1435-1452	36
1507	Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. 2004 , 308, 446-53	108
1506	Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. 2004 , 110, 1996-2002	255
1505	Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. 2004 , 75, 453-9	91
1504	2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. 2004 , 76, 1002-9	83
1503	Cannabinoid antagonist SR-141716 inhibits endotoxic hypotension by a cardiac mechanism not involving CB1 or CB2 receptors. 2004 , 287, H595-600	48
1502	Distinct expression profiles of the peripheral cannabinoid receptor in lymphoid tissues depending on receptor activation status. 2004 , 172, 2111-7	39
1501	Purification and mass spectroscopic analysis of human CB2 cannabinoid receptor expressed in the baculovirus system. 2004 , 64, 225-36	25
1500	Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain. 2004 , 20, 2311-20	138
1499	Are oral cannabinoids safe and effective in refractory neuropathic pain?. 2004 , 8, 173-7	54
1498	Aberrant cannabinoid signaling impairs oviductal transport of embryos. 2004 , 10, 1074-80	163

1497	The endocannabinoid system and its therapeutic exploitation. 2004 , 3, 771-84	730
1496	Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims. 2004 , 9, 184-90	169
1495	Cannabinoids and neuroinflammation. 2004 , 141, 775-85	232
1494	Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonoyl-2-chloroethylamide. 2004 , 141, 1118-30	121
1493	Cannabinoid receptor-independent actions of the aminoalkylindole WIN 55,212-2 on trigeminal sensory neurons. 2004 , 142, 257-66	32
1492	Involvement of cannabinoid receptors in gut motility and visceral perception. 2004 , 141, 1335-45	72
1491	Role of different brain structures in the behavioural expression of WIN 55,212-2 withdrawal in mice. 2004 , 142, 1309-17	23
1490	Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. 2004 , 142, 1247-54	106
1489	Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. 2004 , 142, 1354-60	96
1488	The cannabinomimetic arachidonoyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. 2004 , 142, 1361-7	39
1487	Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. 2004 , 142, 558, 647-57	89
1486	Very low doses of delta 8-THC increase food consumption and alter neurotransmitter levels following weight loss. 2004 , 77, 675-84	31
1485	The effect of SR 141716 and apomorphine on sensorimotor gating in Swiss mice. 2004 , 77, 839-45	23
1484	Anandamide transport. 2004 , 104, 117-35	88
1483	Arachidonoyl ethanolamide induces apoptosis of uterine cervix cancer cells via aberrantly expressed vanilloid receptor-1. 2004 , 93, 182-8	93
1482	Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. 2004 , 2, 34	15
1481	Potentialiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide. 2004 , 486, 53-9	18
1480	Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. 2004 , 489, 21-7	56

1479	The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat. 2004 , 493, 65-74	26
1478	Cannabinoid agonists induce contractile responses through Gi/o-dependent activation of phospholipase C in the bovine ciliary muscle. 2004 , 494, 55-62	35
1477	Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors. 2004 , 495, 43-53	21
1476	Endocannabinoids and food consumption: comparisons with benzodiazepine and opioid palatability-dependent appetite. 2004 , 500, 37-49	58
1475	Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors. 2004 , 505, 1-9	80
1474	Comparison of cannabinoid ligands affinities and efficacies in murine tissues and in transfected cells expressing human recombinant cannabinoid receptors. 2004 , 23, 233-43	81
1473	On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures. 2004 , 68, 1691-8	153
1472	Cannabinoids and the human uterus during pregnancy. 2004 , 190, 2-9; discussion 3A	64
1471	Cannabinoids in pain and inflammation. 2004 , 12, 99-114	28
1470	Inhibition by anandamide and synthetic cannabimimetics of the release of [3H]D-aspartate and [3H]GABA from synaptosomes isolated from the rat hippocampus. 2004 , 29, 1553-61	19
1469	Development of a 3D model for the human cannabinoid CB1 receptor. 2004 , 47, 3048-57	77
1468	Le nouveau paysage du cannabis I. Données récentes sur la neurobiologie des endocannabinoïdes et du cannabis. 2004 , 2, 14-23	
1467	Role of endocannabinoid system in mental diseases. 2004 , 6, 213-24	40
1466	Cannabinoids for the pharmaceutical industry. 2004 , 140, 83-93	19
1465	[Cannabinoids in multiple sclerosis. Opportunity or hazard?]. 2004 , 75, 1022-6	0
1464	Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. 2004 , 53, 723-8	98
1463	Anandamide inhibits the DOI-induced head-twitch response in mice. 2004 , 171, 382-9	22
1462	Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB1 receptor antagonist. 2004 , 177, 35-45	21

1461	Post-triptan era for the treatment of acute migraine. 2004 , 8, 393-8	16
1460	Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. 2004 , 79, 187-205	51
1459	Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study. 2004 , 53, 208-13	229
1458	Cannabinoid signaling in glial cells. 2004 , 48, 267-77	187
1457	The endogenous cannabinoid system and its role in nociceptive behavior. 2004 , 61, 149-60	159
1456	Synthesis and biological evaluation of 1,8-naphthyridin-4(1H)-on-3-carboxamide derivatives as new ligands of cannabinoid receptors. 2004 , 12, 1921-33	31
1455	The anandamide membrane transporter. Structure-activity relationships of anandamide and oleoylethanolamine analogs with phenyl rings in the polar head group region. 2004 , 12, 5161-9	18
1454	Theoretical analysis of the NMR and electronic structure of novel 8-THC derivatives. 2004 , 674, 131-138	2
1453	Cannabis-associated psychosis: current status of research. 2004 , 18, 895-910	47
1452	Endocannabinoids and exercise. 2004 , 38, 536-41	244
1451	Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. 2004 , 47, 627-43	167
1450	Cannabinoids in multiple sclerosis: do they have a therapeutic role?. 2004 , 64, 1-11	24
1449	Endocannabinoid receptor antagonists: potential for obesity treatment. 2004 , 3, 345-60	28
1448	Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. 2004 , 10, 417-24	167
1447	[Cannabis and cannabinoid receptors: from pathophysiology to therapeutic options]. 2004 , 160, 639-49	2
1446	R(+)-methanandamide-induced cyclooxygenase-2 expression in H4 human neuroglioma cells: possible involvement of membrane lipid rafts. 2004 , 324, 621-6	28
1445	Local application of the cannabinoid receptor agonist, WIN 55,212-2, to spinal trigeminal nucleus caudalis differentially affects nociceptive and non-nociceptive neurons. 2004 , 107, 267-275	22
1444	Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. 2004 , 109, 124-31	104

1443	Expression, purification, and isotope labeling of cannabinoid CB2 receptor fragment, CB2(180-233). 2004 , 38, 61-8	15
1442	Cannabis, cannabinoids and reproduction. 2004 , 70, 189-97	144
1441	Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. 2004 , 46, 716-26	41
1440	Cannabinoid signaling in rat cerebellar granule cells: G-protein activation, inhibition of glutamate release and endogenous cannabinoids. 2004 , 47, 81-91	40
1439	Hypothesis: cannabinoid therapy for the treatment of gliomas?. 2004 , 47, 315-23	64
1438	Role of cannabinoid receptors in inhibiting macrophage costimulatory activity. 2004 , 4, 265-78	40
1437	Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex--involvement of Na(+)/K(+)-ATPase. 2004 , 44, 529-38	68
1436	Cannabinoid receptor-independent suppression of the superoxide generation of human neutrophils (PMN) by CP55 940, but not by anandamide. 2004 , 75, 969-77	21
1435	Role of the endocannabinoid system in Alzheimer's disease: new perspectives. 2004 , 75, 1907-15	51
1434	The role of endogenous cannabinoids in the hypothalamo-pituitary-adrenal axis regulation: in vivo and in vitro studies in CB1 receptor knockout mice. 2004 , 75, 2959-70	103
1433	SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. 2004 , 310, 905-14	114
1432	Arachidonylethanolamide induces apoptosis of human glioma cells through vanilloid receptor-1. 2004 , 63, 956-63	51
1431	Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. 2004 , 92, 3562-74	96
1430	Anandamides and Diet. 2004 ,	
1429	The peripheral cannabinoid receptor Cb2, frequently expressed on AML blasts, either induces a neutrophilic differentiation block or confers abnormal migration properties in a ligand-dependent manner. 2004 , 104, 526-34	61
1428	Ceramide sensitizes astrocytes to oxidative stress: protective role of cannabinoids. 2004 , 380, 435-40	45
1427	New perspectives in the studies on endocannabinoid and cannabis: abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. 2004 , 96, 362-6	68
1426	New perspectives in the studies on endocannabinoid and cannabis: 2-arachidonoylglycerol as a possible novel mediator of inflammation. 2004 , 96, 367-75	38

1425	Biosynthesis and Degradation of Anandamide, An Endogenous Ligand of Cannabinoid Receptors. 179-187	1
1424	Experimental methods to study the role of the peripheral cannabinoid receptor in immune function. 2006 , 123, 19-40	3
1423	Cannabinoid receptors and their relationships with neuropsychiatric disorders. 2005 , 18, 15-9	23
1422	2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cells. 2005 , 386, 583-9	42
1421	The anandamide membrane transporter and the therapeutic implications of its inhibition. 2005 , 2, 141-150	21
1420	Is there a role for the endocannabinoid system in the etiology and treatment of melancholic depression?. 2005 , 16, 333-52	147
1419	Differential response to acute and repeated stress in cannabinoid CB1 receptor knockout newborn and adult mice. 2005 , 16, 431-40	60
1418	Molecular neurobiological methods in marijuana-cannabinoid research. 2006 , 123, 1-17	5
1417	Coronary vasodilator effects of endogenous cannabinoids in vasopressin-precontracted unpaced rat isolated hearts. 2005 , 46, 348-55	36
1416	Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. 2005 , 78, 231-8	94
1415	Peripheral Cannabinoid Analgesia: Neuronal and Immune Mechanisms. 2005 , 8, 103-116	1
1414	The role of the endocannabinoid system in the regulation of energy homeostasis. 2005 , 12, 338-351	25
1413	[Drug-craving animal models and mechanisms]. 2005 , 126, 24-9, 23	
1412	CB(1) cannabinoid receptor stimulation modulates transient receptor potential vanilloid receptor 1 activities in calcium influx and substance P Release in cultured rat dorsal root ganglion cells. 2005 , 97, 377-85	44
1411	The cannabinoid receptor agonist WIN 55212-2 inhibits neurogenic inflammations in airway tissues. 2005 , 98, 77-82	16
1410	Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3. 2005 , 16, 499-510	13
1409	Endocannabinoids in the regulation of appetite and body weight. 2005 , 16, 297-313	156
1408	A role for cannabinoid CB1 receptors in mood and anxiety disorders. 2005 , 16, 315-31	120

1407	Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. 2005 , 16, 275-96	40
1406	SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. 2005 , 16, 363-72	26
1405	Behavioral Effects of Endocannabinoids. 2005 ,	
1404	The Role of Endocannabinoids in the Development, Progression, and Treatment of Neurodegenerative Diseases. 2005 ,	
1403	Endocannabinoids in Inflammation and Immune Response. 2005 ,	3
1402	The Relationship between Endocannabinoid Conformation and Endocannabinoid Interaction at the Cannabinoid Receptors. 2005 ,	
1401	Endocannabinoids in Fertilization, Pregnancy, and Development. 2005 ,	
1400	Endocannabinoids and Intracellular Signaling. 2005 ,	
1399	Endocannabinoids as Retrograde Messengers in Synaptic Transmission. 2005 ,	
1398	Look Back in Ananda's 40 Years of Research on Cannabinoids. 2005 ,	
1397	Endocannabinoid Receptor Genetics and Marijuana Use. 2005 ,	
1396	Occurrence, Biosynthesis, and Metabolism of Endocannabinoids. 2005 ,	
1395	Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. 2005 , 105, 1214-21	56
1394	Biological Links between Cannabinoids and HIV Infection. 2005 , 13-32	1
1393	Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. 2005 , 29, 915-22	49
1392	Structure-activity relationships for 1-alkyl-3-(1-naphthoyl)indoles at the cannabinoid CB(1) and CB(2) receptors: steric and electronic effects of naphthoyl substituents. New highly selective CB(2) receptor agonists. 2005 , 13, 89-112	218
1391	Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptors. 2005 , 13, 3309-20	47
1390	Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities. 2005 , 13, 5463-74	26

1389	Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. 2005 , 15, 783-6	40
1388	Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor. 2005 , 15, 3758-62	33
1387	Novel 3,4-diarylpyrazolines as potent cannabinoid CB1 receptor antagonists with lower lipophilicity. 2005 , 15, 4794-8	52
1386	Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D activity. 2005 , 339, 113-20	45
1385	Design of on-target FAAH inhibitors. 2005 , 12, 1157-8	2
1384	Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. 2005 , 40, 75-83	72
1383	Expression of human peripheral cannabinoid receptor for structural studies. 2005 , 14, 2638-53	83
1382	Further advances in the synthesis of endocannabinoid-related ligands. 2005 , 7, E496-502	10
1381	Cannabinoid receptors and their role in neuroprotection. 2005 , 7, 37-50	143
1380	Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. 2005 , 48, 7166-71	57
1379	Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. 2005 , 93, 299-309	60
1378	Ras/ERK signalling in cannabinoid tolerance: from behaviour to cellular aspects. 2005 , 93, 984-91	52
1377	Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. 2005 , 95, 437-45	357
1376	Endocannabinoids and liver disease--review. 2005 , 25, 921-6	29
1375	Biosynthesis and purification of a hydrophobic peptide from transmembrane domains of G-protein-coupled CB2 receptor. 2005 , 65, 450-8	16
1374	Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. 2005 , 66, 138-50	23
1373	Effects of cannabinoid receptor activation on rabbit bisected vas deferens strips. 2005 , 32, 702-7	2
1372	Review article: endocannabinoids and their receptors in the enteric nervous system. 2005 , 22, 667-83	120

1371	Cannabinoid influence on cytokine profile in multiple sclerosis. 2005 , 140, 580-5	47
1370	Activation of cannabinoid CB2 receptor negatively regulates IL-12p40 production in murine macrophages: role of IL-10 and ERK1/2 kinase signaling. 2005 , 145, 441-8	101
1369	Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. 2005 , 145, 636-45	36
1368	Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. 2005 , 146, 467-76	136
1367	Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. 2005 , 146, 809-16	52
1366	Can we develop neurally acting drugs for the treatment of migraine?. 2005 , 4, 741-50	46
1365	Cannabinoid-based drugs as anti-inflammatory therapeutics. 2005 , 5, 400-11	549
1364	The endocannabinoid signalling system: Implications for anaesthesia and the pain clinic. 2005 , 16, 71-80	
1363	Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. 2005 , 17, 25-37	124
1362	WIN 55,212-2-induced reduction of cocaine hyperlocomotion: possible inhibition of 5-HT(3) receptor function. 2005 , 517, 68-73	34
1361	Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. 2005 , 520, 164-71	46
1360	A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. 2005 , 528, 65-72	83
1359	Cannabis and endocannabinoid modulators: Therapeutic promises and challenges. 2005 , 5, 185-199	37
1358	Developmental expression of cannabinoid receptors in the chick retinotectal system. 2005 , 156, 176-82	16
1357	Effects of cannabinoids on nitric oxide production by chondrocytes and proteoglycan degradation in cartilage. 2005 , 69, 635-40	26
1356	A spectrophotometric assay for fatty acid amide hydrolase suitable for high-throughput screening. 2005 , 69, 1187-93	17
1355	Differential CB1 and CB2 cannabinoid receptor-inotropic response of rat isolated atria: endogenous signal transduction pathways. 2005 , 69, 1705-13	46
1354	Central glucocorticoid receptors modulate the expression of spinal cannabinoid receptors induced by chronic morphine exposure. 2005 , 1059, 20-7	19

- 1353 [Cardiac and vascular effects of cannabinoids: toward a therapeutic use?]. **2005**, 54, 89-96 4
- 1352 The endocannabinoid system: a new approach to control cardiovascular disease. **2005**, 7, 17-26 6
- 1351 Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists. **2005**, 10, 693-702 147
- 1350 Inhibition of leukocyte function and interleukin-2 gene expression by 2-methylarachidonyl-(2'-fluoroethyl)amide, a stable congener of the endogenous cannabinoid receptor ligand anandamide. **2005**, 205, 107-15 14
- 1349 The endocannabinoid signaling system: pharmacological and therapeutic aspects. **2005**, 81, 248-62 63
- 1348 CB1 receptor antagonists for the treatment of nicotine addiction. **2005**, 81, 387-95 113
- 1347 The role of the cannabinoid system in nicotine addiction. **2005**, 81, 381-6 56
- 1346 The endocannabinoid signalling system: biochemical aspects. **2005**, 81, 224-38 166
- 1345 Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. **2005**, 81, 407-16 25
- 1344 Evidence for novel cannabinoid receptors. **2005**, 106, 133-45 303
- 1343 Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?. **2005**, 166, 3-18 192
- 1342 Arachidonic acid mediates non-capacitative calcium entry evoked by CB1-cannabinoid receptor activation in DDT1 MF-2 smooth muscle cells. **2005**, 205, 58-67 7
- 1341 Potential role of CB2 receptors in Cannabis smokers with chronic hepatitis C. **2005**, 42, 975-6; author reply 976-7 13
- 1340 Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. **2005**, 42, 959-961 8
- 1339 Reply:. **2005**, 42, 976-977 2
- 1338 Tritiation of the cannabinoid receptor antagonist SR144528 involving lithium aluminum tritide reduction; assessment of the kinetic isotope effect by ³H-NMR. **2005**, 48, 589-596 5
- 1337 The CB receptor agonist WIN 55,212-2 fails to elicit disruption of prepulse inhibition of the startle in Sprague-Dawley rats. **2005**, 177, 264-71 39
- 1336 CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. **2005**, 179, 498-508 57

1335	Regulation of food intake by oleoylethanolamide. 2005 , 62, 708-16	141
1334	Molecular complexity in establishing uterine receptivity and implantation. 2005 , 62, 1964-73	69
1333	Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. 2005 , 15, 4417-20	24
1332	[Cannabinoids--signal transduction and mode of action]. 2005 , 19, 528-34	5
1331	Cannabinoids in Models of Chronic Inflammatory Conditions. 2005 , 4, 11-18	7
1330	Harm reduction--the cannabis paradox. 2005 , 2, 17	11
1329	Dose and behavioral context dependent inhibition of movement and basal ganglia neural activity by Delta-9-tetrahydrocannabinol during spontaneous and treadmill locomotion tasks in rats. 2005 , 55, 1-16	19
1328	Endogenous cannabinoids as local message in and between the nervous and immune system. 2005 , 5, 19-27	2
1327	Preclinical science regarding cannabinoids as analgesics: an overview. 2005 , 10 Suppl A, 7A-14A	12
1326	Control of Synaptic Transmission in the CNS Through Endocannabinoid-Mediated Retrograde Signaling. 2005 , 269-281	
1325	Localization of cannabinoid receptors using immunoperoxidase methods. 2006 , 123, 41-69	1
1324	The endocannabinoid system in chronic liver disease. 2005 , 4, 248-254	15
1323	Cannabinoids and Susceptibility to Neurological Infection by Free-Living Amebae. 2005 , 51-65	
1322	Prevention of preterm labour. 2005 , 153-170	
1321	CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. 2005 , 46, 1988-92	40
1320	[Brain effects of cannabis--neuroimaging findings]. 2005 , 27, 70-8	11
1319	The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation. 2005 , 5, 671-5	30
1318	Pharmacological properties and therapeutic possibilities for drugs acting upon endocannabinoid receptors. 2005 , 4, 685-96	14

1317	Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. 2005 , 289, H533-41	68
1316	Regulation of gonadotropin-releasing hormone secretion by cannabinoids. 2005 , 146, 4491-9	83
1315	Participation of the cannabinoid system in the regulation of emotional-like behaviour. 2005 , 11, 3421-9	36
1314	Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. 2005 , 11, 2647-68	20
1313	The endocannabinoid arachidonyl ethanolamide (anandamide) increases pulmonary arterial pressure via cyclooxygenase-2 products in isolated rabbit lungs. 2005 , 289, H2491-6	46
1312	Ethanol induces higher BEC in CB1 cannabinoid receptor knockout mice while decreasing ethanol preference. 2005 , 40, 54-62	35
1311	Role of endogenous cannabinoids in cognition and emotionality. 2005 , 5, 659-70	67
1310	CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches. 2005 , 5, 651-8	10
1309	CB1 cannabinoid receptor ligands. 2005 , 5, 631-40	64
1308	Therapeutic perspectives of inhibitors of endocannabinoid degradation. 2005 , 4, 697-707	14
1307	Sensory-Motor Integration in the Medial Medulla. 2005 , 3, 115-143	4
1306	Cannabinoids and Herpesviruses. 2005 , 33-49	
1305	Review: The endocannabinoid system: a new therapeutic target for cardiovascular risk factor management. 2005 , 5, 121-124	8
1304	N-acylphosphatidylethanolamine-hydrolyzing phospholipase D is an important determinant of uterine anandamide levels during implantation. 2005 , 280, 23429-32	93
1303	Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. 2005 , 280, 18488-97	72
1302	Cannabinoid receptor binding to membrane homogenates and cannabinoid-stimulated [35S]GTPgammaS binding to membrane homogenates or intact cultured cells. 2006 , 123, 149-62	6
1301	Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. 2005 , 78, 1192-7	145
1300	Rapid, nongenomic responses to ecdysteroids and catecholamines mediated by a novel <i>Drosophila</i> G-protein-coupled receptor. 2005 , 25, 6145-55	183

1299	[Cannabinoids in multiple sclerosis -- therapeutically reasonable?]. 2005 , 73, 463-9	1
1298	Cannabinoide bei multipler Sklerose?. 2005 , 32, 208-216	
1297	Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. 2005 , 312, 875-83	247
1296	Identification of a high-affinity binding site involved in the transport of endocannabinoids. 2005 , 102, 17852-7	145
1295	Cannabinoid receptor type 2 gene is associated with human osteoporosis. 2005 , 14, 3389-96	168
1294	A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. 2005 , 25, 2530-6	121
1293	NMR structural comparison of the cytoplasmic juxtamembrane domains of G-protein-coupled CB1 and CB2 receptors in membrane mimetic dodecylphosphocholine micelles. 2005 , 280, 3605-12	26
1292	Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. 2005 , 174, 3281-9	179
1291	Glycine receptors in CNS neurons as a target for nonretrograde action of cannabinoids. 2005 , 25, 7499-506	86
1290	Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. 2005 , 68, 69-83	40
1289	The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. 2005 , 314, 868-75	64
1288	The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. 2005 , 54, 1741-50	70
1287	Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors. 2005 , 315, 828-38	112
1286	2-Arachidonoyl-glycerol suppresses interferon-gamma production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2. 2005 , 77, 966-74	20
1285	VR1-mediated depressor effects during high-salt intake: role of anandamide. 2005 , 46, 986-91	42
1284	In vitro metabolism of diarylpyrazoles, a novel group of cannabinoid receptor ligands. 2005 , 33, 508-17	10
1283	Endocannabinoid receptor antagonists and other emerging pharma-cological strategies for weight reduction. 2005 , 5, 549-56	7
1282	CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. 2005 , 102, 3093-8	419

1281	From cannabis to endocannabinoids in multiple sclerosis: a paradigm of central nervous system autoimmune diseases. 2005 , 4, 667-75	11
1280	Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. 2005 , 137, 217-23	63
1279	Infectious Diseases and Substance Abuse. 2005 ,	1
1278	Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. 2005 , 365, 1389-97	1252
1277	Structural requirements for cannabinoid receptor probes. 2005 , 209-46	40
1276	Enantiomeric cannabidiol derivatives: synthesis and binding to cannabinoid receptors. 2005 , 3, 1116-23	60
1275	The spinal basis of opioid tolerance and physical dependence: Involvement of calcitonin gene-related peptide, substance P, and arachidonic acid-derived metabolites. 2005 , 26, 1346-55	36
1274	The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. 2005 , 48, 5059-87	277
1273	Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. 2005 , 129, 437-53	216
1272	The endocannabinoid system and the treatment of obesity. 2005 , 37, 270-5	75
1271	Cannabinoids as Therapeutics. 2005 ,	13
1270	The development of Sativex [®] as natural cannabis-based medicine. 2005 , 231-263	16
1269	The use of cannabinoids in multiple sclerosis. 2005 , 14, 859-69	3
1268	2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. 2005 , 18, 25-31	30
1267	The endocannabinoid system: physiology and pharmacology. 2005 , 40, 2-14	229
1266	Cannabinoid receptor as a novel target for the treatment of prostate cancer. 2005 , 65, 1635-41	181
1265	High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. 2005 , 48, 6423-9	36
1264	Design, synthesis, and binding studies of new potent ligands of cannabinoid receptors. 2005 , 48, 7343-50	41

1263	Adamantyl cannabinoids: a novel class of cannabinergic ligands. 2005 , 48, 4576-85	59
1262	Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide 2005 , 48, 7351-62	36
1261	Hormonal regulation of food intake. 2005 , 85, 1131-58	267
1260	Different pharmacological profile of two closely related endocannabinoid ester analogs. 2005 , 77, 1425-40	4
1259	Role of lipids and lipid signaling in the development of cannabinoid tolerance. 2005 , 77, 1543-58	18
1258	Lipid rafts: a nexus for endocannabinoid signaling?. 2005 , 77, 1640-50	18
1257	The search for the palmitoylethanolamide receptor. 2005 , 77, 1685-98	188
1256	Cannabinoids and ceramide: two lipids acting hand-by-hand. 2005 , 77, 1723-31	59
1255	Recent developments in cannabinoid ligands. 2005 , 77, 1767-98	31
1254	Endocannabinoid lipids and mediated system: implications for alcoholism and neuropsychiatric disorders. 2005 , 77, 1569-83	27
1253	Natural cannabinoids: templates for drug discovery. 2005 , 78, 454-66	46
1252	Cannabinoid receptor I activation markedly inhibits human decidualization. 2005 , 229, 65-74	39
1251	Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. 2005 , 28, 189-94	62
1250	The conformation of the cytoplasmic helix 8 of the CB1 cannabinoid receptor using NMR and circular dichroism. 2005 , 1668, 1-9	41
1249	Structural and functional differences between cyclooxygenases: fatty acid oxygenases with a critical role in cell signaling. 2005 , 338, 34-44	42
1248	Effects of the endocannabinoid noladin ether on body weight, food consumption, locomotor activity, and cognitive index in mice. 2005 , 65, 117-23	31
1247	Identification and characterisation of a novel splice variant of the human CB1 receptor. 2005 , 579, 259-64	99
1246	p38 MAPK is involved in CB2 receptor-induced apoptosis of human leukaemia cells. 2005 , 579, 5084-8	61

1245	Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. 2005 , 118, 327-335	78
1244	Expression and characterization of human CB1 cannabinoid receptor in methylotrophic yeast <i>Pichia pastoris</i> . 2005 , 40, 60-70	27
1243	Emerging properties of cannabinoid medicines in management of multiple sclerosis. 2005 , 28, 272-6	66
1242	Endocannabinoids control the induction of cerebellar LTD. 2005 , 48, 647-59	227
1241	Blood pressure regulation by endocannabinoids and their receptors. 2005 , 48, 1130-8	66
1240	Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. 2005 , 48, 658-72	226
1239	Cannabinoids augment the release of neuropeptide Y in the rat hypothalamus. 2005 , 49, 646-52	89
1238	[The cannabinoid system and its importance in the perinatal period]. 2005 , 63, 433-40	2
1237	The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. 2005 , 7, E625-54	166
1236	Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. 2005 , 65, 2557-67	67
1235	Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. 2005 , 138, 80-7	17
1234	Differential Expression of Cannabinoid Receptors in the Human Colon: Cannabinoids Promote Epithelial Wound Healing. 2005 , 129, 437-453	224
1233	Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. 2005 , 38, 177-88	215
1232	Effects on cell viability. 2005 , 627-42	28
1231	Cannabinoid receptor signaling. 2005 , 53-79	293
1230	Effects on the immune system. 2005 , 385-423	70
1229	The phylogenetic distribution and evolutionary origins of endocannabinoid signalling. 2005 , 283-97	55
1228	Molecular biology of cannabinoid receptors. 2005 , 81-115	35

1227	Cannabinoid Receptors and Their Ligands: Ligand-Ligand and Ligand-Receptor Modeling Approaches. 2005 , 247-281	15
1226	Cardiovascular pharmacology of cannabinoids. 2005 , 599-625	85
1225	Cannabinoid mechanisms of pain suppression. 2005 , 509-54	124
1224	Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists. 2005 , 48, 1823-38	151
1223	Substituted 5,5'-diphenyl-2-thioxoimidazolidin-4-one as CB1 cannabinoid receptor ligands: synthesis and pharmacological evaluation. 2005 , 48, 2509-17	50
1222	Cannabinoids. 2005 ,	22
1221	Marijuana and Cannabinoid Research. 2005 ,	
1220	Arthritis and pain. Neurogenic origin of joint pain. 2006 , 8, 220	161
1219	Oxaza adamantyl cannabinoids. A new class of cannabinoid receptor probes. 2006 , 71, 7800-4	21
1218	New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity. 2006 , 49, 1113-7	55
1217	Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. 2006 , 15, 307-15	53
1216	Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists. 2006 , 49, 872-82	41
1215	Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice. 2006 , 177, 8796-805	87
1214	Biosynthesis of Terpenophenolic Metabolites in Hop and Cannabis. 2006 , 40, 179-210	10
1213	Cell Communication in Nervous and Immune System. 2006 ,	2
1212	Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists. 2006 , 49, 2022-7	50
1211	Inhibition of potassium- and ischemia-evoked [3H] D-aspartate release from isolated bovine retina by cannabinoids. 2006 , 31, 645-53	22
1210	Targeting the CB2 receptor for immune modulation. 2006 , 10, 653-63	45

1209	Cannabinoid receptors as therapeutic targets. 2006 , 46, 101-22	395
1208	Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. 2006 , 50, 814-23	67
1207	Endocannabinoid-mediated synaptic plasticity in the CNS. 2006 , 29, 37-76	620
1206	Plant, synthetic, and endogenous cannabinoids in medicine. 2006 , 57, 553-74	142
1205	Cannabinoids. 2006 , 289-337	1
1204	Endocannabinoid mechanisms of pain modulation. 2006 , 8, E693-708	169
1203	The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. 2006 , 312, 2121-31	65
1202	Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. 2006 , 40, 251-60	59
1201	Activation of G-proteins in brain by endogenous and exogenous cannabinoids. 2006 , 8, E112-7	48
1200	Endogenous cannabinoid signaling through the CB1 receptor is essential for cerebellum-dependent discrete motor learning. 2006 , 26, 8829-37	104
1199	The pharmacology of cannabinoid receptors and their ligands: an overview. 2006 , 30 Suppl 1, S13-8	375
1198	Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. 2006 , 47, 1919-26	100
1197	Endocannabinoids and their receptors as targets for treating metabolic and psychiatric disorders. 2006 , 3, 561-567	1
1196	CB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disorders. 2006 , 49, 4008-16	49
1195	WIN55212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction. 2006 , 46, 1286-300	27
1194	Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. 2006 , 54, 231-46	123
1193	3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. 2006 , 49, 625-36	55
1192	Synthesis of cannabidiols via alkenylation of cyclohexenyl monoacetate. 2006 , 8, 2699-702	34

1191	First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. 2006 , 580, 568-74	23
1190	Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. 2006 , 580, 613-9	78
1189	The effects of charge-neutralizing mutation D6.30N on the functions of CB1 and CB2 cannabinoid receptors. 2006 , 580, 5392-8	13
1188	Effects of delta-9-tetrahydrocannabinol, the primary psychoactive cannabinoid in marijuana, on human sperm function in vitro. 2006 , 85, 653-60	76
1187	Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. 2006 , 3, 167-75	523
1186	Identification of N-arachidonylglycine as the endogenous ligand for orphan G-protein-coupled receptor GPR18. 2006 , 347, 827-32	206
1185	[Maternal cannabis use and intra-uterine growth restriction]. 2006 , 34, 632-7	9
1184	Lipid signaling and synaptic plasticity. 2006 , 12, 425-34	69
1183	Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling. 2006 , 49, 70-9	71
1182	The endocannabinoid system as an emerging target of pharmacotherapy. 2006 , 58, 389-462	1993
1181	Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists. 2006 , 49, 5947-57	51
1180	Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. 2006 , 49, 7502-12	62
1179	Cannabinoid signalling. 2006 , 78, 549-63	304
1178	Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. 2006 , 43, 2169-79	95
1177	Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia. 2006 , 49, 508-18	25
1176	Effect of chronic ethanol exposure and its withdrawal on the endocannabinoid system. 2006 , 49, 619-25	84
1175	Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. 2006 , 396, 113-6	155
1174	Differential effects of cannabis extracts and pure plant cannabinoids on hippocampal neurones and glia. 2006 , 408, 236-41	26

1173	Neuropsychology and neuropharmacology of P3a and P3b. 2006 , 60, 172-85	507
1172	Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. 2006 , 121, 85-93	71
1171	CB2 cannabinoid receptor mediation of antinociception. 2006 , 122, 36-42	138
1170	Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. 2006 , 124, 175-83	82
1169	Site-specific increases in peripheral cannabinoid receptors and their endogenous ligands in a model of neuropathic pain. 2006 , 126, 102-14	152
1168	Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. 2006 , 45, 405-46	276
1167	The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. 2006 , 49, 67-79	345
1166	Seeking a mechanism of action for the novel anticonvulsant lacosamide. 2006 , 50, 1016-29	101
1165	The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. 2006 , 139, 795-802	116
1164	Characterization of CB1 cannabinoid receptor immunoreactivity in postmortem human brain homogenates. 2006 , 140, 635-43	49
1163	The cannabinoid receptor agonist, WIN 55,212-2, inhibits cool-specific lamina I medullary dorsal horn neurons. 2006 , 143, 265-72	4
1162	A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. 2006 , 27, 134-40	85
1161	Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility. 2006 , 47, 1999-2005	26
1160	Cell-cell communication by endocannabinoids during immune surveillance of the central nervous system. 2006 , 43, 281-305	7
1159	[Endogenous cannabinoid receptor ligands--anandamide and 2-arachidonoylglycerol]. 2006 , 126, 67-81	2
1158	Cannabis use improves retention and virological outcomes in patients treated for hepatitis C. 2006 , 18, 1057-63	43
1157	Endocannabinoids in appetite control and the treatment of obesity. 2006 , 5, 272-92	44
1156	Towards a therapeutic use of selective CB2 cannabinoid receptor ligands for atherosclerosis. 2006 , 2, 49-53	8

1155	2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. 2006 , 47, 650-5	42
1154	Cannabinoid receptors in atherosclerosis. 2006 , 17, 519-26	23
1153	Cannabinoids biology: the search for new therapeutic targets. 2006 , 6, 149-61	38
1152	Effects of castration on cannabinoid cb receptor expression and on the biological actions of cannabinoid in the parotid gland. 2006 , 33, 258-63	20
1151	CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. 2006 , 23, 1530-8	222
1150	Cannabinoids attenuate norepinephrine-induced melatonin biosynthesis in the rat pineal gland by reducing arylalkylamine N-acetyltransferase activity without involvement of cannabinoid receptors. 2006 , 98, 267-78	18
1149	The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. 2007 , 101, 87-98	150
1148	The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide. 2006 , 20, 549-62	52
1147	20 th es Journ ^{és} FrancoBelges de Pharmacochimie, Lille 1 ^{er} Juin 2006 [Reports Abstracts. 2006 , 20, 621-627	
1146	The Pharmacology of SR 141716A: A Review. 2006 , 5, 43-58	16
1145	Hu 210: a potent tool for investigations of the cannabinoid system. 2001 , 7, 131-45	37
1144	BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury. 2003 , 9, 343-58	25
1143	Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). 2006 , 12, 21-38	278
1142	The endocannabinoid system: current pharmacological research and therapeutic possibilities. 2006 , 98, 124-34	42
1141	Addictive drugs and their relationship with infectious diseases. 2006 , 47, 330-42	98
1140	Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists. 2006 , 68, 334-40	5
1139	2-arachidonoylglycerol: a possible multifunctional lipid mediator in the nervous and immune systems. 2000 , 905, 344-6	7
1138	Delta-9-tetrahydrocannabinol, the major psychoactive component in marijuana, inhibits macrophage chemotaxis to Acanthamoeba. 2006 , 53 Suppl 1, S15-7	4

1137	Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats. 2006 , 18, 949-56	90
1136	Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. 2006 , 18, 831-8	95
1135	The obesity pipeline: current strategies in the development of anti-obesity drugs. 2006 , 5, 919-31	164
1134	The neurobiology of itch. 2006 , 7, 535-47	676
1133	Cannabinoids and cancer: pros and cons of an antitumour strategy. 2006 , 148, 123-35	101
1132	Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. 2006 , 148, 102-13	143
1131	In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?. 2006 , 149, 145-54	92
1130	Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors. 2006 , 149, 898-908	63
1129	Analysis of the effects of cannabinoids on identified synaptic connections in the caudate-putamen by paired recordings in transgenic mice. 2006 , 575, 789-806	48
1128	Nuclear magnetic resonance for studying recognition processes between anandamide and cannabinoid receptors. 2006 , 41, 1117-23	5
1127	SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. 2006 , 39, 125-34	37
1126	Enantioselective synthesis of 1-methoxy- and 1-deoxy-2'-methyl-delta8-tetrahydrocannabinols: new selective ligands for the CB2 receptor. 2006 , 14, 247-62	17
1125	Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor. 2006 , 14, 2386-97	19
1124	Targeting the endocannabinoid system in treating brain disorders. 2006 , 15, 351-65	40
1123	3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data. 2006 , 49, 554-66	22
1122	Participation of the endocannabinoid system in the effect of TNF-alpha on hypothalamic release of gonadotropin-releasing hormone. 2006 , 1088, 238-50	21
1121	The endocannabinoid system as a target for the treatment of visceral obesity and metabolic syndrome. 2006 , 1083, 270-305	24
1120	Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. 2006 , 1074, 514-36	386

1119	Hypothalamic regulatory pathways and potential obesity treatment targets. 2006 , 29, 33-48	8
1118	Cannabinoids in medicine: A review of their therapeutic potential. 2006 , 105, 1-25	332
1117	R(+)-methanandamide elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in human neuroglioma cells. 2006 , 23, 90-4	13
1116	Implication of cannabinoids in neurological diseases. 2006 , 26, 579-91	11
1115	Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. 2006 , 26, 407-23	39
1114	Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. 2006 , 283, 75-83	45
1113	[Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain--a randomized controlled trial]. 2006 , 118, 327-35	58
1112	Short-term ischemia usually used for ischemic preconditioning down-regulates central cannabinoid receptors in the gerbil hippocampus. 2006 , 111, 8-14	16
1111	Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. 2006 , 126, 177-87	123
1110	The agonists for nociceptors are ubiquitous, but the modulators are specific: P2X receptors in the sensory neurons are modulated by cannabinoids. 2006 , 453, 353-60	17
1109	[Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. 2006 , 57, 801-7	86
1108	The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats. 2006 , 184, 26-35	56
1107	The acute effects of cannabinoids on memory in humans: a review. 2006 , 188, 425-44	361
1106	Identification of in vitro metabolites of JWH-015, an aminoalkylindole agonist for the peripheral cannabinoid receptor (CB2) by HPLC-MS/MS. 2006 , 386, 1345-55	64
1105	Cannabinoid-induced immune suppression and modulation of antigen-presenting cells. 2006 , 1, 50-64	128
1104	Drugs of abuse, immune modulation, and AIDS. 2006 , 1, 280-95	92
1103	Cannabinoid receptors and endocannabinoids: evidence for new players. 2006 , 8, E298-306	164
1102	Endocannabinoid signaling directs periimplantation events. 2006 , 8, E425-32	32

1101	The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. 2006 , 9, 301-12	245
1100	Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. 2006 , 39, 155-62	220
1099	Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. 2006 , 538, 154-62	23
1098	The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. 2006 , 542, 179-83	30
1097	Effect of anandamide on nonadrenergic noncholinergic-mediated relaxation of rat corpus cavernosum. 2006 , 544, 138-45	21
1096	Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model. 2006 , 547, 65-74	52
1095	Synergistic antinociceptive effects of anandamide, an endocannabinoid, and nonsteroidal anti-inflammatory drugs in peripheral tissue: a role for endogenous fatty-acid ethanolamides?. 2006 , 550, 68-77	40
1094	R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor. 2006 , 72, 1697-706	50
1093	Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. 2006 , 1071, 10-23	618
1092	Therapeutic action of cannabinoid on axonal injury induced by peroxynitrite. 2006 , 1076, 238-42	1
1091	Cannabinoid system in the budgerigar brain. 2006 , 1087, 105-13	11
1090	Cannabinoids, opioids and eating behavior: the molecular face of hedonism?. 2006 , 51, 85-107	261
1089	The endocannabinoid system: body weight and metabolic regulation. 2006 , 8 Suppl 4, S24-35	19
1088	In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. 2006 , 181, 57-67	55
1087	Lipopolysaccharide and cyclic AMP regulation of CB(2) cannabinoid receptor levels in rat brain and mouse RAW 264.7 macrophages. 2006 , 181, 82-92	37
1086	Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. 2006 , 21, 237-45	47
1085	Receptor-independent actions of cannabinoids on cell membranes: focus on endocannabinoids. 2006 , 111, 114-44	133
1084	A transmembrane helix-bundle from G-protein coupled receptor CB2: biosynthesis, purification, and NMR characterization. 2006 , 83, 46-61	27

1083	Endocannabinoids. 2006 , 108, 877-889	9
1082	Expression of functional CB1 cannabinoid receptors in retinoic acid-differentiated P19 embryonal carcinoma cells. 2006 , 83, 1128-40	9
1081	Cannabinoid agonist WIN55,212-2 induces apoptosis in cerebellar granule cells via activation of the CB1 receptor and downregulation of bcl-xL gene expression. 2006 , 83, 1058-65	15
1080	Cannabinoid receptor agonists inhibit Ca(2+) influx to synaptosomes from rat brain. 2006 , 76, 157-62	6
1079	Cannabinoid-1 receptor: a novel target for the treatment of neuropsychiatric disorders. 2006 , 10, 203-10	31
1078	Implantation. 2006 , 147-188	6
1077	Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. 2006 , 291, G364-71	134
1076	New anti-inflammatory agents to reduce atherosclerosis. 2006 , 112, 130-7	2
1075	Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. 2006 , 4, 239-57	157
1074	Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. 2006 , 30 Suppl 1, S7-S12	100
1073	Cannabinoid receptors as therapeutic targets. 2006 , 12, 1751-69	52
1072	Receptor-independent effects of endocannabinoids on ion channels. 2006 , 12, 227-39	66
1071	Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. 2007 , 17, 175-91	184
1070	Endocannabinoid system in frog and rodent testis: type-1 cannabinoid receptor and fatty acid amide hydrolase activity in male germ cells. 2006 , 75, 82-9	91
1069	The endocannabinoid system: A new player in the neurochemical control of vestibular function?. 2006 , 11, 207-12	4
1068	Characterization of peripheral human cannabinoid receptor (hCB2) expression and pharmacology using a novel radioligand, [35S]Sch225336. 2006 , 281, 28143-51	20
1067	Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T cells is regulated by translocation of Bad to mitochondria. 2006 , 4, 549-62	59
1066	Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. 2006 , 66, 6748-55	250

1065	Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. 2006 , 70, 101-11	132
1064	Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. 2006 , 295, 761-75	916
1063	A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. 2006 , 316, 780-8	105
1062	Release of anandamide from blood cells. 2006 , 44, 488-91	53
1061	Chemotaxis of human peripheral blood eosinophils to 2-arachidonoylglycerol: comparison with other eosinophil chemoattractants. 2006 , 140 Suppl 1, 3-7	39
1060	Relationships between the autonomic nervous system, humoral factors and immune functions in the intestine. 2006 , 74, 215-27	24
1059	The role of the endocannabinoid system in the control of energy homeostasis. 2006 , 30 Suppl 1, S33-8	67
1058	Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol. 2006 , 319, 1211-8	43
1057	Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils. 2006 , 281, 12908-18	78
1056	Neuronal control of skin function: the skin as a neuroimmunoendocrine organ. 2006 , 86, 1309-79	418
1055	Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. 2006 , 316, 969-82	237
1054	Cannabinoids in Cancer Pain Management. 2006 , 20, 43-46	7
1053	Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. 2006 , 39, 143-51	124
1052	Endocannabinoid system and its role in energy regulation. 2006 , 1, 557-569	2
1051	Jekyll and hyde: two faces of cannabinoid signaling in male and female fertility. 2006 , 27, 427-48	186
1050	Antinociceptive effect of spinally administered cannabinergic and 2-adrenoceptor drugs on the formalin test in rat: possible interactions. 2006 , 20, 67-74	23
1049	Insights into Receptor Function and New Drug Development Targets. 2006 ,	1
1048	The endocannabinoid system and cardiovascular risk: pathophysiologic role and developing therapeutic interventions. 2006 , 15, 255-9	

1047	Molecular composition of the endocannabinoid system at glutamatergic synapses. 2006 , 26, 5628-37	404
1046	The CB1 cannabinoid receptor is the major cannabinoid receptor at excitatory presynaptic sites in the hippocampus and cerebellum. 2006 , 26, 2991-3001	362
1045	Peripheral cannabinoid receptor, CB2, regulates bone mass. 2006 , 103, 696-701	417
1044	The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. 2006 , 103, 11393-8	131
1043	The emerging role of the endocannabinoid system in endocrine regulation and energy balance. 2006 , 27, 73-100	649
1042	New natural noncannabinoid ligands for cannabinoid type-2 (CB2) receptors. 2006 , 26, 709-30	31
1041	Alkylamides from Echinacea are a new class of cannabinomimetics. Cannabinoid type 2 receptor-dependent and -independent immunomodulatory effects. 2006 , 281, 14192-206	178
1040	Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. 2006 , 70, 786-92	121
1039	Delta9-tetrahydrocannabinol and endogenous cannabinoid anandamide directly potentiate the function of glycine receptors. 2006 , 69, 991-7	124
1038	N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. 2006 , 103, 2428-33	156
1037	Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. 2006 , 281, 26465-72	275
1036	Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. 2007 , 27, 2396-402	210
1035	Mitogenic activity and signaling mechanism of 2-(14,15- epoxyeicosatrienoyl)glycerol, a novel cytochrome p450 arachidonate metabolite. 2007 , 27, 3023-34	26
1034	Retrograde endocannabinoid inhibition of goldfish retinal cones is mediated by 2-arachidonoyl glycerol. 2007 , 24, 257-67	20
1033	Latest advances in the cannabinoids. 2007 , 17, 1457-1476	20
1032	The role of the endocannabinoid system in gametogenesis, implantation and early pregnancy. 2007 , 13, 501-13	75
1031	Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. 2007 , 82, 532-41	85
1030	Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans. 2007 , 7, 380-5	96

1029	Microglial activation and its implications in the brain diseases. 2007 , 14, 1189-97	689
1028	The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. 2007 , 7, 769-79	41
1027	Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. 2007 , 71, 1512-24	67
1026	Recent advances in Cannabis sativa research: biosynthetic studies and its potential in biotechnology. 2007 , 8, 237-43	61
1025	The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. 2007 , 5, 73-80	212
1024	Cannabinoids and cardiovascular disease: the outlook for clinical treatments. 2007 , 5, 175-85	15
1023	A possible role for the endocannabinoid system in the neurobiology of depression. 2007 , 3, 25	33
1022	PLANT AND BRAIN CANNABINOIDS: THE CHEMISTRY OF MAJOR NEW PLAYERS IN PHYSIOLOGY. 2007 , 49-75	
1021	Cannabinoid system and neuroinflammation: implications for multiple sclerosis. 2007 , 14, 182-7	19
1020	Endocannabinoids in TNF-alpha and ethanol actions. 2007 , 14, 188-92	7
1019	Anandamide inhibits endothelin-1 production by human cultured endothelial cells: a new vascular action of this endocannabinoid. 2007 , 79, 12-6	16
1018	The seek of neuroprotection: introducing cannabinoids. 2007 , 2, 131-9	40
1017	The expression of the peripheral cannabinoid receptor on cells of the immune system and non-Hodgkin's lymphomas. 2007 , 48, 1389-99	14
1016	Induction of preferential chemotaxis of unstimulated B-lymphocytes by 2-arachidonoylglycerol in immunized mice. 2007 , 51, 1013-9	28
1015	Cannabis and the brain. 2007 , 81-100	
1014	Cannabis and psychosis: what is the link?. 2007 , 39, 131-42	33
1013	Opposing actions of endocannabinoids on cholangiocarcinoma growth: recruitment of Fas and Fas ligand to lipid rafts. 2007 , 282, 13098-113	83
1012	Cannabinoid (CB1) receptor activation inhibits trigeminovascular neurons. 2007 , 320, 64-71	83

1011	Involvement of the 90-kDa heat shock protein (Hsp-90) in CB2 cannabinoid receptor-mediated cell migration: a new role of Hsp-90 in migration signaling of a G protein-coupled receptor. 2007 , 72, 1289-300	28
1010	Endocannabinoids and Energy Homeostasis. 2007 , 49-67	
1009	Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. 2007 , 82, 1382-9	93
1008	Canabinoides. 2007 , 533-551	
1007	Regulation of female fertility by the endocannabinoid system. 2007 , 10, 207-16	18
1006	Cannabidiol, unlike synthetic cannabinoids, triggers activation of RBL-2H3 mast cells. 2007 , 81, 1512-22	36
1005	Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. 2007 , 5, 81-97	81
1004	Endocannabinoid signaling in midbrain dopamine neurons: more than physiology?. 2007 , 5, 268-77	34
1003	Endocannabinoids, cannabinoid receptors and inflammatory stress: an interview with Dr. P[[corrected] Pacher. Interviewed by Helene F. Rosenberg. 2007 , 82, 1390-2	
1002	Effects of anandamide and noxious heat on intracellular calcium concentration in nociceptive drg neurons of rats. 2007 , 98, 929-38	23
1001	Antiobesity Pharmacotherapy: Current Treatment Options and Future Perspectives. 2007 ,	
1000	Neurotransmitter effects on tumor cells and leukocytes. 2007 , 39, 99-121	20
999	Association of candidate gene polymorphisms with bone mineral density in community-dwelling Japanese women and men. 2007 , 19, 791	2
998	Central obesity and the cardiometabolic syndrome in Hispanics. 2007 , 4, 609-621	1
997	2-Arachidonoylglycerol enhances the phagocytosis of opsonized zymosan by HL-60 cells differentiated into macrophage-like cells. 2007 , 30, 1199-205	24
996	[Pharmacognosical study during 40 years]. 2007 , 127, 1593-620	3
995	Marijuana: Pharmacology and Interaction with the Endocannabinoid System. 2007 ,	
994	Cannabinoids in Tourette's syndrome. 2007 ,	1

993	Influence of nicotinic receptor modulators on CB2 cannabinoid receptor agonist (JWH133)-induced antinociception in mice. 2007 , 18, 691-7	18
992	Increased depressor response to N-arachidonoyl-dopamine during high salt intake: role of the TRPV1 receptor. 2007 , 25, 2426-33	13
991	Acute anorectic response to cannabinoid CB1 receptor antagonist/inverse agonist AM 251 in rats: indirect behavioural mediation. 2007 , 18, 591-600	32
990	The endocannabinoid system: a new target for the regulation of energy balance and metabolism. 2007 , 6, 46-50	23
989	Endocannabinoid system and pathophysiology of adipogenesis: current management of obesity. 2007 , 4, 307-319	2
988	Endocannabinoid regulation of matrix metalloproteinases: implications in ischemic stroke. 2007 , 5, 311-8	6
987	Peripheral tissue-brain interactions in the regulation of food intake. 2007 , 66, 131-55	55
986	Blockade of central cyclooxygenase (COX) pathways enhances the cannabinoid-induced antinociceptive effects on inflammatory temporomandibular joint (TMJ) nociception. 2007 , 132, 23-32	36
985	Biochemical and mass spectrometric characterization of the human CB2 cannabinoid receptor expressed in <i>Pichia pastoris</i> --importance of correct processing of the N-terminus. 2007 , 55, 225-35	24
984	The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain. 2007 , 53, 169-77	39
983	Ultra-low dose cannabinoid antagonist AM251 enhances cannabinoid anticonvulsant effects in the pentylenetetrazole-induced seizure in mice. 2007 , 53, 763-70	33
982	Anti-inflammatory property of the cannabinoid agonist WIN-55212-2 in a rodent model of chronic brain inflammation. 2007 , 144, 1516-22	70
981	Effects of Marijuana on the Lung and Immune Defenses. 2007 , 253-275	3
980	The Endocannabinoid System and the Therapeutic Potential of Cannabinoids. 2007 , 125-143	2
979	Understanding metabolic homeostasis and imbalance: what is the role of the endocannabinoid system?. 2007 , 120, S18-24; discussion S24	49
978	Structural divergence among cannabinoids influences membrane dynamics: a 2H solid-state NMR analysis. 2007 , 1768, 2049-59	7
977	The expression of receptors for endocannabinoids in human and rodent skeletal muscle. 2007 , 364, 105-10	131
976	Integrated physiology and pathophysiology of CB1-mediated effects of the endocannabinoid system. 2007 , 33, 97-107	19

975	Characterization of two duplicate zebrafish Cb2-like cannabinoid receptors. 2007 , 389, 36-44	31
974	BfCBR: a cannabinoid receptor ortholog in the cephalochordate <i>Branchiostoma floridae</i> (Amphioxus). 2007 , 399, 65-71	18
973	Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis. 2007 , 112, 533-42	30
972	Involvement of cannabinoid CB2 receptors in the IgE-mediated triphasic cutaneous reaction in mice. 2007 , 80, 414-9	19
971	Analogs of SR-141716A (Rimonabant) alter d-amphetamine-evoked [3H] dopamine overflow from preloaded striatal slices and amphetamine-induced hyperactivity. 2007 , 81, 63-71	4
970	Effects of cannabinoid receptors on skeletal muscle oxidative pathways. 2007 , 267, 63-9	108
969	Temporal variation in CB2R levels following T lymphocyte activation: evidence that cannabinoids modulate CXCL12-induced chemotaxis. 2007 , 7, 360-71	55
968	Suppressive effects of cannabidiol on antigen-specific antibody production and functional activity of splenocytes in ovalbumin-sensitized BALB/c mice. 2007 , 7, 773-80	48
967	Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type <i>Cannabis sativa</i> . 2007 , 581, 2929-34	152
966	Synaptic function and modulation of glycine receptor channels in the hypoglossal nucleus. 2007 , 39, 294-304	3
965	Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality. 2007 , 50, 5471-84	61
964	Hemopressin is an inverse agonist of CB1 cannabinoid receptors. 2007 , 104, 20588-93	187
963	The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. 2007 , 50, 2875-85	42
962	Eicosanoids in non-febrile thermoregulation. 2007 , 162, 15-25	13
961	Targeting cannabinoid agonists for inflammatory and neuropathic pain. 2007 , 16, 951-65	83
960	Marijuana and the Cannabinoids. 2007 ,	34
959	Emerging drugs in neuropathic pain. 2007 , 12, 113-26	56
958	Endocannabinoids in the dentate gyrus. 2007 , 163, 319-37	5

957	Treatment of the Obese Patient. 2007,	3
956	Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. 2007, 58 Suppl, 113-29	7
955	The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species. 2007, 21, 2798-806	108
954	Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. 2007, 50, 6493-500	76
953	Endocannabinoid regulates blood pressure via activation of the transient receptor potential vanilloid type 1 in Wistar rats fed a high-salt diet. 2007, 321, 763-9	32
952	Impact of weight-loss medications on the cardiovascular system: focus on current and future anti-obesity drugs. 2007, 7, 273-88	17
951	Functional neurochemistry of the basal ganglia. 2007, 83, 19-66	12
950	C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. 2007, 50, 4048-60	37
949	Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. 2007, 21, 1788-800	191
948	Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. 2007, 293, G137-45	85
947	Il sistema endocannabinoide e l'obesità prospettive terapeutiche. 2007, 8, 9-18	1
946	Endocannabinoids and synaptic function in the CNS. 2007, 13, 127-37	141
945	Immune-Mediated Diseases. 2007,	4
944	[Endocannabinoid system: from metabolic to neuroendocrine effects]. 2007, 68 Suppl 1, 12-7	0
943	Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. 2007, 79, 5582-93	73
942	Modulation of the endocannabinoid system: therapeutic potential against cocaine dependence. 2007, 56, 406-17	17
941	Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. 2007, 56, 360-6	61
940	The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. 2007, 56, 367-81	104

939	Endocannabinoids and neurodegenerative diseases. 2007 , 56, 382-92	80
938	Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity. 2007 , 97, 109-17	54
937	The blockade of the endocannabinoid CB1 receptors and its influence on cardiometabolic risk: Lesson from Rimonabant In Obesity (RIO) trials. 2007 , 1303, 146-154	3
936	Analgesic, Anti-inflammatory, and Anti-pyretic Activity. 2007 , 983-1116	2
935	Neural control of blood pressure: focusing on capsaicin-sensitive sensory nerves. 2007 , 7, 37-46	23
934	Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. 2007 , 13, 790-804	1
933	Phytocannabinoids in Cannabis sativa: recent studies on biosynthetic enzymes. 2007 , 4, 1649-63	64
932	From active ingredients to the discovery of the targets: the cannabinoid receptors. 2007 , 4, 1693-706	10
931	Medicinal chemistry endeavors around the phytocannabinoids. 2007 , 4, 1707-28	18
930	Blocking the cannabinoid receptors: drug candidates and therapeutic promises. 2007 , 4, 1805-27	28
929	Discovery and isolation of anandamide and other endocannabinoids. 2007 , 4, 1828-41	23
928	Genetic polymorphisms of the endocannabinoid system. 2007 , 4, 1926-32	19
927	The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. 2007 , 121, 2172-80	114
926	CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. 2007 , 23, 507-17	100
925	Antiapoptotic mechanism of cannabinoid receptor 2 agonist on cisplatin-induced apoptosis in the HEI-OC1 auditory cell line. 2007 , 85, 896-905	30
924	Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors. 2007 , 15, 5406-16	14
923	Discovery of 1,1-dioxo-1,2,6-thiadiazine-5-carboxamide derivatives as cannabinoid-like molecules with agonist and antagonist activity. 2007 , 15, 7480-93	10
922	Novel, potent THC/anandamide (hybrid) analogs. 2007 , 15, 7850-64	14

921	2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: discovery of CB2 receptor selective compounds. 2007 , 17, 4030-4	29
920	Sulfonamide derivatives as new potent and selective CB2 cannabinoid receptor agonists. 2007 , 17, 5133-5	24
919	N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability. 2007 , 17, 6299-304	38
918	Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry. 2007 , 361, 162-8	50
917	Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. 2007 , 13, 492-7	292
916	Cannabis, the mind and society: the hash realities. 2007 , 8, 885-95	247
915	Stimulation of epithelial CB1 receptors inhibits contractions of the rat prostate gland. 2007 , 150, 227-34	22
914	Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. 2007 , 150, 153-63	80
913	The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. 2007 , 150, 693-701	71
912	Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. 2007 , 150, 519-25	91
911	Genetic and pharmacological approaches to evaluate the interaction between the cannabinoid and cholinergic systems in cognitive processes. 2007 , 150, 758-65	17
910	Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. 2007 , 151, 427-40	62
909	Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers. 2007 , 151, 1061-70	74
908	Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. 2007 , 152, 765-77	103
907	Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB2) in rodents and primates. 2007 , 151, 1262-71	12
906	PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. 2007 , 152, 805-14	139
905	The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. 2007 , 152, 825-31	184
904	Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. 2007 , 152, 633-48	56

903	The orphan receptor GPR55 is a novel cannabinoid receptor. 2007 , 152, 1092-101	1053
902	Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. 2007 , 152, 1111-20	48
901	CB2 cannabinoid receptors promote mouse neural stem cell proliferation. 2007 , 25, 629-34	107
900	Interactions of cannabidiol with endocannabinoid signalling in hippocampal tissue. 2007 , 25, 2093-102	25
899	Cannabinoids modulate Olig2 and polysialylated neural cell adhesion molecule expression in the subventricular zone of post-natal rats through cannabinoid receptor 1 and cannabinoid receptor 2. 2007 , 26, 1548-59	63
898	Cannabinoid regulation in identified synapse of terrestrial snail. 2007 , 26, 3207-14	14
897	Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. 2007 , 102, 1488-1496	65
896	Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. 2007 , 102, 1105-14	164
895	The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. 2007 , 103, 2505-17	20
894	C-terminal truncated cannabinoid receptor 1 coexpressed with G protein trimer in Sf9 cells exists in a precoupled state and shows constitutive activity. 2007 , 274, 6106-15	5
893	Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors. 2007 , 101, 287-93	53
892	Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. 2007 , 1137, 161-9	67
891	An endocannabinoid mechanism in relapse to drug seeking: a review of animal studies and clinical perspectives. 2007 , 53, 1-16	84
890	CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. 2007 , 122, 259-70	86
889	Cyclosporine attenuates the adenylyl cyclase superactivation induced by chronic cannabinoid treatment. 2007 , 557, 20-2	10
888	Acute and chronic administration of the cannabinoid receptor agonist CP 55,940 attenuates tumor-evoked hyperalgesia. 2007 , 558, 73-87	44
887	Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. 2007 , 562, 82-91	48
886	The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. 2007 , 570, 50-6	35

885	Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. 2007 , 573, 206-13	14
884	The endocannabinoid system in the regulation of cardiometabolic risk factors. 2007 , 100, 7P-17P	10
883	Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential. 2007 , 100, 27P-32P	17
882	Changes of gonadal CB1 cannabinoid receptor mRNA in the gilthead seabream, <i>Sparus aurata</i> , during sex reversal. 2007 , 150, 263-9	9
881	Endocannabinoid control of sperm motility: the role of epididymus. 2007 , 153, 320-2	62
880	The endocannabinoid network: insight into the regulation of the neuroendocrine and metabolic systems. 2007 , 2, 53-8	1
879	Differential regulation of endocannabinoid synthesis and degradation in the uterus during embryo implantation. 2007 , 83, 62-74	74
878	Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. 2007 , 173, 21-30	147
877	Immune control by endocannabinoids - new mechanisms of neuroprotection?. 2007 , 184, 127-35	47
876	Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. 2007 , 189, 17-22	51
875	Significance of cardiac cannabinoid receptors in regulation of cardiac rhythm, myocardial contractility, and electrophysiologic processes in heart. 2007 , 34, 28-35	5
874	The endocannabinoid system and its protective role in ischemic and cytotoxic injuries of brain neurons. 2007 , 1, 93-112	1
873	Calcium-induced modulation of synaptic transmission. 2007 , 1, 28-37	
872	Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. 2007 , 50, 3851-6	74
871	MDMA attenuates THC withdrawal syndrome in mice. 2007 , 193, 75-84	15
870	Effects of SR141716 and WIN 55,212-2 on tolerance to ethanol in rats using the acute and rapid procedures. 2007 , 194, 139-49	14
869	Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats. 2007 , 195, 27-39	49
868	Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. 2007 , 80, 50-9	71

867	Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. 2007 , 17, 347-61	102
866	Expression of cannabinoid receptors and neurotrophins in human gliomas. 2007 , 28, 304-10	32
865	Rimonabant: the role of endocannabinoid type 1 receptor antagonism in modulating the weight and lipid profile of obese patients. 2007 , 9, 359-66	2
864	An overview on the biochemistry of the cannabinoid system. 2007 , 36, 3-14	21
863	Targeting astrocytomas and invading immune cells with cannabinoids: a promising therapeutic avenue. 2007 , 36, 36-44	4
862	Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: neuroprotection versus neurotoxicity. 2007 , 35, 245-54	36
861	Cannabinoid CB2 receptor-mediated anti-nociception in models of acute and chronic pain. 2007 , 36, 26-35	72
860	Secondary metabolism in cannabis. 2008 , 7, 615-639	186
859	Effects of acute systemic and intra-cerebral stimulation of cannabinoid receptors on sensorimotor gating, locomotion and spatial memory in rats. 2008 , 198, 375-85	45
858	The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. 2008 , 3, 117-29	45
857	Rimonabant: new data and emerging experience. 2008 , 10, 71-8	10
856	A MBP-FAAH fusion protein as a tool to produce human and rat fatty acid amide hydrolase: expression and pharmacological comparison. 2008 , 34, 127-33	22
855	Preclinical assessment of novel therapeutics on the cough reflex: cannabinoid agonists as potential antitussives. 2008 , 186 Suppl 1, S66-9	5
854	Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. 2000 , 75, 2434-44	306
853	Loss of cannabinoid-stimulated guanosine 5'-O-(3-[(35)S]Thiotriphosphate) binding without receptor down-regulation in brain regions of anandamide-tolerant rats. 2000 , 75, 2478-84	34
852	Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. 1999 , 72, 2032-8	74
851	Cannabinoids in pancreatic cancer: correlation with survival and pain. 2008 , 122, 742-50	95
850	Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: novel agonists for the CB1 receptor. 2008 , 43, 513-39	16

849	Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. 2008 , 16, 322-35	30
848	Novel sterically hindered cannabinoid CB1 receptor ligands. 2008 , 16, 7510-5	13
847	Discovery of a novel class of selective human CB1 inverse agonists. 2008 , 18, 1199-206	11
846	Arylsulfonamide CB2 receptor agonists: SAR and optimization of CB2 selectivity. 2008 , 18, 1725-9	26
845	Novel ketooxazole based inhibitors of fatty acid amide hydrolase (FAAH). 2008 , 18, 2109-13	26
844	The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives. 2008 , 18, 3310-4	26
843	Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. 2008 , 15, 1207-19	79
842	Efficient one-pot synthetic approaches for cannabinoid analogues and their application to biologically interesting (–)-hexahydrocannabinol and (+)-hexahydrocannabinol. 2008 , 49, 3283-3287	43
841	Regulation of endocannabinoid signaling by stress: implications for stress-related affective disorders. 2008 , 32, 1152-60	168
840	Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. 2008 , 51, 7216-33	51
839	Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists. 2008 , 51, 5019-34	40
838	Indol-3-yl-tetramethylcyclopropyl ketones: effects of indole ring substitution on CB2 cannabinoid receptor activity. 2008 , 51, 1904-12	72
837	Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain. 2008 , 51, 4932-47	48
836	Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. 2008 , 1139, 434-49	139
835	Pharmacological Properties of Cannabinoid Receptors in the Avian Brain: Similarity of Rat and Chicken Cannabinoid1 Receptor Recognition Sites and Expression of Cannabinoid2 Receptor-Like Immunoreactivity in the Embryonic Chick Brain. 2008 , 88, 213-222	
834	The endocannabinoid system in brain reward processes. 2008 , 154, 369-83	178
833	Interactions between CB(1) receptors and TRPV1 channels mediated by 12-HPETE are cytotoxic to mesencephalic dopaminergic neurons. 2008 , 155, 253-64	24
832	Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. 2008 , 155, 547-57	36

831	MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. 2008 , 155, 1104-16	57
830	Delta9-Tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration in vitro as well as its growth and metastasis in vivo. 2008 , 27, 339-46	108
829	Cannabinoid type 1 receptor: another arrow in the adipocytes' bow. 2008 , 20 Suppl 1, 130-8	60
828	The group IV afferent neuron expresses multiple receptor alterations in cardiomyopathic rats: evidence at the cannabinoid CB1 receptor. 2008 , 586, 835-45	16
827	The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. 2008 , 153, 199-215	1082
826	CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. 2008 , 153, 216-25	55
825	Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. 2008 , 153, 226-39	82
824	Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. 2008 , 153, 271-6	21
823	CB2 receptors as new therapeutic targets for liver diseases. 2008 , 153, 286-9	74
822	CB2 receptor-mediated migration of immune cells: it can go either way. 2008 , 153, 299-308	151
821	The peripheral cannabinoid receptor knockout mice: an update. 2008 , 153, 309-18	91
820	Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. 2008 , 153, 319-34	286
819	In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. 2008 , 153, 358-66	31
818	Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands. 2008 , 153, 335-46	48
817	Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. 2008 , 153, 252-62	159
816	CB2 receptors in the brain: role in central immune function. 2008 , 153, 240-51	222
815	Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2-arachidonylglycerol. 2008 , 107, 987-1000	21
814	Advances in the field of cannabinoid--opioid cross-talk. 2008 , 13, 213-24	84

813	Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. 2008 , 13, 147-59	224
812	Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. 2008 , 13, 239-52	82
811	The endogenous cannabinoid system and drug addiction: 20 years after the discovery of the CB1 receptor. 2008 , 13, 143-6	11
810	Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. 2008 , 125, 263-71	45
809	Cannabinoid receptors: where they are and what they do. 2008 , 20 Suppl 1, 10-4	364
808	Endocannabinoids: some like it fat (and sweet too). 2008 , 20 Suppl 1, 100-9	35
807	The endocannabinoid system and energy metabolism. 2008 , 20, 850-7	81
806	Overexpression of a fatty acid amide hydrolase compromises innate immunity in Arabidopsis. 2008 , 56, 336-349	48
805	The anti-apoptotic activity associated with phosphatidylinositol transfer protein alpha activates the MAPK and Akt/PKB pathway. 2008 , 1783, 1700-6	4
804	The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). 2008 , 76, 726-37	72
803	The cannabinoid receptor agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral mechanisms. 2008 , 1215, 69-75	36
802	Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. 2008 , 1240, 213-20	57
801	Localization of CB1 cannabinoid receptor mRNA in the brain of the chick (<i>Gallus domesticus</i>). 2008 , 1245, 61-73	9
800	The alpha subunit of Go interacts with promyelocytic leukemia zinc finger protein and modulates its functions. 2008 , 20, 884-91	12
799	Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents. 2008 , 579, 215-24	12
798	Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. 2008 , 581, 19-29	49
797	Bidirectional roles of the brain 2-arachidonoyl-sn-glycerol in the centrally administered vasopressin-induced adrenomedullary outflow in rats. 2008 , 582, 62-9	13
796	Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. 2008 , 583, 322-39	59

795	Cannabis and the developing brain: insights from behavior. 2008 , 585, 441-52	90
794	Modulation of opioids via protection of anandamide degradation by fatty acid amide hydrolase. 2008 , 600, 50-8	35
793	Anandamide effects on 5-HT(3) receptors in vivo. 2008 , 596, 98-101	27
792	The challenge of treating obesity: the endocannabinoid system as a potential target. 2008 , 108, 823-31	11
791	Activation of cannabinoid receptors prevents antigen-induced asthma-like reaction in guinea pigs. 2008 , 12, 2381-94	29
790	The endocannabinoid system in cancer-potential therapeutic target?. 2008 , 18, 176-89	53
789	Cannabinoid receptors 1 and 2 (CB1 and CB2), their distribution, ligands and functional involvement in nervous system structures--a short review. 2008 , 90, 501-11	300
788	Effects of intrahippocampal cannabinoid receptor agonist and antagonist on radial maze and T-maze delayed alternation performance in rats. 2008 , 91, 91-6	23
787	Modulation of pain transmission by G-protein-coupled receptors. 2008 , 117, 141-61	128
786	Endocannabinoids in the retina: from marijuana to neuroprotection. 2008 , 27, 501-26	117
785	CB1 Cannabinoid Receptors: Molecular Biology, Second Messenger Coupling and Polarized Trafficking in Neurons. 2008 , 59-73	5
784	CB2 Cannabinoid Receptors: Molecular, Signaling, and Trafficking Properties. 2008 , 75-90	5
783	An Historical Introduction to the Endocannabinoid and Endovanilloid Systems. 2008 , 3-13	1
782	Discovery of boronic acids as novel and potent inhibitors of fatty acid amide hydrolase. 2008 , 51, 7057-60	52
781	[Endocannabinoid system: new perspectives in the global management of cardiometabolic risk factors]. 2008 , 130, 615-22	
780	[Endocannabinoid system and bowel inflammation]. 2008 , 131, 513-7	2
779	Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. 2008 , 51, 7327-43	151
778	Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. 2008 , 8, 1037-48	89

777	Early endothelial dysfunction as a marker of vasculogenic erectile dysfunction in young habitual cannabis users. 2008 , 20, 566-73	57
776	Synthesis and Cannabinoid Activity of a Variety of 2,3-Substituted 1-Benzo[b]thiophen Derivatives and 2,3-Substituted Benzofuran: Novel Agonists for the CB1 Receptor. 2008 , 61, 484	5
775	Role of CB2 receptors in neuroprotective effects of cannabinoids. 2008 , 286, S91-6	92
774	Aspects of endocannabinoid signaling in periimplantation biology. 2008 , 286, S3-11	53
773	The endocannabinoid system in vertebrate male reproduction: a comparative overview. 2008 , 286, S24-30	42
772	Regulation of male fertility by the endocannabinoid system. 2008 , 286, S17-23	37
771	Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. 2008 , 286, S66-78	129
770	Endocannabinoid functions controlling neuronal specification during brain development. 2008 , 286, S84-90	123
769	The effects of <i>Morinda citrifolia</i> L. (noni) on the immune system: its molecular mechanisms of action. 2008 , 115, 502-6	82
768	Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors. 2008 , 52, 321-8	37
767	CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain. 2008 , 53, 309-16	34
766	Peripheral cannabinoids attenuate carcinoma-induced nociception in mice. 2008 , 433, 77-81	33
765	Differential coupling of the human cannabinoid receptors hCB1R and hCB2R to the G-protein G(alpha)i2beta1gamma2. 2008 , 447, 68-72	10
764	The cannabinoid CP55,940 prolongs survival and improves locomotor activity in <i>Drosophila melanogaster</i> against paraquat: implications in Parkinson's disease. 2008 , 61, 404-11	55
763	Pharmacological enhancement of endocannabinoid signaling reduces the cholinergic toxicity of diisopropylfluorophosphate. 2008 , 29, 1037-43	24
762	Cannabinoid receptor stimulation is anti-inflammatory and improves memory in old rats. 2008 , 29, 1894-901	68
761	Endocannabinoids mediate neuron-astrocyte communication. 2008 , 57, 883-93	372
760	Methanandamide activation of a novel current in mouse trigeminal ganglion sensory neurons in vitro. 2008 , 54, 172-80	10

759	Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. 2008 , 55, 1095-104	22
758	Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. 2008 , 151, 104-10	61
757	Fatty acid amide hydrolase inhibition enhances the anti-allodynic actions of endocannabinoids in a model of acute pain adapted for the mouse. 2008 , 154, 1554-61	22
756	Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. 2008 , 90, 374-81	68
755	Labelling and biological evaluation of [(11C)methoxy-Sch225336: a radioligand for the cannabinoid-type 2 receptor. 2008 , 35, 793-800	34
754	Endocannabinoids, metabolic regulation, and the role of diet. 2008 , 28, 641-50	26
753	Cannabinoids inhibit insulin secretion and cytosolic Ca ²⁺ oscillation in islet beta-cells via CB1 receptors. 2008 , 145, 49-53	89
752	Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease. 2020 , 10,	6
751	VF-13, a chimeric peptide of VD-hemopressin(β) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects. 2020 , 175, 108178	2
750	Design, Synthesis, and Physicochemical and Pharmacological Profiling of 7-Hydroxy-5-oxopyrazolo[4,3-]pyridine-6-carboxamide Derivatives with Antiosteoarthritic Activity In Vivo. 2020 , 63, 7369-7391	11
749	Anti-apoptotic and Immunomodulatory Effect of CB2 Agonist, JWH133, in a Neonatal Rat Model of Hypoxic-Ischemic Encephalopathy. 2020 , 8, 65	2
748	Medical potential of cannabis: an overview. 2020 , 419-448	2
747	Lifetime Average Cannabis Use in Relation to Hypertriglyceridemic Waist Phenotype in U.S. Adults: A Population-Based Cross-Sectional Study. 2020 , 5, 246-254	1
746	Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review. 2020 , 14, 34	14
745	From to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases. 2020 , 11, 124	45
744	Endocannabinoid Modulation of Microglial Phenotypes in Neuropathology. 2020 , 11, 87	41
743	Activation of cannabinoid receptor 2 protects rat hippocampal neurons against Aβ-induced neuronal toxicity. 2020 , 735, 135207	9
742	Cannabinoids and Cannabinoid Receptors: The Story so Far. 2020 , 23, 101301	50

741	Comprehending and improving cannabis specialized metabolism in the systems biology era. 2020 , 298, 110571	14
740	Shifting the Paradigm on Cannabis Safety. 2020 ,	2
739	, the Endocannabinoid System and Immunity-the Journey from the Bedside to the Bench and Back. 2020 , 21,	34
738	Phytocannabinoid drug-drug interactions and their clinical implications. 2020 , 215, 107621	6
737	Improved identification of phytocannabinoids using a dedicated structure-based workflow. 2020 , 219, 121310	16
736	Functionalized Cannabinoid Subtype 2 Receptor Ligands: Fluorescent, PET, Photochromic and Covalent Molecular Probes. 2020 , 15, 1374-1389	7
735	Bioactive lipids, inflammation and chronic diseases. 2020 , 159, 133-169	41
734	Clinical trials and novel therapeutics in dermatomyositis. 2020 , 25, 213-228	3
733	Neuroprotection Following Concussion: The Potential Role for Cannabidiol. 2020 , 47, 289-300	4
732	Targeting Peripherally Restricted Cannabinoid Receptor 1, Cannabinoid Receptor 2, and Endocannabinoid-Degrading Enzymes for the Treatment of Neuropathic Pain Including Neuropathic Orofacial Pain. 2020 , 21,	20
731	CB1 Receptor-Dependent and Independent Induction of Lipolysis in Primary Rat Adipocytes by the Inverse Agonist Rimonabant (SR141716A). 2020 , 25,	5
730	Cannabinoids in the Treatment of Back Pain. 2020 , 87, 166-175	5
729	Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects. 2020 , 16, 381-396	28
728	Evaluation of cannabinoid receptors Type 1 and Type 2 mRNA expression in mature versus immature spermatozoa from fertile and infertile males. 2020 , 52, e13532	2
727	Signalling profiles of a structurally diverse panel of synthetic cannabinoid receptor agonists. 2020 , 175, 113871	15
726	Effect of cannabinoid-serotonin interactions in the regulation of neuropeptide Y1 receptors expression in rats: the role of CB1 and 5-HT2C receptor. 2020 , 29, 561-571	2
725	Effects of topical treatment of cannabidiol extract in a unique manuka factor 5 manuka honey carrier on second intention wound healing on equine distal limb wounds: a preliminary study. 2020 , 98, 250-255	3
724	Histone methyltransferase G9a diminishes expression of cannabinoid CB receptors in primary sensory neurons in neuropathic pain. 2020 , 295, 3553-3562	7

723	Interactions Between Alcohol and the Endocannabinoid System. 2020 , 44, 790-805	19
722	The Effectiveness of Topical Cannabidiol Oil in Symptomatic Relief of Peripheral Neuropathy of the Lower Extremities. 2020 , 21, 390-402	45
721	The anticonvulsant effects of cannabidiol in experimental models of epileptic seizures: From behavior and mechanisms to clinical insights. 2020 , 111, 166-182	20
720	Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement. 2020 , 157, 307-311	10
719	Understanding the neurobiological effects of drug abuse: Lessons from zebrafish models. 2020 , 100, 109873	10
718	Crosstalk between the M muscarinic acetylcholine receptor and the endocannabinoid system: A relevance for Alzheimer's disease?. 2020 , 70, 109545	9
717	Circadian Misalignment of the 24-hour Profile of Endocannabinoid 2-Arachidonoylglycerol (2-AG) in Obese Adults. 2020 , 105,	4
716	Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's Disease. 2020 , 25,	14
715	Abnormal Cannabidiol Affects Production of Pro-Inflammatory Mediators and Astrocyte Wound Closure in Primary Astrocytic-Microglial Cocultures. 2020 , 25,	3
714	Activation and Signaling Mechanism Revealed by Cannabinoid Receptor-G Complex Structures. 2020 , 180, 655-665.e18	88
713	[Dependence and Cytotoxicity of Components of Cannabis]. 2020 , 140, 205-214	
712	β-Adrenoceptor agonist induces peripheral antinociception via the endocannabinoid system. 2020 , 72, 96-103	1
711	The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders. 2020 , 26, 586-602	21
710	Cannabinoids as anticancer therapeutic agents. 2020 , 19, 961-989	23
709	A Guide to Targeting the Endocannabinoid System in Drug Design. 2020 , 21,	42
708	Endocannabinoid-Mediated Neuromodulation in the Olfactory Bulb: Functional and Therapeutic Significance. 2020 , 21,	5
707	Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. 2020 , 11, 833	17
706	Endocannabinoid System Components as Potential Biomarkers in Psychiatry. 2020 , 11, 315	39

705	Applications of Knoevenagel condensation reaction in the total synthesis of natural products. 2020 , 151, 439-482	24
704	Cannabis sativa: Much more beyond Tetrahydrocannabinol. 2020 , 157, 104822	30
703	Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies. 2020 , 11, 217-250	12
702	Fluorinated CRA13 analogues: Synthesis, in vitro evaluation, radiosynthesis, in silico and in vivo PET study. 2020 , 99, 103834	2
701	Treatment studies with cannabinoids in anorexia nervosa: a systematic review. 2021 , 26, 407-415	4
700	Synthesis and Biological Evaluation of Endocannabinoid Uptake Inhibitors Derived from WOBE437. 2021 , 16, 145-154	0
699	LPS-mediated neutrophil VEGF-A release is modulated by cannabinoid receptor activation. 2021 , 109, 621-631	8
698	A Brain on Cannabinoids: The Role of Dopamine Release in Reward Seeking and Addiction. 2021 , 11,	13
697	CB allosteric modulators and their therapeutic potential in CNS disorders. 2021 , 106, 110163	8
696	Cannabis and the Gut-Brain Axis Communication in HIV Infection. 2021 , 6, 92-104	2
695	Shape matters: The application of activity-based in vitro bioassays and chiral profiling to the pharmacological evaluation of synthetic cannabinoid receptor agonists in drug-infused papers seized in prisons. 2021 , 13, 628-643	9
694	Electroacupuncture Reduces Inflammation but Not Bone Loss on Periodontitis in Arthritic Rats. 2021 , 44, 116-128	1
693	Review of the Endocannabinoid System. 2021 , 6, 607-615	33
692	Lipid metabolism in astrocytic structure and function. 2021 , 112, 123-136	8
691	Role of cannabinoids in alcohol-induced neuroinflammation. 2021 , 104, 110054	7
690	Morphine Induces Upregulation of Neuronally Expressed CB2 Receptors in the Spinal Dorsal Horn of Rats. 2021 , 6, 137-147	1
689	Endocannabinoid modulation of dopamine release during reward seeking, interval timing, and avoidance. 2021 , 104, 110031	4
688	Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD. 2021 , 105, 110118	16

687	Biased agonism at the cannabinoid receptors - Evidence from synthetic cannabinoid receptor agonists. 2021 , 78, 109865	11
686	The effect of cannabidiol on canine neoplastic cell proliferation and mitogen-activated protein kinase activation during autophagy and apoptosis. 2021 , 19, 253-265	4
685	Perioperative Cannabis as a Potential Solution for Reducing Opioid and Benzodiazepine Dependence. 2021 , 156, 181-190	5
684	AM251, a cannabinoid receptor 1 antagonist, prevents human fibroblasts differentiation and collagen deposition induced by TGF- β An in vitro study. 2021 , 892, 173738	2
683	Cannabinoids as Key Regulators of Inflammasome Signaling: A Current Perspective. 2020 , 11, 613613	9
682	Resilience to fear: The role of individual factors in amygdala response to stressors. 2021 , 110, 103582	1
681	The endocannabinoid system - current implications for drug development. 2021 , 290, 2-26	3
680	Phytocannabinoid Pharmacology: Medicinal Properties of Constituents Aside from the "Big Two". 2021 , 84, 142-160	7
679	Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors. 2021 , 61, 441-463	17
678	Cannabinoid receptor Type 1 densities reflect social organization in <i>Microtus</i> . 2021 , 529, 1004-1017	2
677	Cannabis Phytochemicals: A Review of Phytocannabinoid Chemistry and Bioactivity as Neuroprotective Agents. 2021 , 74, 388	3
676	Cannabinoid use and self-injurious behaviours: A systematic review and meta-analysis. 2021 , 278, 85-98	8
675	Cannabis-Induced Neuroactivity: Research Trends and Commercial Prospects. 2021 , 159-185	4
674	The Endocannabinoid System. 2021 , 39-45	
673	Imaging Cannabinoid Receptors: A Brief Collection of Covalent and Fluorescent Probes for CB1 and CB2 Receptors. 2021 , 74, 416	2
672	The endocannabinoid system in the adipose organ. 2021 , 1	5
671	Cannabis use and posttraumatic stress disorder comorbidity: Epidemiology, biology and the potential for novel treatment approaches. 2021 , 157, 143-193	3
670	The Chemistry of Cannabis and Cannabinoids. 2021 , 74, 369	5

669	What Role Does the Endocannabinoid System Play in the Pathogenesis of Obesity?. 2021 , 13,	4
668	Cannabinoid Receptors and Ligands: Lessons from CNS Disorders and the Quest for Novel Treatment Venues. 2021 , 1297, 43-64	0
667	Effects of Cannabinoid Agonists and Antagonists on Sleep in Laboratory Animals. 2021 , 1297, 97-109	3
666	Biosynthesis and synthetic biology of psychoactive natural products. 2021 , 50, 6950-7008	7
665	Immunomodulation by cannabinoids: Current uses, mechanisms, and identification of data gaps to be addressed for additional therapeutic application. 2021 , 91, 1-59	0
664	Optical Control of Cannabinoid Receptor 2-Mediated Ca Release Enabled by Synthesis of Photoswitchable Probes. 2021 , 143, 736-743	10
663	Endocannabinoid-serotonin systems interaction in health and disease. 2021 , 259, 83-134	3
662	BIONOTE as an Innovative Biosensor for Measuring Endocannabinoid Levels. 2021 , 21,	1
661	Medicinal Cannabis: an overview for health-care providers. 2021 , 75-101	1
660	Integrating Endocannabinoid Signalling In Depression. 2021 , 71, 2022-2034	6
659	Relevance of Peroxisome Proliferator Activated Receptors in Multitarget Paradigm Associated with the Endocannabinoid System. 2021 , 22,	7
658	The Role of Cannabinoids as Anticancer Agents in Pediatric Oncology. 2021 , 13,	2
657	Cannabinoids and Sleep/Wake Control. 2021 , 1297, 83-95	2
656	Cannabis and Endocannabinoid System. 2021 , 001-006	
655	Cannabinoid Receptor 2 (CB2). 2021 , 55-62	
654	Endocannabinoidsystem und Stress. 2021 , 40, 35-42	1
653	A Glucuronic Acid-Palmitoylethanolamide Conjugate (GLUPEA) Is an Innovative Drug Delivery System and a Potential Bioregulator. 2021 , 10,	2
652	WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2.	

651	Neurotransmitters, Cell Types, and Circuit Mechanisms of Motor Skill Learning and Clinical Applications. 2021 , 12, 616820	1
650	The endocannabinoid system and drug-associated contextual memories. 2021 ,	2
649	Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel. 2021 , 12, 926	3
648	The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?. 2021 ,	4
647	: Interdisciplinary Strategies and Avenues for Medical and Commercial Progression Outside of CBD and THC. 2021 , 9,	7
646	Cannabinoid Receptor 1 and 2 Signaling Pathways Involved in Sepsis. 2021 , 56, 673-681	1
645	A review on the syntheses of Dronabinol and Epidiolex as classical cannabinoids with various biological activities including those against SARS-COV2. 2021 , 18, 2517-2534	2
644	Cannabinoids in Audiogenic Seizures: From Neuronal Networks to Future Perspectives for Epilepsy Treatment. 2021 , 15, 611902	3
643	Cannabis use and cannabis use disorder. 2021 , 7, 16	32
642	Synthesis and receptor dependent 4D-QSAR studies of 4,5-dihydro-1,3,4-oxadiazole derivatives targeting cannabinoid receptor. 2021 , 32, 175-190	1
641	Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders. 2020 , 11, 618065	5
640	Expression of Cannabinoid Receptor GPR55 in Human Gingival Fibroblasts and Anti-inflammatory Effects of Cannabidiol via GPR55. 2021 , 63, 11-23	
639	A systematic, integrative review of the effects of the endocannabinoid system on inflammation and neurogenesis in animal models of affective disorders. 2021 , 93, 353-367	1
638	Cannabinoid Signalling in Immune-Reproductive Crosstalk during Human Pregnancy. 2021 , 9,	0
637	Acute effects of cannabis consumption on exercise performance: a systematic and umbrella review. 2021 , 61, 551-561	1
636	Characterization of Estrogenic Activity and Site-Specific Accumulation of Bisphenol-A in Epididymal Fat Pad: Interfering Effects on the Endocannabinoid System and Temporal Progression of Germ Cells. 2021 , 22,	0
635	Cannabidiol and Other Cannabinoids in Demyelinating Diseases. 2021 , 22,	2
634	The use of zebrafish as a non-traditional model organism in translational pain research: the knowns and the unknowns. 2021 ,	5

633	Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies. 2021 , 162, S5-S25	17
632	THC Reduces Ki67-Immunoreactive Cells Derived from Human Primary Glioblastoma in a GPR55-Dependent Manner. 2021 , 13,	3
631	Advancing the science on cannabis concentrates and behavioural health. 2021 , 40, 900-913	6
630	Sex differences and the endocannabinoid system in pain. 2021 , 202, 173107	14
629	Molecular Mechanism of Autophagy and Its Regulation by Cannabinoids in Cancer. 2021 , 13,	5
628	Cannabinoids, reward processing, and psychosis. 2021 , 1	4
627	Efficacy of Phytocannabinoids in Epilepsy Treatment: Novel Approaches and Recent Advances. 2021 , 18,	8
626	Cannabis Effect on Female Reproductive Health.	1
625	Cannabinoid Receptor Agonist Inhibits Atrial Electrical Remodeling in a Tachypaced Rat Model. 2021 , 12, 642398	2
624	Endocannabinoid-mediated neuromodulation in the main olfactory bulb at the interface of environmental stimuli and central neural processing. 2021 ,	2
623	Synthesis, Molecular Pharmacology, and Structure-Activity Relationships of 3-(Indanoyl)indoles as Selective Cannabinoid Type 2 Receptor Antagonists. 2021 , 64, 6381-6396	4
622	Cerebrovascular Complications Associated with Marijuana Use. 2021 , 21, 25	0
621	The Endogenous Cannabinoid and the Nitricoxidergic Systems Differently Influence Heat and Cold Stress-Induced Analgesia. 2021 , 48, 34-39	
620	Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors. 2021 , 12, 636228	1
619	Oxa-adamantyl cannabinoids. 2021 , 38, 127882	2
618	Endocannabinoid system and its modulation of brain, gut, joint and skin inflammation. 2021 , 48, 3665-3680	2
617	Characterization of Subtype Selective Cannabinoid CB Receptor Agonists as Potential Anti-Inflammatory Agents. 2021 , 14,	2
616	Mini-review: The therapeutic role of cannabinoids in neuroHIV. 2021 , 750, 135717	4

615	WIN55,212-2, a Dual Modulator of Cannabinoid Receptors and G Protein-Coupled Inward Rectifier Potassium Channels. 2021 , 9,	0
614	Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. 2021 , 11,	5
613	Effects of prenatal synthetic cannabinoid exposure on the cerebellum of adolescent rat offspring. 2021 , 7, e06730	1
612	Cannabinoid Receptor Type-2 in B Cells Is Associated with Tumor Immunity in Melanoma. 2021 , 13,	2
611	Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB/CB Receptor Interaction. 2021 , 26,	0
610	Effect of synthetic cannabinoids (JWH-018) on antibody response to HBV vaccination.	
609	Anti-inflammatory and antinociceptive effects of the selective cannabinoid CB receptor agonist ABK5. 2021 , 145, 319-326	2
608	Global Trends in Cannabis and Cannabidiol Research from the Year 1940 to 2019. 2021 , 22, 579-591	1
607	The Interplay between the Immune and the Endocannabinoid Systems in Cancer. 2021 , 10,	6
606	Cannabinoid Signaling in Auditory Function and Development. 2021 , 14, 678510	0
605	Biosynthesis of Nature-Inspired Unnatural Cannabinoids. 2021 , 26,	3
604	Shattering the Carotids. 2021 , 52, e160-e163	2
603	Hippocampal TRPV1 channels in the modulation of contextual fear conditioning.	
602	Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010. 2021 , 10, 111-163	2
601	Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism. 2021 , 10,	5
600	ECaryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. 2021 , 12, 590201	5
599	Cannabis and Cannabinoids in Reproduction and Fertility: Where We Stand. 2021 , 1	3
598	Cannabis and the skin. 2021 , 39, 784-795	6

597	Worms get the munchies: the endocannabinoid AEA induces hedonic amplification in <i>C. elegans</i> by modulating the activity of the AWC chemosensory neuron.	
596	Mechanisms of endocannabinoid transport in the brain. 2021 ,	5
595	Cannabinoid 2 receptors regulate dopamine 2 receptor expression by a beta-arrestin 2 and GRK5-dependent mechanism in neuronal cells. 2021 , 753, 135883	4
594	Cannabinoid CB receptors are expressed in glutamate neurons in the red nucleus and functionally modulate motor behavior in mice. 2021 , 189, 108538	7
593	The role of endocannabinoids in consolidation, retrieval, reconsolidation, and extinction of fear memory. 2021 , 73, 984-1003	2
592	Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies. 2021 , 26,	1
591	Therapeutic Attributes of Endocannabinoid System against Neuro-Inflammatory Autoimmune Disorders. 2021 , 26,	1
590	Targeting the endocannabinoid system for management of HIV-associated neuropathic pain: A systematic review. 2021 , 10, 109-118	4
589	SARs for the Antiparasitic Plant Metabolite Pulchrol. 3. Combinations of New Substituents in A/B-Rings and A/C-Rings. 2021 , 26,	
588	Zerumbone Ameliorates Neuropathic Pain Symptoms via Cannabinoid and PPAR Receptors Using In Vivo and In Silico Models. 2021 , 26,	3
587	The cannabinoid system and microglia in health and disease. 2021 , 190, 108555	17
586	Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy. 2021 , 10,	6
585	Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (THC). 2021 , 1	2
584	Sex Differences in Tolerance to Delta-9-Tetrahydrocannabinol in Mice With Cisplatin-Evoked Chronic Neuropathic Pain. 2021 , 8, 684115	0
583	Effects of a CB Subtype Selective Agonist ABK5-1 on Cytokine Production in Microglia. 2021 , 2, 85-93	1
582	Endocannabinoidome and its role in neurological disorders-A comprehensive update of existing literature. 2021 , 5, 034-047	0
581	Rational design of cannabinoid type-1 receptor allosteric modulators: Org27569 and PSNCBAM-1 hybrids. 2021 , 41, 116215	0
580	Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?. 2021 , 206, 173192	3

579	Expression of the putative cannabinoid receptor GPR55 is increased in endometrial carcinoma. 2021 , 156, 449-460	1
578	Enantioselective Organocatalytic Synthesis of Bicyclic Resorcinols an Intramolecular Friedel-Crafts-Type 1,4-Addition: Access to Cannabidiol Analogues. 2021 , 363, 4067-4074	0
577	Cannabis and Autoimmunity: Possible Mechanisms of Action. 2021 , 10, 261-271	5
576	Development of [F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain. 2021 , 22,	3
575	Cannabis-based medicines and pain: a review of potential synergistic and entourage effects. 2021 , 11, 395-403	15
574	Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist. 2021 , 12, 702675	4
573	Endocannabinoids in immune regulation and immunopathologies. 2021 , 164, 242-252	5
572	Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox. 2021 , 12, 720734	4
571	Early Consumption of Cannabinoids: From Adult Neurogenesis to Behavior. 2021 , 22,	2
570	Targeting the Endocannabinoid System in the Treatment of Posttraumatic Stress Disorder: A Promising Case of Preclinical-Clinical Translation?. 2021 ,	6
569	The endocannabinoid system in social anxiety disorder: from pathophysiology to novel therapeutics. 2021 ,	1
568	Targeting cannabinoid receptor 2 (CB2) limits collagen production-An in vitro study in a primary culture of human fibroblasts. 2021 ,	0
567	Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19. 2021 , 1, 285-304	
566	Therapeutic potential of the cannabinoid receptor 2 in neuropsychiatry.	0
565	Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists. 2021 , 220, 113354	
564	A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of Ecaryophyllene, a dietary cannabinoid. 2021 , 140, 111639	6
563	Synthesis and molecular targets of N-13-hydroxy-octadienoyl-ethanolamine, a novel endogenous bioactive 15-lipoxygenase-derived metabolite of N-linoleoyl-ethanolamine found in the skin and saliva. 2021 , 1866, 158954	1
562	Gamma-Aminobutyric Acid (GABA) and the Endocannabinoids: Understanding the Risks and Opportunities.	1

561	Cannabinoids Drugs and Oral Health-From Recreational Side-Effects to Medicinal Purposes: A Systematic Review. 2021 , 22,	4
560	Cannabidiol modulation of oxidative stress and signalling. 2021 , 5, NS20200080	5
559	Theoretical calculation of some chemical properties of the cannabidiol (CBD) molecule.	1
558	The Pathophysiology and the Therapeutic Potential of Cannabinoids in Prostate Cancer. 2021 , 13,	5
557	The Effect of Orally Administered Low-Dose Dronabinol on Retinal Blood Flow and Oxygen Metabolism in Healthy Subjects. 2021 , 37, 360-366	1
556	The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. 2021 , 22,	14
555	Biased Coupling to β Arrestin of Two Common Variants of the CB Cannabinoid Receptor. 2021 , 12, 714561	1
554	and Autism, an Intriguing Connection Revisited. 2021 , 12,	2
553	Cannabis and Inflammation in HIV: A Review of Human and Animal Studies. 2021 , 13,	2
552	In vivo Bidirectional Modulation of Cannabinoid on the Activity of Globus Pallidus in Rats. 2021 , 468, 123-138	
551	The CB Receptor as a Novel Therapeutic Target for Epilepsy Treatment. 2021 , 22,	4
550	Association of Breast Tumour Expression of Cannabinoid Receptors CBR1 and CBR2 with Prognostic Factors and Survival in Breast Cancer Patients. 2021 , 11,	1
549	Development of fluorinated and methoxylated benzothiazole derivatives as highly potent and selective cannabinoid CB receptor ligands. 2021 , 114, 105191	1
548	A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse.. 2021 ,	2
547	Endocannabinoids, cannabinoids and the regulation of anxiety. 2021 , 195, 108626	4
546	2-Arachidonoylglycerol as an Endogenous Cue Negatively Regulates Attachment of the Mussel <i>Perna viridis</i> . 2021 , 8,	1
545	Pharmacological and toxicological activities of β -humulene and its isomers: A systematic review. 2021 , 115, 255-274	4
544	Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials. 2021 , 99, 2888-2905	2

543	New perspectives on the role of the neurosteroid pregnenolone as an endogenous regulator of type-1 cannabinoid receptor (CB1R) activity and function. 2021 , e13034	1
542	Successful and Unsuccessful Brain Aging in Pets: Pathophysiological Mechanisms behind Clinical Signs and Potential Benefits from Palmitoylethanolamide Nutritional Intervention. 2021 , 11,	0
541	Rational Remodeling of Atypical Scaffolds for the Design of Photoswitchable Cannabinoid Receptor Tools. 2021 , 64, 13752-13765	1
540	Endocannabinoid-mediated synaptic plasticity and substance use disorders. 2021 ,	
539	The role of endocannabinoid pathway in the neuropathology of Alzheimer's disease: Can the inhibitors of MAGL and FAAH prove to be potential therapeutic targets against the cognitive impairment associated with Alzheimer's disease?. 2021 , 174, 305-322	3
538	Pharmacological and Toxicological Effects of Phytocannabinoids and Recreational Synthetic Cannabinoids: Increasing Risk of Public Health. 2021 , 14,	3
537	An Evaluation of Understudied Phytocannabinoids and Their Effects in Two Neuronal Models. 2021 , 26,	2
536	Effect of dexamethasone on gene expression of cannabinoid receptor type 1 and adenosine monophosphate-activated protein kinase in the hypothalamus of broilers (<i>Gallus domesticus</i>). 2021 , 260, 111018	
535	Photosensitizer IR700DX-6T- and IR700DX-mbc94-mediated photodynamic therapy markedly elicits anticancer immune responses during treatment of pancreatic cancer. 2021 , 172, 105811	0
534	An overview on plants cannabinoids endorsed with cardiovascular effects. 2021 , 142, 111963	6
533	A review of the effects of acute and chronic cannabinoid exposure on the stress response. 2021 , 63, 100945	0
532	Pharmacological potential of JWH133, a cannabinoid type 2 receptor agonist in neurodegenerative, neurodevelopmental and neuropsychiatric diseases. 2021 , 909, 174398	0
531	Amygdalar endocannabinoids are affected by predator odor stress in a sex-specific manner and modulate acoustic startle reactivity in female rats. 2021 , 15, 100387	0
530	Potential of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease. 2021 , 90, 102196	3
529	Synthetic cannabinoids (SC). 2022 , 415-446	
528	Cannabinoids: a class of unique natural products with unique pharmacology. 2021 , 32, 5-15	3
527	Assessment of Cannabidiol and Δ^9 -Tetrahydrocannabinol in Mouse Models of Medulloblastoma and Ependymoma. 2021 , 13,	14
526	The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R). 2021 , 1-23	0

525	Putative effects of cannabidiol in depression and synaptic plasticity. 2021 , 459-467	1
524	Natural molecules as epigenetic modifiers in reproduction. 2021 , 373-389	
523	A computational prospective on isoform-selective CB2 inhibitors. 2021 , 45, 12688-12699	
522	Effects of Cannabinoids on Sleep and their Therapeutic Potential for Sleep Disorders. 2021 , 18, 217-227	6
521	Other Phytocannabinoids. 2021 , 87-92	
520	Cannabinoids and Cancer Pain. 2021 , 211-220	
519	Drug-Resistant Temporal Lobe Epilepsy Alters the Expression and Functional Coupling to Gβ _i /o Proteins of CB1 and CB2 Receptors in the Microvasculature of the Human Brain. 2020 , 14, 611780	2
518	Cannabinoids and Breast Cancer. 2021 , 103-122	
517	Therapeutic potential of cannabinoids in combination cancer therapy. 2021 , 79, 100774	9
516	Endocannabinoid signaling in liver pathologies. 226-239	1
515	Analgesic, anti-inflammatory, and anti-pyretic activity ¹ . 2002 , 670-773	8
514	The endogenous cannabinoid system in the control of food intake and energy balance. 2006 , 189-200	1
513	Cannabinoid targets for pain therapeutics. 2005 , 149-164	1
512	Potential use of cannabimimetics in the treatment of cancer. 2005 , 165-181	2
511	The Endocannabinoid System. 2008 , 343-384	2
510	Therapeutic potential of cannabinoid-based drugs. 2007 , 601, 395-413	38
509	Anatomical Distribution of Receptors, Ligands and Enzymes in the Brain and in the Spinal Cord: Circuitries and Neurochemistry. 2008 , 161-201	33
508	Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. 2008 , 49, 101-32	76

507	Rapid, Non-Genomic Responses to Ecdysteroids and Catecholamines Mediated by a Novel <i>Drosophila</i> G-Protein-Coupled Receptor. 2009 , 425-443	5
506	Cannabinoid Receptor Mediated Analgesia: Novel Targets for Chronic Pain States. 2009 , 337-351	1
505	Endogenous cannabinoid ligands. 1996 , 402, 95-101	6
504	Cannabinoids and immunity to <i>Legionella pneumophila</i> infection. 1996 , 402, 103-9	3
503	Cannabinoid receptor expression in immune cells. 1996 , 402, 119-29	23
502	Overview of Non-CB1/CB2 Cannabinoid Receptors: Chemistry and Modeling. 2013 , 29-51	1
501	Cannabinoid Modulation of Dopaminergic Circuits in Neurodegenerative and Neuropsychiatric Disorders. 2013 , 73-101	1
500	Endocannabinoid-Mediated Modulation of Excitatory and Inhibitory Synaptic Transmission. 2003 , 99-109	2
499	A Novel Neuromodulator in Basal Ganglia. 2002 , 661-673	1
498	Marijuana, receptors and immunomodulation. 1995 , 373, 103-13	30
497	Cannabinoid receptors and the cytokine network. 1998 , 437, 215-22	21
496	Cannabinoid receptor agonists enhance syncytia formation in MT-2 cells infected with cell free HIV-1MN. 1998 , 437, 223-9	23
495	Pharmacology of Cannabis. 1998 , 113-129	2
494	The endogenous cannabimimetic eicosanoid, anandamide, induces arachidonate release in J774 mouse macrophages. 1997 , 407, 341-6	15
493	Cannabinoids. 2014 , 487-510	1
492	Cannabinoid-Alcohol Interactions. 2015 , 363-391	3
491	Cannabinoids and Endocannabinoids. 2016 , 1811-1841	2
490	Cannabinoid Receptors and Their Ligands in Brain and Other Tissues. 1999 , 177-185	2

489	Cannabinoid Ligand-Receptor Signaling During Early Pregnancy in the Mouse. 1999 , 393-409	1
488	Cannabinoid Geometry and Biological Activity. 1999 , 65-90	3
487	Pharmacology of Cannabinoids. 2007 , 97-123	2
486	Preclinical Pharmacological and Brain Bioassay Systems for CB1 Cannabinoid Receptors. 2009 , 329-360	1
485	Cannabinoid Receptor Genetics and Evolution. 2009 , 123-149	4
484	Neuroreceptors and Neuromediators. 2010 , 7-15	3
483	Substance Use Disorders: Cognitive Sequelae, Behavioral Manifestations, Neuroimaging Correlates, and Novel Interventions. 2019 , 697-728	2
482	Novel Anti-inflammatory and Vasodilatory β Endocannabinoid Epoxide Regioisomers. 2019 , 1161, 219-232	2
481	Medical Marijuana for Chronic Pain. 2020 , 197-209	1
480	Constituents of Cannabis Sativa. 2021 , 1264, 1-13	9
479	Neuromolecular Mechanisms of Cannabis Action. 2021 , 1264, 15-28	3
478	Metabolism and physiological significance of anandamide and 2-arachidonoylglycerol, endogenous cannabinoid receptor ligands. 2004 , 211-237	9
477	Endothelium-derived hyperpolarizing factor--a critical appraisal. 1998 , 50, 107-33	40
476	Cannabinoid CB2 Receptor Mechanism of Cannabis sativa L.. 2017 , 227-247	1
475	Cannabinoids and Mitochondria. 2017 , 211-235	1
474	Targeting Phosphodiesterases in Pharmacotherapy for Substance Dependence. 2017 , 17, 413-444	2
473	Cannabinoids and pain. 2007 , 265-306	31
472	Integration of endocannabinoid signaling into the neural network regulating stress-induced activation of the hypothalamic-pituitary-adrenal axis. 2009 , 1, 289-306	18

471	Endocannabinoid receptor pharmacology. 2009 , 1, 37-63	24
470	Genetic models of the endocannabinoid system. 2009 , 1, 111-39	8
469	Cannabinoids: potential targets for bladder dysfunction. 2011 , 425-51	25
468	Pathophysiology of Portal Hypertension. 2015 , 3631-3665	5
467	PET Imaging of Endocannabinoid System. 2014 , 249-319	5
466	Marihuana. 1996 , 83-158	13
465	Pharmacology of Endocannabinoids and Their Receptors. 2020 , 415-445	2
464	CBD Suppression of EAE Is Correlated with Early Inhibition of Splenic IFN- γ CD8+ T Cells and Modest Inhibition of Neuroinflammation. 2021 , 16, 346-362	10
463	Brain Imaging of Cannabinoid Receptors. 2014 , 37-79	2
462	In Silico Chemogenomics Knowledgebase and Computational System Neuropharmacology Approach for Cannabinoid Drug Research. 2016 , 183-195	2
461	Marijuana. 2007 , 747-754	1
460	Cannabis. 2019 , 143-175	0
459	Differential effect of interferon-alpha treatment on AEA and 2-AG levels. 2020 , 90, 248-258	4
458	Inhibitors of arachidonoyl ethanolamide hydrolysis.. 1994 , 269, 22937-22940	164
457	Biochemistry and pharmacology of arachidonylethanolamide, a putative endogenous cannabinoid. 1997 , 38, 2383-2398	79
456	Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. 2021 , 64, 123-149	13
455	Effects of cannabinoid administration for pain: A meta-analysis and meta-regression. 2019 , 27, 370-382	24
454	Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. 2020 , 10, 158	19

453	The endocannabinoid system. 2020 , 64, 485-499	12
452	The cannabinoid system and cytokine network. 2000 , 225, 1-8	165
451	Making sense of medical marijuana. 1999 , 111, 159-65	10
450	[Toward a therapeutic use of cannabinoid CB(2) receptor in atherosclerosis]. 2006 , 22, 7-9	1
449	Novel therapeutic and drug development strategies for tobacco use disorder: endocannabinoid modulation. 2020 , 15, 1065-1080	3
448	Cardiovascular effects of (-)-11-OH-delta 8-tetrahydrocannabinol-dimethylheptyl in rats. 1996 , 28, 332-6	46
447	Antagonism of LPS and IFN-gamma induction of iNOS in human saphenous vein endothelium by morphine and anandamide by nitric oxide inhibition of adenylate cyclase. 1998 , 31, 813-20	74
446	TRPV1 blockers as potential new treatments for psychiatric disorders. 2020 , 33,	2
445	Cannabis: pharmacology and toxicology in animals and humans. 1996 , 91, 1585-1614	298
444	The Cannabinoid System and Cytokine Network. 2000 , 225, 1-8	1
443	The genes encoding the peripheral cannabinoid receptor and alpha-L-fucosidase are located near a newly identified common virus integration site, Evi11. 1997 , 71, 6796-804	40
442	Retroviral insertions in Evi12, a novel common virus integration site upstream of Tra1/Grp94, frequently coincide with insertions in the gene encoding the peripheral cannabinoid receptor Cnr2. 1999 , 73, 3595-602	22
441	Mechanism of the hypotensive action of anandamide in anesthetized rats. 1996 , 28, 682-6	113
440	Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats. 1997 , 29, 1204-10	123
439	Production and physiological actions of anandamide in the vasculature of the rat kidney. 1997 , 100, 1538-46	276
438	Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. 2003 , 111, 43-50	114
437	Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. 2003 , 111, 1231-40	56
436	Endocannabinoids and the regulation of body fat: the smoke is clearing. 2003 , 112, 323-6	50

435	Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R(+)-WIN55,212. 2003 , 111, 1231-1240	137
434	Food for thought: endocannabinoid modulation of lipogenesis. 2005 , 115, 1130-3	32
433	Fatty acid amide hydrolase deficiency limits early pregnancy events. 2006 , 116, 2122-31	114
432	Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?. 2010 , 120, 2646-8	9
431	Microglial activation underlies cerebellar deficits produced by repeated cannabis exposure. 2013 , 123, 2816-31	75
430	Inhibition of salivary secretion by activation of cannabinoid receptors. 2006 , 231, 1421-9	32
429	Anandamide, a Natural Ligand for the Peripheral Cannabinoid Receptor Is a Novel Synergistic Growth Factor for Hematopoietic Cells. 1997 , 90, 1448-1457	5
428	Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors During B-Cell Differentiation. 1998 , 92, 3605-3615	7
427	Expression of endocannabinoid system components in human airway epithelial cells: impact of sex and chronic respiratory disease status. 2020 , 6,	9
426	Cannabinoid Antagonists. 2006 , 187-198	2
425	Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression. 2011 , 152-175	2
424	Cannabinoid receptors and endocannabinoids: Evidence for new players. 2006 , 8, E298	118
423	Arrestin 1/2 Aggravates Podocyte Apoptosis of Diabetic Nephropathy via Wnt/ β Catenin Pathway. 2018 , 24, 1724-1732	11
422	Marijuana and Cannabinoids. 2001 , 1, 61-85	9
421	Sourcing the Code. 2002 , 2, 73-103	11
420	Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. 2008 , 3, e1640	194
419	Ulcerative colitis induces changes on the expression of the endocannabinoid system in the human colonic tissue. 2009 , 4, e6893	78
418	The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas. 2010 , 5, e8702	64

417	THC Prevents MDMA Neurotoxicity in Mice. 2010 , 5, e9143	44
416	The effect of anandamide on uterine nitric oxide synthase activity depends on the presence of the blastocyst. 2011 , 6, e18368	16
415	Lysophosphatidylinositol causes neurite retraction via GPR55, G13 and RhoA in PC12 cells. 2011 , 6, e24284	40
414	Increasing antiproliferative properties of endocannabinoids in N1E-115 neuroblastoma cells through inhibition of their metabolism. 2011 , 6, e26823	32
413	Anandamide induces sperm release from oviductal epithelia through nitric oxide pathway in bovines. 2012 , 7, e30671	31
412	Interaction between lysophosphatidic acid, prostaglandins and the endocannabinoid system during the window of implantation in the rat uterus. 2012 , 7, e46059	30
411	Differences in the endocannabinoid system of sperm from fertile and infertile men. 2012 , 7, e47704	53
410	The second intracellular loop of the human cannabinoid CB2 receptor governs G protein coupling in coordination with the carboxyl terminal domain. 2013 , 8, e63262	19
409	Anandamide reduces intracellular Ca ²⁺ concentration through suppression of Na ⁺ /Ca ²⁺ exchanger current in rat cardiac myocytes. 2013 , 8, e63386	15
408	Identification of genes expressed by human airway eosinophils after an in vivo allergen challenge. 2013 , 8, e67560	43
407	The natural product magnolol as a lead structure for the development of potent cannabinoid receptor agonists. 2013 , 8, e77739	26
406	Medicinal Cannabis: In Vitro Validation of Vaporizers for the Smoke-Free Inhalation of Cannabis. 2016 , 11, e0147286	46
405	Cannabinoid Receptors Are Overexpressed in CLL but of Limited Potential for Therapeutic Exploitation. 2016 , 11, e0156693	4
404	Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment. 2016 , 11, e0161954	16
403	Potential Therapeutical Contributions of the Endocannabinoid System towards Aging and Alzheimer's Disease. 2015 , 6, 400-5	23
402	Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. 1996 , 16, 4322-34	465
401	Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. 1999 , 19, 4544-58	905
400	Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. 2003 , 23, 4850-7	582

399	The endocrine disruptor DEHP and the ECS: analysis of a possible crosstalk. 2020 , 9, 101-110	1
398	Endo-cannabinoids system and the toxicity of cannabinoids with a biotechnological approach. 2017 , 16, 688-711	8
397	FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. 2014 , 5, 2475-86	42
396	Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases. 2019 , 26, 3300-3340	9
395	Endocannabinoid signaling in the etiology and treatment of major depressive illness. 2014 , 20, 3795-811	48
394	Role of the Endocannabinoidome in Human and Mouse Atherosclerosis. 2019 , 25, 3147-3164	3
393	Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives. 2019 , 23, 2016-2101	3
392	Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants. 2015 , 13, 760-75	36
391	TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling. 2018 , 16, 137-150	45
390	Cannabidiol Adverse Effects and Toxicity. 2019 , 17, 974-989	121
389	The "Entourage Effect": Terpenes Coupled with Cannabinoids for the Treatment of Mood Disorders and Anxiety Disorders. 2020 , 18, 87-96	47
388	Old Strategies and New Perspectives in Modulating the Endocannabinoid System. 2019 , 15, 159-173	3
387	The endocannabinoid system and pain. 2009 , 8, 403-21	298
386	Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. 2011 , 5, 15-21	13
385	Do Cannabinoids Confer Neuroprotection Against Epilepsy? An Overview. 2017 , 11, 61-73	4
384	Distribution of CB1 cannabinoid receptors in the rat amygdaloid complex. 2004 , 54, 369-378	3
383	Cannabinoids: for better and for worse?. 2020 , 22, 201-204	4
382	Cannabinoids and the endocannabinoid system in reward processing and addiction: from mechanisms to interventions?. 2020 , 22, 241-250	20

381	Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson's Disease. 2020 , 11, 595635	23
380	New Insights Into Peptide Cannabinoids: Structure, Biosynthesis and Signaling. 2020 , 11, 596572	3
379	(Endo)Cannabinoids and Gynaecological Cancers. 2020 , 13,	3
378	Low Basal CB2R in Dopamine Neurons and Microglia Influences Cannabinoid Tetrad Effects. 2020 , 21,	8
377	CB2 Receptor in Microglia: The Guardian of Self-Control. 2020 , 22,	27
376	Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. 2008 , 14, 2474-86	135
375	The Use of Medicinal Marijuana for Posttraumatic Stress Disorder: A Review of the Current Literature. 2015 , 17,	16
374	The role of cannabinoids in prostate cancer: Basic science perspective and potential clinical applications. 2012 , 28, 9-14	15
373	Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?. 2016 , 11, 1896-1899	17
372	Role of aryl hydrocarbon receptor in mesenchymal stromal cell activation: A minireview. 2017 , 9, 152-158	4
371	Non-opioid Analgesics and the Endocannabinoid System. 2020 , 37, 309-315	2
370	Concise Synthesis of (-)-Perrottetinene with Bibenzyl Cannabinoid. 2010 , 31, 2712-2714	9
369	Medical Cannabis in Children. 2020 , 11,	5
368	RGS3 Suppresses cAMP Response Element (CRE) Activity Mediated by CB2 Cannabinoid Receptor in HEK293 Cells. 2009 , 19, 1506-1513	1
367	The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief. 2011 , 2011,	13
366	Mental Health and Cognition in Older Cannabis Users: a Review. 2020 , 23, 242-249	7
365	Protective role of neuronal and lymphoid cannabinoid CB receptors in neuropathic pain. 2020 , 9,	16
364	Cannabinoid receptor 2 engagement promotes group 2 innate lymphoid cell expansion and enhances airway hyperreactivity. 2021 ,	3

363	Comprehensive inventory of cannabinoids in Cannabis sativa L.: Can we connect genotype and chemotype?. 1	1
362	Cannabinoids: an Effective Treatment for Chemotherapy-Induced Peripheral Neurotoxicity?. 2021, 1	1
361	Endocannabinoid System Unlocks the Puzzle of Autism Treatment Microglia. 2021, 12, 734837	1
360	CB2 Receptor Involvement in the Treatment of Substance Use Disorders. 2021, 11,	3
359	Innovative Clinical-Organizational Model to Ensure Appropriateness and Quality in the Management of Medical Cannabis: An Italian Regional Case. 2021, 9,	1
358	New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists. 2021, 22,	1
357	WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2. 2021, 9, e12262	1
356	Novel Non-invasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy. 2021,	4
355	Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?. 2021, 26,	2
354	The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells.. 2021, 28, 457-470	2
353	The CB Receptor Positive Allosteric Modulator, ZCZ011, Attenuates Naloxone-Precipitated Diarrhea and Weight Loss in Oxycodone-Dependent Mice. 2021,	0
352	Current review of hemp-based medicines in dogs. 2021, 44, 870-882	0
351	The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products. 2021, 157, 112600	2
350	The strengths and limits of cannabinoids and their receptors in cancer: Insights into the role of tumorigenesis-underlying mechanisms and therapeutic aspects. 2021, 144, 112279	0
349	Oligonucleotide Chips for Expression Analysis: Principles and Practical Procedures. 2001, 85-103	
348	Medical Management of Traumatic Neuropathies. 2001, 13, 343-363	4
347	Electrophysiological Effects of Cannabinoids in the Basal Ganglia. 2002, 275-296	
346	Induction of COX-2 expression by the endocannabinoid derivative R(+)-methanandamide. 2003, 525, 145-52	

- 345 Molecular Validation of Pain Targets. **2003**,
- 344 Local Neuroimmune Interactions in Visceral Hyperalgesia Bradykinin, Neurotrophins, and Cannabinoids. **2003**,
- 343 Microarray Analysis of Lipid Metabolism in Drug Abuse, Neurological and Psychiatric Disorders. **2004**, 215-236
- 342 Metabolism and Signal Transduction of Endogenous Marijuana-like Substances. **2005**, 5, 73-81
- 341 Cannabinoids. **2006**, 521-539 1
- 340 The Somatosensory System. **2006**, 7-30
- 339 Treatment of Nicotine Dependence. **2006**, 303-318
- 338 Endokannabinoidnaya sistema: struktura i potentsial'nye vozmozhnosti v regulyatsii massy tela. **2006**, 3, 2-11
- 337 The plasticity of alcohol addiction suggests novel approaches to pharmacological intervention. **2007**, 103-122
- 336 Involvement of the Endocannabinoid System in Metabolism and Fertility. **2007**, 385-396
- 335 CB-2 Cannabinoid Receptor. **2007**, 1-8
- 334 Pharmacologie des r cepteurs cannabino des. **2007**, 191, 933-940 1
- 333 Endocannabinoid Mechanisms of Pain Modulation. **2008**, 737-764
- 332 The Therapeutic Potential of Drugs that Target Cannabinoid Receptors or Modulate the Tissue Levels or Actions of Endocannabinoids. **2008**, 637-686 0
- 331 Activation of G-Proteins in Brain by Endogenous and Exogenous Cannabinoids. **2008**, 719-729
- 330 Further Advances in the Synthesis of Endocannabinoid-Related Ligands. **2008**, 687-696
- 329 Bibliographie. **2008**, 161-182
- 328 The EC System and GutBrain Interactions Relevant to Satiety. **2008**, 155-160

- 327 Potential Use of Opioid Antagonists in the Treatment of Marijuana Abuse and Dependence. **2009**, 299-314
- 326 Cannabimimetics. **2009**,
- 325 Cannabinoids and Pruritus. **2009**, 377-390
- 324 The Relaxation System. **2009**, 131-159
- 323 Endocannabinoid Mediated Long-Term Depression at Inhibitory Synapses. **2011**, 149-166
- 322 Cannabis. **2011**, 102-114
- 321 The Endocannabinoid System: A Janus-faced Modulator of Inflammation in the Intestinal Microcirculation. **2011**, 16-25
- 320 Cannabinoids in the Brain: Their Metabolism, Roles, and Involvement in Neurological Disorders. **2011**, 133-157
- 319 The Effects of Cannabinoids on Immune Cells, Responses and Diseases. **2012**, 307-359
- 318 Leptina e anorexia nervosa. **2012**, 24, 165-180
- 317 Overview of Nonclassical Cannabinoid Receptors. **2013**, 3-27 o
- 316 Endocannabinoid Signaling and the Regulation of the Serotonin System. **2013**, 239-254
- 315 Cue-Elicited Craving for Cannabis Activates the Reward Neurocircuitry Associated with the Neuropathology of Addiction. **2013**, 55-71
- 314 Endocannabinoids, Monoamines and Stress. **2013**, 173-212
- 313 Current Cannabinoid Receptor Nomenclature and Pharmacological Principles. **2013**, 25-54
- 312 Involvement of Serotonergic System in Cannabinoid Analgesia. **2013**, 277-295
- 311 Anatomical, Biochemical, and Behavioral Evidence for Cannabinoid Modulation of Noradrenergic Circuits: Role of Norepinephrine in Cannabinoid-Induced Aversion. **2013**, 135-156
- 310 Novel Mechanisms of G Protein-Coupled Receptor Oligomer and Ion Channel Interactions in Nociception. **2014**, 347-364 1

309 Central Analgesic Activity. **2014**, 1-104

308 The Endocannabinoid System: A Dynamic Signalling System at the Crossroads Between Metabolism and Disease. **2014**, 155-187

307 Pathophysiology of Portal Hypertension. **2014**, 1-41

306 Neurobiologie des endocannabinoïdes mise en relation avec les effets du tétrahydrocannabinol du chanvre indien. **2014**, 198, 527-539

305 Arachidonate Derivatives as Endogenous Cannabinoid Substances. **1996**, 167-195

304 The Role of Anandamide and Related Fatty Acid Ethanolamides as Endogenous Ligands for the CB1 and CB2 Cannabinoid Receptors. **1996**, 157-164

303 Psychomimetic Drugs, Marijuana, and 5-HT Antagonists. **1998**,

302 Nichtlineare Dynamik und das Unerwartete in der Psychiatrie. **1999**, 267-279

301 Marihuana and the Immune System. **1999**, 317-325

300 Marihuana and the Treatment of Glaucoma. **1999**, 591-595

299 Cannabinoids and the Brain.

298 Cannabinoids and Endothelial Dysfunction. **2015**, 6, 114-119

297 Central Analgesic Activity. **2016**, 1785-1874

296 Endogene Cannabinoide und das Endocannabinoidsystem. **2016**, 1-13

295 Receptores cannabinoides y vías de modulación del dolor.. **2016**, 7, 93-103

294 Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. **2016**, 1-27

293 NeuroAIDS in Drug Abusers: Associations with Oral Manifestations. **2017**, 325-345

292 Endocannabinoids, Stress, and Negative Affect. **2017**, 53-78

- 291 The Psychoneuroimmunological Influences of Recreational Marijuana. **2017**, 123-142
- 290 The Relaxation System Theoretical Construct. **2017**, 137-168
- 289 Endogene Cannabinoide und das Endocannabinoidsystem. **2018**, 411-420
- 288 Pharmakologie und Toxikologie synthetischer Cannabinoidrezeptor-Agonisten. **2018**, 389-409 1
- 287 Abuse of Cannabinoids.
- 286 Synthesis of 3-Aroylindoles as Intermediates of Cannabimimetics and Elucidation of Their Physicochemical Properties. **2018**, 96, 910 2
- 285 Anticancer Herbs for Improving the Quality of Life. **2018**, 5, 1-11
- 284 Cannabis, Cannabinoide und das Endocannabinoidsystem. **2019**, 1-36
- 283 CHAPTER 11:Cannabinoids as a Therapeutic Approach in Multiple Sclerosis. **2019**, 241-263
- 282 Pharmacodynamics of cannabinoids. **2019**, 3, 011-018 1
- 281 Cannabinoids and Mental Health, Part 1: The Endocannabinoid System and Exogenous Cannabinoids. **2019**, 57, 7-10 1
- 280 The expression of cannabinoid-related genes in multiple disease cell lines.
- 279 Protective role of neuronal and lymphoid cannabinoid CB2 receptors in neuropathic pain.
- 278 Anti-inflammatory dopamine- and serotonin-based endocannabinoid epoxides reciprocally regulate cannabinoid receptors and the TRPV1 channel.
- 277 The use of cannabinoids in epilepsy as an example: medical, social, and legal aspects. **2020**, 12, 125-130
- 276 Hypothalamic endocannabinoids in obesity: an old story with new challenges. **2021**, 78, 7469-7490 0
- 275 Plasmatic endocannabinoids are decreased in subjects with ultra-high risk of psychosis. **2021**, 1
- 274 Hippocampal Cb receptors: an untold story. **2021**, 0

- 273 research trends, challenges, and new-age perspectives. **2021**, 24, 103391 6
- 272 Cellular and behavioral basis of cannabinoid and opioid interactions: Implications for opioid dependence and withdrawal. **2020**, 8
- 271 Terrestrosin D, a spirostanol saponin from *Tribulus terrestris* L. with potential hepatorenal toxicity. **2022**, 283, 114716 2
- 270 Endocannabinoid System. **2021**, 7-56
- 269 Therapeutic Interventions of Endocannabinoid Signaling in Obesity-Related Cardiovascular Dysfunction. **2020**, 267-281
- 268 Endocannabinoids: the lipid effectors of metabolic regulation in health and disease. **2020**, 297-320 0
- 267 Cannabinoid receptor type 2 as a therapeutic target for Parkinson's disease. **2020**, 557-573 0
- 266 Cannabis and Psychosis: A Review of the Risk Factors Involved. **2020**, 11, 1949-1990 0
- 265 Mechanisms of Action and Pharmacokinetics of Cannabis. **2020**, 25, 1-3 7
- 264 Cannabinoids and Their Receptors. 1-6
- 263 Medicinal cannabis: Pharmaceutical forms and recent analytical methodologies. **2020**, 31-63 1
- 262 Current state of knowledge on the use of medical marijuana in some neurological diseases. **2020**, 36, 205-225
- 261 Expression of the endocannabinoid system in the human airway epithelial cells ¶Impact of sex and chronic respiratory disease status.
- 260 Cannabidiol selectively modulates interleukin (IL)-1¶and IL-6 production in toll-like receptor activated human peripheral blood monocytes. **2021**, 464, 153016 4
- 259 Legionella Infection and Cannabinoids. **2005**, 67-75
- 258 The anandamide membrane transporter and the therapeutic implications of its inhibition. **2005**, 2, 141-150 4
- 257 Neuroreceptors and Mediators. **2009**, 13-22 3
- 256 PET Imaging of the Endocannabinoid System. **2021**, 319-426 0

255	Neuroprotective Properties of Cannabinoids in Cellular and Animal Models: Hypotheses and Facts.	
254	Cannabis for medical and scientific purposes: the Colombian landscape. 2021 , 49,	
253	Functional CB1 cannabinoid receptors in human vascular endothelial cells. 2000 , 346 Pt 3, 835-40	88
252	N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. 2000 , 351 Pt 3, 817-24	92
251	Delta-9-tetrahydrocannabinol (THC) in the treatment of end-stage open-angle glaucoma. 2002 , 100, 215-22; discussion 222-4	22
250	Inhibition of lymphocyte activation by catecholamines: evidence for a non-classical mechanism of catecholamine action. 1995 , 85, 544-9	54
249	Cannabis related psychiatric syndromes: a selective review. 1994 , 36, 121-8	5
248	Heat shock protein 90 is an essential molecular chaperone for CB2 cannabinoid receptor-mediated signaling in trabecular meshwork cells. 2012 , 18, 2839-46	4
247	Chemistry, metabolism, and toxicology of cannabis: clinical implications. 2012 , 7, 149-56	139
246	Getting high on the endocannabinoid system. 2013 , 2013, 14	12
245	Recent data on cannabinoids and their pharmacological implications in neuropathic pain. 2008 , 1, 365-75	4
244	Anti-invasion Effects of Cannabinoids Agonist and Antagonist on Human Breast Cancer Stem Cells. 2017 , 16, 1479-1486	15
243	CD200-CD200R signaling and diseases: a potential therapeutic target?. 2019 , 11, 297-309	6
242	Myocardial Infarction Secondary to Marijuana-Induced Coronary Vasospasm. 2020 , 8, 76-78	4
241	Decreasing sperm quality in mice subjected to chronic cannabidiol exposure: New insights of cannabidiol-mediated male reproductive toxicity. 2021 , 351, 109743	2
240	Parkinson's disease related alterations in cannabinoid transmission. 2021 , 178, 82-96	0
239	Cannabis exposure during adolescence: A uniquely sensitive period for neurobiological effects. 2022 , 161, 95-120	0
238	Astroglial CB1 Cannabinoid Receptors Mediate CP 55,940-Induced Conditioned Place Aversion Through Cyclooxygenase-2 Signaling in Mice. 2021 , 15, 772549	1

237	The Vertical and Horizontal Pathways in the Monkey Retina Are Modulated by Typical and Atypical Cannabinoid Receptors. 2021 , 10,	1
236	Nanoscale Sub-Compartmentalization of the Dendritic Spine Compartment. 2021 , 11,	1
235	Dose-Related Inhibition of Capsaicin Responses by Cannabinoids CBG, CBD, THC and their Combination in Cultured Sensory Neurons. 2021 , 14, 3603-3614	0
234	The Role of Cannabinoids in Bone Metabolism: A New Perspective for Bone Disorders. 2021 , 22,	0
233	Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses.. 2021 , 12, 777804	5
232	The Endocannabinoid System as a Pharmacological Target for New Cancer Therapies. 2021 , 13,	2
231	Orchestration of the circadian clock and its association with Alzheimer's disease: Role of endocannabinoid signaling. 2021 , 73, 101533	0
230	Lipid endocannabinoids in energy metabolism, stress and developmental programming. 2021 , 542, 111522	0
229	Genetic Variants of Fatty Acid Amide Hydrolase Modulate Acute Inflammatory Responses to Colitis in Adult Male Mice.. 2021 , 15, 764706	0
228	Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy. 2022 , 69, 1-9	4
227	Cannabis: l'antidouleur du futur?. 2021 , N° 128, 32-38	
226	Medical Cannabis for Gynecologic Pain Conditions: A Systematic Review.. 2022 , 139, 287-296	5
225	A Review of Associations between Externalizing Behaviors and Prenatal Cannabis Exposure: Limitations & Future Directions.. 2022 , 10,	
224	Endocannabinoid system and cannabis hyperemesis syndrome: a narrative update. 2022 , 34, 1-8	0
223	The Endocannabinoid System in <i>Caenorhabditis elegans</i> . 2021 , 1	0
222	Cannabis: l'antidouleur du futur?. 2021 , N° 519 - janvier, 42-48	
221	New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders.. 2022 , 23,	1
220	Components of the Endocannabinoid System and Effects of Cannabinoids Against Bone Diseases: A Mini-Review.. 2021 , 12, 793750	0

219	Endocannabinoid-Mediated Control of Neural Circuit Excitability and Epileptic Seizures.. 2021 , 15, 781113	1
218	CB2R Deficiency Exacerbates Imiquimod-Induced Psoriasiform Dermatitis and Itch Through the Neuro-Immune Pathway.. 2022 , 13, 790712	0
217	Development of high-affinity fluorinated ligands for cannabinoid subtype 2 receptor, and in vitro evaluation of a radioactive tracer for imaging.. 2022 , 232, 114138	1
216	G Protein-Coupled Receptors in Osteoarthritis.. 2021 , 12, 808835	
215	Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential.. 2022 , 11, 4	8
214	Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease.. 2022 , 19, 4	3
213	Clinical effects of a single dose of cannabinoids to patients with chronic lymphocytic leukemia.. 2022 , 1-11	2
212	Novel potential avenues for the therapy of Tourette syndrome: Cannabinoid- and steroid-based interventions. 2022 ,	
211	Cannabinoid receptor type 2 agonist JWH-133 decreases cathepsin B secretion and neurotoxicity from HIV-infected macrophages.. 2022 , 12, 233	
210	Transcriptomic Profiling in Mice With CB1 receptor Deletion in Primary Sensory Neurons Suggests New Analgesic Targets for Neuropathic Pain.. 2021 , 12, 781237	1
209	Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects.. 2022 , 27,	1
208	Marijuana, a Journey through the Endocannabinoid System: Unmasking the Paradoxical Effect - Part 1.	
207	Modulatory role of the Endocannabinoidome in the pathophysiology of the gastrointestinal tract. 2021 , 106025	1
206	Between Science and Big Business: Tapping Mary Jane's Uncharted Potential.. 2022 , 8, 156-168	0
205	Gut microbiome and health: mechanistic insights.. 2022 ,	39
204	A Cannabinoid 2-Selective Agonist Inhibits Allogeneic Skin Graft Rejection .. 2021 , 12, 804950	0
203	The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation.. 2021 , 12, 806417	1
202	Cannabidiol and substance use disorder: Dream or reality.. 2022 , 207, 108948	1

201	Overview of the Endocannabinoid System and Endocannabinoidome. 2022 , 1-40	
200	"The Two Sides of the Same Coin"-Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained.. 2022 , 14,	2
199	Receptor mechanisms underlying the CNS effects of cannabinoids: CB receptor and beyond.. 2022 , 93, 275-333	1
198	Du THC contre la douleur. 2022 , N° 140, 48-51	
197	Mixed effects and mechanisms of cannabinoids for triple-negative breast cancer treatment. 2022 , 637-654	
196	Cannabinoids and sleep. 2022 ,	
195	The Synaptic Interactions of Alcohol and the Endogenous Cannabinoid System.. 2022 , 42, 03	1
194	Sialic Acid-Binding Ig-Like Lectins (Siglecs). 2022 , 311-496	
193	Detection of Cannabinoid Receptor Type 2 in Native Cells and Zebrafish with a Highly Potent, Cell-Permeable Fluorescent Probe.	1
192	Roles of the Cannabinoid System in the Basal Ganglia in Parkinson's Disease.. 2022 , 16, 832854	1
191	Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis.. 2022 , 1	0
190	Candidate Therapeutics by Screening for Multitargeting Ligands: Combining the CB2 Receptor With CB1, PPAR α and 5-HT $_4$ Receptors.. 2022 , 13, 812745	1
189	Expression and Functions of the CB Receptor in Human Leukocytes.. 2022 , 13, 826400	0
188	Neurological Benefits, Clinical Challenges, and Neuropathologic Promise of Medical Marijuana: A Systematic Review of Cannabinoid Effects in Multiple Sclerosis and Experimental Models of Demyelination.. 2022 , 10,	6
187	Clinical Evidence of Cannabinoids in Migraine: A Narrative Review.. 2022 , 11,	1
186	Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells.. 2022 ,	0
185	Endocannabinoid System in Polycystic Kidney Disease.. 2022 , 1-9	0
184	Overview of Cannabis including Kampo Medicine and Therapy for Treatment of Dementia: A Review.. 2021 , 12, 713228	0

183	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia.. 2022 , 1	0
182	Cortical thickness differences are associated with cellular component morphogenesis of astrocytes and excitatory neurons in nonsuicidal self-injuring youth.. 2022 ,	0
181	Medical Cannabis in Pediatric Oncology: Friend or Foe?. 2022 , 15,	0
180	Minimum Alveolar Concentration of Isoflurane in Rats Chronically Treated with the Synthetic Cannabinoid WIN 55,212-2.. 2022 , 12,	
179	L. Bioactive Compounds and Their Protective Role in Oxidative Stress and Inflammation.. 2022 , 11,	5
178	Impact of Cannabinoid Compounds on Skin Cancer.. 2022 , 14,	0
177	Cannabinoids as anticancer drugs: current status of preclinical research.. 2022 ,	4
176	Endocannabinoid Modulation in Neurodegenerative Diseases: In Pursuit of Certainty.. 2022 , 11,	2
175	Anti-Microbial Activity of Phytocannabinoids and Endocannabinoids in the Light of Their Physiological and Pathophysiological Roles.. 2022 , 10,	4
174	Cannabinoids: Therapeutic Use in Clinical Practice.. 2022 , 23,	14
173	Class A and C GPCR dimers in neurodegenerative diseases.. 2022 ,	
172	Cannabis as a potential compound against various malignancies, legal aspects, advancement by exploiting nanotechnology and clinical trials.. 2022 , 1-17	1
171	A critical review of cannabis in medicine and dentistry: A look back and the path forward.. 2022 ,	0
170	Potential Neuroprotective Effect of Cannabinoids in Covid-19 Patients.. 2022 ,	0
169	Reviewing the Role of the Endocannabinoid System in the Pathophysiology of Depression.. 2021 , 12, 762738	8
168	Inflammatory Biomarkers in Addictive Disorders.. 2021 , 11,	3
167	Curcumae Longae Rhizoma and Saussureae Radix Inhibit Nitric Oxide Production and Cannabinoid Receptor 2 Down-regulation.. 2022 , 36, 227-232	0
166	Uprawa konopi innych niż konopie indyjskie na potrzeby przemysłu farmaceutycznego na tle regulacji polskich oraz zagranicznych. 2021 , 26-59	

165	Endocannabinoid System of the Blood-Brain Barrier: Current Understandings and Therapeutic Potentials.. 2021 ,	1
164	Anti-Inflammatory Activity of a CB2 Selective Cannabinoid Receptor Agonist: Signaling and Cytokines Release in Blood Mononuclear Cells.. 2021 , 27,	1
163	Cannabinoids in Breast Cancer: Differential Susceptibility According to Subtype.. 2021 , 27,	2
162	Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review.. 2021 , 12, 790803	2
161	The Role of Cannabidiol in Neurological Disorders. 2021 , 25,	2
160	Medicinal Cannabis and Central Nervous System Disorders.. 2022 , 13, 881810	0
159	Endocannabinoid signaling in oligodendroglia.. 2022 ,	0
158	Acute and long-term effects of cannabinoids on hypertension and kidney injury.. 2022 , 12, 6080	1
157	Protective effects of cannabinoid type 2 receptor against microglia overactivation and neuronal pyroptosis in sepsis-associated encephalopathy.. 2022 ,	0
156	Data_Sheet_1.docx. 2020 ,	
155	Table_1.DOCX. 2018 ,	
154	Table_1.docx. 2020 ,	
153	Table_2.docx. 2020 ,	
152	Chronic Administration of Cannabinoid Receptor 2 Agonist (JWH-133) Increases Ectopic Ovarian Tumor Growth and Endocannabinoids (Anandamide and 2-Arachidonoyl Glycerol) Levels in Immunocompromised SCID Female Mice.. 2022 , 13, 823132	
151	A Complete Patent Analysis of Cannabis/Marijuana in Drug Delivery and Disease Conditions. 2022 , 1-34	1
150	Cannabis in Healthcare: Ethnobotanical and Pharmaceutical Perspectives and Legal Status in Turkey and the Middle East. 2022 , 131-154	
149	Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Dermatomyositis Patients with Refractory Skin Disease A Randomized Clinical Trial.. 2022 ,	0
148	for Medical Use: Versatile Plant Rather Than a Single Drug.. 2022 , 13, 894960	3

- 147 Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.. **2022**, 23, 0
- 146 Beyond monoamines: I. Novel targets and radiotracers for Positron emission tomography imaging in psychiatric disorders.. **2022**, 1
- 145 Impact of Δ^9 -Tetrahydrocannabinol on Rheumatoid Arthritis Synovial Fibroblasts Alone and in Co-Culture with Peripheral Blood Mononuclear Cells. **2022**, 10, 1118 0
- 144 Inhibition of mitochondrial permeability transition pore and antioxidant effect of Delta-9-tetrahydrocannabinol reduces aluminium phosphide-induced cytotoxicity and dysfunction of cardiac mitochondria. **2022**, 105117 0
- 143 Role of cannabinoids and the endocannabinoid system in modulation of diabetic cardiomyopathy. **2022**, 13, 387-407
- 142 Getting to the heart of cannabis health risks.. **2022**, 185, 1623-1625
- 141 The Microbiome and Gut Endocannabinoid System in the Regulation of Stress Responses and Metabolism. **2022**, 16, 0
- 140 Simultaneous Assessment of Serum Levels and Pharmacologic Effects of Cannabinoids on Endocannabinoids and -Acylethanolamines by Liquid Chromatography-Tandem Mass Spectrometry.. **2022**, 1
- 139 Evidence-based Potential Therapeutic Applications of Cannabinoids in Wound Management.. **2022**,
- 138 Addiction and human male fertility: A systematic review and a critical appraisal.. **2022**, 1
- 137 Cannabinoids modulate proliferation, differentiation, and migration signaling pathways in oligodendrocytes. 0
- 136 Osteogenic growth peptide is a potent anti-inflammatory and bone preserving hormone via cannabinoid receptor type 2. 11, 1
- 135 Cannabinoids and the endocannabinoid system in fibromyalgia: A review of preclinical and clinical research. **2022**, 108216 1
- 134 Regulation of glutamate homeostasis in the nucleus accumbens by astrocytic CB1 receptors and its role in cocaine-motivated behaviors. **2022**, 3, 100022
- 133 Efficacy of cannabis and its constituents in disease management: Insights from clinical studies. **2022**, 29, 0
- 132 Identification of a novel fatty acid binding protein-5-CB2 receptor-dependent mechanism regulating anxiety behaviors in the prefrontal cortex. 0
- 131 Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection. 13,
- 130 Augmented anandamide signalling in the substantia nigra pars reticulata mediates panicolytic-like effects in mice confronted by *Crotalus durissus terrificus* pit vipers. 1

- 129 Endocannabinoids, Anandamide and 2-Arachidonoylglycerol, as Prognostic Markers of Sepsis Outcome and Complications.
- 128 Cannabinoids and Endocannabinoids. **2022**, 1-29
- 127 Perspectives of industrial hemp cultivation. **2022**, 1-36
- 126 Cannabinoid Analogue WIN 55212 $\bar{2}$ Protects Paraquat-Induced Lung Injury and Enhances Macrophage M2 Polarization. ○
- 125 Cannabis bei Krebs $\bar{1}$ welchen Einsatz haben wir Evidenz?.
- 124 Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders. 13, ○
- 123 Cannabinoids and brain damage: A systematic review on a frequently overlooked issue. **2022**, 23, ○
- 122 Proposed mechanisms of cannabinoid hyperemesis syndrome $\bar{1}$ how can cannabinoid pathways both relieve and cause vomiting?. **2022**, 175-200 ○
- 121 Cannabinoids. **2022**,
- 120 A GPCR-based yeast biosensor for biomedical, biotechnological, and point-of-use cannabinoid determination. **2022**, 13, ○
- 119 Structure-Based Design, Optimization, and Development of [18F]LU13: A Novel Radioligand for Cannabinoid Receptor Type 2 Imaging in the Brain with PET. **2022**, 65, 9034-9049 1
- 118 Cannabinoid receptors are expressed in equine synovium and upregulated with synovitis. ○
- 117 Yin-Yang control of energy balance by lipids in the hypothalamus: The endocannabinoids vs bile acids case. **2022**,
- 116 Linking medicinal cannabis to autotaxin-lysophosphatic acid signaling.
- 115 Metabolic Messengers: endocannabinoids. ○
- 114 Role of Gut Microbiota in Cannabinoid-Mediated Suppression of Inflammation. 2,
- 113 Cannabidiol for the treatment of autism spectrum disorder: hope or hype?. **2022**, 239, 2713-2734 ○
- 112 Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits. 16,

111	Enzymatic inhibitive determination of AB-Fubinaca and AB-Pinaca on screen printed carbon tetratiofulvalene electrodes modified with nanoparticles and carbon nanotubes. 2022 , 100515	1
110	Recent Advances on Type-2 Cannabinoid (CB2) Receptor Agonists and Their Therapeutic Potential. 2022 , 29,	0
109	Beta-caryophyllene prevents the defects in trabecular bone caused by Vitamin D deficiency through pathways instated by increased expression of klotho. 2022 , 11, 528-540	
108	Effects of Δ -THC and Type-1 Cannabinoid Receptor Agonists in the Elevated Plus Maze Test of Anxiety: A Systematic Review and Meta-Analysis.	0
107	Cannabinoid Type 1 Receptors in the Basolateral Amygdala Regulate ACPA-Induced Place Preference and Anxiolytic-Like Behaviors.	0
106	Roles of cannabinoid CB1 and CB2 receptors in the modulation of psychostimulant responses. 1-34	0
105	Cannabis and the Brain: Friend or Foe?.	
104	N-acylethanolamide metabolizing enzymes are upregulated in human neural progenitor-derived neurons exposed to sub-lethal oxidative stress. 16,	0
103	Current knowledge of the implication of lipid mediators in psoriasis. 13,	3
102	Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility. 2022 , 11, 2569	2
101	Plant and fungi derived analgesic natural products targeting voltage-gated sodium and calcium channels. 2022 , 16, 198-215	0
100	Cannabinoid Receptors and Glial Response Following a Basal Forebrain Cholinergic Lesion.	0
99	The Endocannabinoid System and Eating Behaviours: a Review of the Current State of the Evidence.	0
98	MAGL inhibitor NanoMicellar formulation (MAGL-NanoMicellar) for the development of an antiglaucoma eye drop. 2022 , 625, 122078	
97	Lysophosphatidylinositol Induced Morphological Changes and Stress Fiber Formation through the GPR55-RhoA-ROCK Pathway. 2022 , 23, 10932	0
96	Strategies to improve Cannabis cultivation: optimizing plant growth and phytocannabinoid biosynthesis. 2023 , 77-108	0
95	The impact of biotechnology and genomics on an ancient crop: Cannabis sativa. 2023 , 177-204	0
94	Kaolin sulfonic acid nanoparticles: An efficient and reusable heterogeneous catalyst for the synthesis of highly substituted pyrazoles via a green protocol. 2022 , 4, 100505	0

93	Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. 2022 , 89-103	2
92	Emerging Role of Cannabinoid System Modulators in Treatment of Cancer. 2022 , 179-201	0
91	Resultados preclínicos de cannabinoides y dolor (algunos). 2022 ,	0
90	Discovering monoacylglycerol lipase inhibitors by a combination of fluorogenic substrate assay and activity-based protein profiling. 13,	0
89	Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities. 2022 , 101194	4
88	Positive Allosteric Modulators of Glycine Receptors and Their Potential Use in Pain Therapies. 2022 , 74, 933-961	0
87	Machine Learning and Computational Chemistry for the Endocannabinoid System. 2023 , 477-493	0
86	Distinct Activation Mechanisms Regulate Subtype Selectivity of Cannabinoid Receptors.	0
85	Effects of Ecaryophyllene, A dDietary Cannabinoid, in Animal Models of Drug Addiction. 2022 , 20,	0
84	Endocannabinoid-Binding Receptors as Drug Targets. 2023 , 67-94	0
83	Disruption of Tonic Endocannabinoid Signaling Triggers the Generation of a Stress Response.	0
82	Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies. 2022 , 114237	1
81	Biosynthesis and metabolism of endocannabinoids and their congeners from the monoacylglycerol and N-acyl-ethanolamine families. 2022 , 205, 115261	0
80	Cannabinoids and Endocannabinoids. 2022 , 2129-2157	0
79	The Therapeutic Potential of the Endocannabinoid System in Age-Related Diseases. 2022 , 10, 2492	0
78	Cannabinol: History, Syntheses, and Biological Profile of the Greatest Minor Cannabinoid. 2022 , 11, 2896	1
77	G protein-coupled receptors in cochlea: Potential therapeutic targets for hearing loss. 15,	0
76	Endocannabinoid signaling in the central nervous system.	0

75	Molecular Insights into Epigenetics and Cannabinoid Receptors. 2022 , 12, 1560	2
74	Study the Effect of Cannabidiol Topical on Antinociceptive and Anti-inflammatory Activities in Animal Model.	0
73	Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease. Publish Ahead of Print,	1
72	The results of a unique dietary supplement (nutraceutical formulation) used to treat the symptoms of long-haul COVID. 9,	0
71	Pharmacognosy and Effects of Cannabinoids in the Vascular System.	1
70	Voltage dependence of the cannabinoid CB1 receptor. 13,	0
69	Immunomodulatory actions of cannabinoids: Clinical correlates and therapeutic opportunities for allergic inflammation. 2022 ,	0
68	Endocannabinoids and related compounds as modulators of angiogenesis: Concepts and clinical significance.	0
67	Evaluation of the anti-inflammatory effects of selected cannabinoids and terpenes from Cannabis Sativa employing human primary leukocytes. 2022 , 170, 113458	0
66	The Endocannabinoid System in the Central Nervous System: Emphasis on the Role of the Mitochondrial Cannabinoid Receptor 1 (mtCB1R). 2022 , 565-587	0
65	Cannabinoids and drug metabolizing enzymes: potential for drug-drug interactions and implications for drug safety and efficacy.	1
64	Cys-loop receptors on cannabinoids: All high?. 13,	1
63	Endocannabinoid System Biomarkers in Alzheimer's Disease.	0
62	Rational drug design of CB2 receptor ligands: from 2012 to 2021. 2022 , 12, 35242-35259	0
61	Reliable prediction of cannabinoid receptor 2 ligand by machine learning based on combined fingerprints. 2023 , 152, 106379	0
60	Phytocannabinoids, the Endocannabinoid System and Male Reproduction. 2023 , 41, 1	0
59	Chronic pain in Alzheimer's disease: Endocannabinoid system. 2023 , 360, 114287	0
58	Monoethanolamine Treatment of Fish Wastes and Salmon Guts to Increase It Palmitoylethanolamide and Anandamide Contents.	0

57	In Vitro Characterization of 6-Methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole (ZCZ011) at the Type 1 Cannabinoid Receptor: Allosteric Agonist or Allosteric Modulator?. 2022 , 5, 1279-1291	0
56	Cannabinoids in Late Life Parkinson's Disease and Dementia: Biological Pathways and Clinical Challenges. 2022 , 12, 1596	1
55	Design, synthesis, and structure-activity relationships of diindolylmethane derivatives as cannabinoid CB2 receptor agonists.	0
54	Cannabinoid CB2 Receptors in Neurodegenerative Proteinopathies: New Insights and Therapeutic Potential. 2022 , 10, 3000	0
53	Meta-analysis and review of cannabinoids extraction and purification techniques.	0
52	N-[1,3-Dialkyl(aryl)-2-oxoimidazolidin-4-ylidene]-aryl(alkyl)sulphonamides as Novel Selective Human Cannabinoid Type 2 Receptor (hCB2R) Ligands; Insights into the Mechanism of Receptor Activation/Deactivation. 2022 , 27, 8152	0
51	2-Arylpropionic Acid Pyrazolamides as Cannabinoid CB2 Receptor Inverse Agonists Endowed with Anti-Inflammatory Properties. 2022 , 15, 1519	0
50	Impact of cannabis use on immune cell populations and the viral reservoir in people with HIV on suppressive antiretroviral therapy..	0
49	Differential Regulation of MMPs, Apoptosis and Cell Proliferation by the Cannabinoid Receptors CB1 and CB2 in Vascular Smooth Muscle Cells and Cardiac Myocytes. 2022 , 10, 3271	0
48	Understanding the Dynamics of the Structural States of Cannabinoid Receptors and the Role of Different Modulators. 2022 , 12, 2137	0
47	Bakuchiol and ethyl (linoleate/oleate) synergistically modulate endocannabinoid tone in keratinocytes and repress inflammatory pathway mRNAs. 2022 , 100178	0
46	Docking and Molecular Dynamic Investigations of Phenylspirodrimanes as Cannabinoid Receptor-2 Agonists. 2023 , 28, 44	1
45	GABAergic Neurotransmission in Human Tissues Is Modulated by Cannabidiol. 2022 , 12, 2042	0
44	The endocannabinoid system in the visual process. 2022 , 100159	1
43	Cannabinoid Compounds as a Pharmacotherapeutic Option for the Treatment of Non-Cancer Skin Diseases. 2022 , 11, 4102	1
42	The Endocannabinoid System as a Target for Neuroprotection/Neuroregeneration in Perinatal Hypoxic-Ischemic Brain Injury. 2023 , 11, 28	2
41	Update on the controversial identity of cells expressing cnr2 gene in the nervous system.	0
40	Linking medicinal cannabis to autotaxin-lysophosphatidic acid signaling. 2023 , 6, e202201595	0

- 39 Phytochemical Constituents and Derivatives of Cannabis sativa; Bridging the Gap in Melanoma Treatment. **2023**, 24, 859 ○
- 38 How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases. **2023**, 14, 204062232211432 ○
- 37 Quantification of Endocannabinoids from Biological Samples Using Liquid Chromatography Tandem Mass Spectrometry. **2023**, 115-127 ○
- 36 The antinociceptive activity and mechanism of action of cannabigerol. **2023**, 158, 114163 ○
- 35 N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R). **2023**, 248, 115109 ○
- 34 Cannabinoid effects in the microvasculature [CB, or not CB? That is the question! A mini-review. **2022**, 1-6 ○
- 33 Microglial Cannabinoid CB2 Receptors in Pain Modulation. **2023**, 24, 2348 ○
- 32 Endocannabinoid system and epigenetics in spermatogenesis and testicular cancer. **2023**, ○
- 31 Endocannabinoid System: Chemical Characteristics and Biological Activity. **2023**, 16, 148 ○
- 30 Characterization of URB Series Synthetic Cannabinoids by HRMS and UHPLC/MS/MS. **2023**, 16, 201 1
- 29 Cannabinoids Transmogrify Cancer Metabolic Phenotype via Epigenetic Reprogramming and a Novel CBD Biased G Protein-Coupled Receptor Signaling Platform. **2023**, 15, 1030 ○
- 28 The Endocannabinoid System as a Potential Therapeutic Target for HIV-1-Associated Neurocognitive Disorder. ○
- 27 Establishment of a point of departure for CBD hepatotoxicity employing human HepaRG spheroids. **2023**, 488, 153469 ○
- 26 Endocannabinoid system: An untold story in hypertensive nephropathy. **2023**, 20, em481 ○
- 25 The chronological evolution of fluorescent GPCR probes for bioimaging. **2023**, 480, 215040 ○
- 24 Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective. **2023**, 11, 469 ○
- 23 A Visual Identification Method of Analog Instrument Panel Based on Faster R-CNN. **2022**, ○
- 22 Endocannabinoid System and Exogenous Cannabinoids in Depression and Anxiety: A Review. **2023**, 13, 325 ○

- 21 Scientific Validation of Cannabidiol for Management of Dog and Cat Diseases. **2023**, 11, 227-246 ○
- 20 The Anti-Tumorigenic Role of Cannabinoid Receptor 2 in Colon Cancer: A Study in Mice and Humans. **2023**, 24, 4060 ○
- 19 The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19. **2023**, 15, 573 1
- 18 Discovery of 4-(1,2,4-Oxadiazol-5-yl)azepan-2-one Derivatives as a New Class of Cannabinoid Type 2 Receptor Agonists for the Treatment of Inflammatory Pain. **2023**, 66, 3460-3483 ○
- 17 A Cross Talk between the Endocannabinoid System and Different Systems Involved in the Pathogenesis of Hypertensive Retinopathy. **2023**, 16, 345 ○
- 16 Pharmacology of Cannabis. **2023**, 251-261 ○
- 15 Protective Effects of Cannabis in Neuroinflammation-Mediated Alzheimer's Disease. **2023**, 48-75 ○
- 14 Deciphering Complex Interactions in Bioactive Lipid Signaling. **2023**, 28, 2622 ○
- 13 Structural basis of selective cannabinoid CB2 receptor activation. **2023**, 14, ○
- 12 Crosstalk between the endocannabinoid and mid-brain dopaminergic systems: Implication in dopamine dysregulation. 17, 1
- 11 Development of the High-Affinity Carborane-Based Cannabinoid Receptor Type 2 PET Ligand [18F]LUZ5-d8. **2023**, 66, 5242-5260 ○
- 10 Cannabinoid Receptor Agonist WIN55, 212-2 Attenuates Injury in the Hippocampus of Rats after Deep Hypothermic Circulatory Arrest. **2023**, 13, 525 ○
- 9 Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases. **2023**, 244, 108394 ○
- 8 Modulation of pulmonary immune function by inhaled cannabis products and consequences for lung disease. **2023**, 24, ○
- 7 Potent dual MAGL/FAAH inhibitor AKU-005 engages endocannabinoids to diminish meningeal nociception implicated in migraine pain. **2023**, 24, ○
- 6 Recent Research on Cannabis sativa L.: Phytochemistry, New Matrices, Cultivation Techniques, and Recent Updates on Its Brain-Related Effects (2018-2023). **2023**, 28, 3387 ○
- 5 Role of integrating cannabinoids and the endocannabinoid system in neonatal hypoxic-ischaemic encephalopathy. 16, ○
- 4 Cannabinoid CB2 receptors modulate alcohol induced behavior, and neuro-immune dysregulation in mice. **2023**, 114439 ○

- 3 The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma. **2023**, 115914
- 2 The conserved endocannabinoid anandamide modulates olfactory sensitivity to induce hedonic feeding in *C. elegans*. **2023**,
- 1 Review of the oral toxicity of cannabidiol (CBD). **2023**, 113799